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Abstract
Risk prediction models are tools that predict an individual’s risk of developing a health
outcome. They were developed to influence patient management by guiding preventive
interventions, with the goal of reducing the incidence of new diseases. Studies
examining their impacts are uncommon, and no consensus regarding their effects has
been reached. This systematic review sought to determine the impact of risk prediction
models for chronic diseases on physician behaviour, patient behaviour, and patient health
outcomes. Twenty-two studies were found to be eligible for review. The results
demonstrated that: 1) physician behaviour may be positively influenced, though a
statistically significant result was not found; 2) alterations in patient behaviour were
inconclusive; and 3) some aspects of patient health outcomes were significantly
improved, such as changes in blood pressure, but these results may be clinically
insignificant. The evidence indicates some effects may exist, though future studies are
required to confirm this effect.
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Chapter 1
1.0

Introduction

The focus of this thesis is on risk prediction models, which are clinical tools that take
formal, evidence-based combinations of predictors and risk factors and generate an
estimated risk for specific, often health-related, endpoints.1 The ability to use patient
characteristics for estimating the risk of an outcome, or ‘event’, can be applied within
many healthcare settings and to many clinical outcomes.2 This thesis will concentrate on
models which are predictive of chronic health outcomes, and that are used mainly in
primary care settings.
Though several definitions of chronic diseases exist, the term is generally applied to
diseases that are of long duration, generally slow progression, and are of noncontagious
origin.3 The prevalence rate of chronic diseases, such as diabetes or heart disease, has
been estimated to be as high as one in three persons in Canada.4,5 This represents a 40
billion CAD economic burden in direct costs for disease management.5,6 Globally,
chronic diseases were responsible for 38 million (68%) deaths in 2012, with the number
projected to rise to over 50 million by 2030, representing the leading cause of death
worldwide.4
Primary care settings are the main arena within which chronic diseases are managed and
their onset prevented.7 Chronic disease prevention and management in the given climate
is gaining increasing importance in primary care settings.6 Given the increasing burden
of chronic diseases, many chronic diseases and conditions are primarily managed in
outpatient settings under the supervision of a primary care physician.5,8 This creates a
collaborative relationship between patient and physician, emphasizing the role of patient
self-management within the context of primary care settings.9,10 Though numerous health
care professionals are involved in chronic disease management, the physician is often
recognized as the locus of care.8 Primary care was selected as the setting of interest with
a particular emphasis on primary care physicians given the intrinsic relationship between
chronic disease prevention and management and primary care settings.
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Risk prediction models may supplement the management of chronic diseases in primary
care. They function well as an educational tool by providing both physicians and patients
with an objective measure of a patient’s risk of disease or outcome.11 They are intended
to help guide, not replace, the clinical decision-making process involved in disease
prevention and management.12 To provide context regarding the development of risk
prediction models, a brief explanation of their history will be provided in the following
section.
1.1

The Framingham Heart Study and the birth of prediction models

The first well-accepted health-related risk prediction model was published in 1976 by
researchers of the first iteration of the Framingham Study, a prospective cohort study
seeking to identify the risk factors for cardiovascular disease (CVD).13,14,15 Prior to the
Framingham Study, the etiology of CVD was unknown. Indeed, the term “risk factor”
wasn’t popularized until 1961 with a publication from the Framingham researchers
identifying the factors of risk of developing coronary heart disease (CHD).16,17
By the 1940s, CVD was responsible for 1 in 2 deaths amongst Americans, and was the
foremost cause of mortality in the United States.17 Former US President Franklin Delano
Roosevelt’s death due to cerebral hemorrhage in 1945 drew greater attention to the
necessity of identifying the cause or causes of CVD.18,19
In recognition of the paucity of funds for research to understand and combat CVD, the
National Heart Act was enacted in 1948, which authorized the funding of the
Framingham Heart Study.20,19 As a result of the study, researchers identified numerous
risk factors for CVD, including age, sex, high blood pressure, smoking status,
dyslipidemia, and diabetes.21,22 The previous medical treatment paradigm began to shift
towards prevention.23 With the findings of the Framingham Study, the groundwork for
preventing not just CVD but many other chronic diseases was established.
1.2

From treatment to prevention

The identification of the predictive risk factors for CVD as well as risk factors for many
other chronic diseases helped promote the concept of disease prevention.19 Through
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epidemiologic investigation, the prevention of CVD became a possibility by providing a
range of modifiable, targetable risk factors for intervention. The identification of risk
factors allowed physicians to not only to continue to treat those afflicted, but also to
target individuals at risk of disease.19,24
The field of risk prediction models is largely focused on CVD, which is understandable
given its origins, but the principle of identifying risk factors and quantifying their
independent and cumulative impact on disease risk have been applied to numerous health
outcomes. For example, the Gail model was developed to predict breast cancer risk,
allowing for the appropriate prescription with tamoxifen, a chemopreventive
medication.25,26 One recent systematic literature search identified 25 models predictive of
the risk of type 2 diabetes mellitus.27 More recently, the first multivariable risk
prediction model for chronic obstructive pulmonary disease (COPD) was created in 2015
incorporating different genotypes in tandem with other clinical variables, such as age or
smoking status, to generate a person’s long-term risk of developing COPD.28
Risk prediction models have become a common method of identifying individuals at risk
for experiencing a targeted health outcome such as cancer or diabetes; they are capable of
generating an individual’s absolute probability or risk of experiencing an event well
before the individual experiences disease onset.29,30 The process of estimating the
absolute risk of particular diseases for individual patients is often recommended as it may
help guide the preventive care activities by health care practitioners.31
The interactive, multifactorial nature of the causes of chronic disease indicate that
preventive measures should target multiple risk factors as opposed to focusing on single
factors31,32. For example, the risk factors of blood pressure or cholesterol levels are
predictive of CVD. However, interventions focused strictly on reducing blood pressure
or cholesterol levels only have a limited effect on absolute cardiovascular risk, indicating
that reductions in multiple risk factors are more effective at preventing cardiovascular
events.32 Risk prediction models are often multivariable models themselves, accounting
for several risk factors in one cohesive equation to generate an absolute risk of disease.33
Reducing a patient’s absolute risk of disease necessitates a multifactorial approach,
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targeting multiple risk factors rather than single ones, a process that may be guided by
use of a risk prediction model.
Clinical guidelines often incorporate and recommend the use of risk prediction models.11
Indeed, one systematic review published in 2010 identified 27 guidelines that
recommended cardiovascular risk assessment in asymptomatic adults, indicating a
movement towards formal risk assessments for patients.34 This shift represents a belief
that model usage to estimate patient risk of disease will correspondingly affect physician
behaviour, such as prescription with preventive medications, thereby affecting patient
behaviours, such as lifestyle modifications, which may result in improved patient health
outcomes.33,35,36 However, though risk prediction models have become quite
commonplace and increasingly recommended for use in clinical practice, consensus
regarding their intended impact has yet to be achieved.37
1.3

Impact analysis

There have been several studies conducted regarding the development and, to a lesser
extent, the validation of risk prediction models.33 Nevertheless, their utility in clinical
practice is unknown due to a dearth of information regarding their impact. Though
systematic reviews have been conducted regarding the impact of risk prediction model
use for single health outcomes or to assess the health economic impact of model use, no
systematic review have examined impact analysis studies of risk prediction models
comprehensively.35,38 There are calls from researchers to assess the impact of risk
prediction model use in clinical practice.33,38 Given the widespread recommendations to
use prediction models, there exists a lack of cohesive evidence to support their
implementation for regular use in the prevention of chronic diseases.
For this reason, this thesis sought to search, collect, and collate the relevant literature
pertaining to the impact of chronic disease risk prediction models on the domains of
practitioner behaviour, patient behaviour, and patient health outcomes to ascertain their
clinical utility in primary care settings. In doing so, a unifying perspective is provided
regarding the potential impact of risk prediction models in primary care settings, thereby
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establishing a foundation from which prediction models may be implemented and most
effectively influence the health of the population.
1.4

Overview of thesis

This thesis was written in accordance with the requirements set forth by Western
University’s School of Graduate and Postdoctoral Studies. The study presented is a
systematic review and meta-analysis of all studies that have conducted an impact analysis
of chronic disease risk prediction models in primary care settings.
The second chapter will explore the often inconsistently used terminology pertaining to
risk prediction models and present methods for their classification. Chapter 3 presents
the literature relevant for the research question, outlines the rationale and need for this
study, and defines the objectives used to guide the study. The methodology employed for
the systematic review and meta-analysis is presented in chapter 4. The results obtained
from the systematic review and meta-analysis are detailed in chapters 5 and 6,
respectively. A discussion and interpretation of the results follows in chapter 7, outlining
the strengths and limitations of the reported study, as well as future directions for
research in this field.
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Chapter 2
2.1

Introduction

The study of risk prediction models is a growing field, with an increasing number of
models being developed every year for a wide array of outcomes. However, the field
itself lacks a consistent method of classification for these models, with several terms (e.g.
‘risk calculator’, ‘clinical prediction model’, etc.) being used to describe similar tools.
This chapter seeks to provide an understanding of risk prediction models, provide an
overview of related terminology, and further classifies risk prediction models according
to a few of their inherent criteria.
2.2

Understanding risk prediction models

The concept of prognosis is central to the practice of medicine, with most diagnostic and
therapeutic actions aimed at improving a patient’s prognosis, a term used to describe a
person’s future health based on a series of characteristics.30,39 One example of a tool used
to improve a patient’s prognosis is a screening test, which allows for the identification
persons with unrecognized disease—the early identification can afford the person and
health care provider greater opportunities for treatment than if the disease had been
identified later.30,40 Similarly, risk prediction models are clinical tools that can improve a
patient’s prognosis. They may promote the initiation of risk reduction strategies by
providing physicians and patients with an absolute risk of developing a specific health
outcome, motivating those at increased risk to take preventive action.41
Risk prediction models generate an estimated probability that a disease is present
(diagnostic models) or will occur in the future (prognostic models) by using an array of
clinical and non-clinical patient characteristics.42,30,39,37 These tools seek to determine the
patient’s global risk, a term used to describe the absolute risk of experiencing an event
over a specific time period, often measured in the magnitude of years for chronic
outcomes and months for acute outcomes.43,22 Global risk is calculated using the
algorithms or multivariable equations underlying the prediction models.44 These global
risk assessment tools often take into account the additive and synergistic effects between
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individual risk factors, placing increases in individual risk factors, or predictors, into
context relative to the overall disease, allowing for a continuum of disease risk to be
expressed and identifying patients most likely to derive benefit from an intervention.45
With the uncovering of the quantitative relationship between these risk factors for
disease, physicians and patients are able to more efficiently manage disease risk by
targeting the global risk.43 The estimates derived from risk prediction models may guide
the management of therapeutic or ameliorative options through informing and fostering
the process of shared decision making.37,46,29 Numerous guidelines, such as those
published by the National Cholesterol Education Program in the United States, the Joint
National Committee, and the American Diabetes Association recommend modifying the
intensity of strategies for risk reduction based on the patient’s global risk.47 Indeed, an
accurate risk prediction model is of no clinical utility if it does not change behaviour and
ultimately health outcomes.48
The estimated global risk is often stratified according to risk thresholds, such as an
individual being at either low, moderate, or high risk of developing the outcome.
Guidelines often recommend that treatment decisions be influenced by these thresholds;
the New Zealand guidelines to manage elevated blood pressure recommend initiating
treatment conversations with patients with a five-year 10% risk of CVD if their blood
pressure is raised (between 150/90 and 169/99 mm Hg).49 Though these thresholds for
intervention are not necessarily based on their evidence-based impact on outcomes, but
rather often representing a vestige from historically-derived levels, they do provide a
simplified cut-off value from which interventions such as pharmacotherapy may be
applied.50
2.3

How have risk prediction models been studied?

Though research in prediction models is varied, it can be categorized generally in three
sequential stages: 1) model development, 2) model validation, and 3) impact
studies.37,51,52 Though the purpose of this thesis is to assess evidence from the third stage,
a brief overview of the first two stages will be given.
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2.3.1

Model development

The purpose of model development involves the steps necessary to create a model that
can calculate the likelihood of risk with a high level of accuracy for any permutation of
predictor variables in a specific population. Steyerberg (2009) outlined seven key steps
to developing a model (Table 1).30
Table 1. Seven steps to developing a prediction model.30,53
Step

Purpose

Description

1

Problem definition and
data inspection.

Understanding the research question, what outcome it
seeks to predict, defining the predictors, with
consideration of the data under study.

2

Coding of predictors.

The predictors are derived from the dataset, and it
must be determined how to code the categorical or
continuous variables.

3

Model specification.

Model specification pertains to predictor selection,
what methods to use to select predictors, and the
management of assumptions used in models.

4

Model estimation.

Once the model is specified, parameters such as the
regression coefficient values must be estimated for
predictors or combination of predictors.

5

Model performance.

The performance of the model, such as how closely
predictions are to the actual outcome, as well as
specific questions regarding the calibration and
discrimination properties of the model.

6

Model validation.

To reduce the likelihood of overfitting, internal
validation of the model would ensure the
reproducibility of the model in the target population.

7

Model presentation.

The model can be presented as its base algorithm, or
in a different format for use in practice, such as a
chart, table, or computerized program.

The information necessary to construct a model is derived from a source or development
population. The source of data for model development is ideally from a prospective
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study of sufficient duration to allow for the natural history of disease to progress, which
allows for optimal documentation of predictors and outcomes, and to obtain a more
accurate measure of the baseline risk.51 Case-control studies are less ideal as they don’t
allow for the absolute risk of the outcome to be calculated given that cases and controls
are sampled from the source population at a ratio not representative of baseline risk. 51,54
Regardless of the study design from which the data are used to construct a model, it
generally applies to a specified target population, a group of persons who share similar
clinical characteristics to the development population.55,56
Predictors are identified from the data source. Predictors are factors that may be
demographic in nature, include clinical history, physical examination results, disease
characteristics, test results, or previous treatments.51 Predictors are not necessarily
causally related to the outcome of interest, but indicate that a patient may be at risk of the
outcome, or in other words, are associated with the outcome.51 Though a greater number
of predictors that are theoretically associated with the outcome may be identified, not all
can or will be included in the final model.
Model performance is measured according to two primary metrics: calibration and
discrimination.30 Calibration is a measure of agreement, or fit, between the expected and
observed endpoints.57 For example, if a model predicts that a person will experience the
outcome with a 5% likelihood, for every 100 people with the same 5% likelihood,
approximately 5 should experience the event of interest. Calibration can be assessed
using the Hosmer-Lemeshow goodness-of-fit test or a calibration plot where predicted
and observed outcomes are plotted on opposing axes, with perfectly calibrated models
generating data points along the 45o line.57,58
Discrimination assesses how well the model can differentiate between those who will
develop the outcome of interest from those who will not.53 With regards to prediction
models, a model with high discriminatory ability can well distinguish risk groups from
one another.59 It is commonly assessed using a performance measure, specifically the
concordance (c) statistic and the area under the Receiver Operating Characteristic (ROC)
curve (AUC), which is identical to the c statistic for binary outcomes.57 The prognostic
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groups may be identified after the creation of a model, such as segmenting the groups
according to quartiles, where the lower quartiles should have worse outcomes than the
upper quartiles.30 Defining the prognostic groups inappropriately, however, may result in
a failure to discriminate between risk levels, with increases in rates of false positives or
negatives.59
Model validation ensures that the purpose of predictive models (providing accurate
predictions of risk for new patients) is met.30 Model development generally concerns
itself with internal validation more so than external validation, assessing whether the
estimates derived from the model apply well to the source population.53 Internal
validation can help identify and in turn, reduce the potential for bias in model
performance, such as overfitting which can lead to unfounded optimism on the part of
the developer.60 Overfitting, or when predictions derived from models are highly
accurate when evaluated on the source data but have a low accuracy in alternate sets of
data, can lead to an overly optimistic perception that the model will perform with the
same high level of accuracy in new subjects from the underlying population.30,61
Overfitted models tend to overestimate the risk of outcome in high risk patients, and
underestimate risk in low risk patients, reducing their applicability to novel populations.2
Identifying and reducing such biases can ensure that the model is applicable and accurate
within its target population.
Validation can be conducted by using a split sample approach. In this case, the dataset is
divided into the development sample and the validation sample; the model is then
developed from one segment of data and validated in the next.I This method can be
considered inefficient as not all available data are used to develop the model.53,60
Alternate methods include cross-validation and bootstrap resampling, which are
validation methods where data are resampled from the development sample.62 In doing
so, all the data are used for development, and validated within the same pool of data,

I

In the field of Machine Learning, the “validation sample” is typically referred to as a test set.
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ensuring the applicability of the model to the source population, as well as reducing the
potential for overfitting.
With the model completed, attention is turned to the presentation of the model, or how it
is presented for clinical use. Model presentation should be appropriate for its intended
setting, and ease its implementation and usage. Risk prediction models generally present
the absolute risk, or the risk of an event in a single group, as opposed to using a relative
measure, such as the relative risk, or the ratio of risk of an event in one group to another
group.63,64 Absolute measures of risk are preferable to inform clinical decision making,
whilst conversely, relative measures of risk are preferable in etiologic research.64,65 This
preference is primarily due to the occlusive nature of relative measures of risk; if one
treatment option reduces risk of adverse outcomes from 5% to 2.5%, in relative terms
there is a 50% reduction in risk, though in absolute terms the risk is only reduced by
2.5%.64,66 Presenting absolute measures of risk reduces the possibility of
misinterpretation compared to presenting relative measures of risk.
At their core, prediction models should allow physicians to input data and calculate or
generate a measure of absolute risk.67 Some risk prediction models present solely their
predictive algorithm, requiring physicians to manually calculate the absolute risk. For
example, the GUSTO-I model, which predicts the 30-day risk of mortality in patients
with acute myocardial infarction, presents to the user simply its regression formula (see
Appendix A for the complete formula).68
Similarly, researchers of the Framingham Heart Study published a cardiovascular
prediction model, predicting for general CVD risk as well as individual CVD events,
including coronary heart disease, cerebrovascular disease, peripheral arterial disease, and
heart failure.22 In this model, physicians would input the patient’s values for several
predictors, and manually calculate the long-term risk. For example, using a Cox model, a
61 year old woman who smokes, is not diabetic, total cholesterol of 180 mg/dL, highdensity lipoprotein (HDL) of 47 mg/dL, and systolic blood pressure of 124 mm Hg,
would have a 10-year estimate of risk of 10.5%.22
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Though these formulas are potentially accurate, their complexity limits applicability in
clinical settings. Simplifications in delivery may increase the accessibility of the model.
Researchers for the Framingham Heart Study aimed to make their complex statistical
models more useful by developing and using a “points system” wherein points associated
with predictors are summed, and the total score corresponds to a calculated 10-year
coronary risk.67 Technological advancements have further reduced the burden of this
barrier to use of models in clinical practice, with computer systems reducing the labour
and likelihood of error associated with manual imputation.69 A transition to simpler
systems can increase the routine use of prediction models in clinical practice.69,70,71
The generated output is not the only aspect of model presentation involved in model
development. It also includes the medium of delivery. Paper-based options, including
score charts or nomograms, can be an effective option for easy application in clinical
settings.53,62,71 The Sheffield Risk Table identifies the absolute risk of coronary death,
and provides the risk through a table format allowing for printed copies to be easily
accessible when calculating risk.72 Reflecting technologic advancements, there has been
a recent trend to program risk prediction models as either mobile phone or tablet apps, or
providing web-based models that could easily calculate a person’s risk of health
outcome.53 One model predicting risk of death at 14 days, and for risk of death or severe
disability at 6 months after traumatic brain injury was developed; the authors chose to
present the model as a web-based tool with predictors that are easily identifiable.73
Another model predicting an infant’s risk of childhood obesity is available as a mobile
phone application.74 Offering multiple formats provides options for physicians in terms
of their own personal preferences, potentially easing their implementation, allowing these
tools to help inform decision making and ultimately affect patient outcomes.48,75
2.3.2

Validation studies

The literature pertaining to prediction model research heavily favours model development
studies, with a comparatively small number of studies assessing validation despite the
importance of assessing model generalizability.37 Further, though numerous guidelines
detailing model development have been published, guidelines pertaining to the
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appropriate methodology for validation or impact analysis are scant.76 Most risk
prediction models are found to be less accurate when used in new populations, possibly
due to inadequate model development, or differences between the development and
validation populations.37,77 Despite the models potentially being internally valid, they
should still be tested or validated in new individuals before implementation in guidelines
or application in practice to ensure their predictive accuracy.48
Validation studies pertain primarily to the external validation of the model. Though
internal validation, or assessing the accuracy of the model within the development
dataset, is equally important to the development of the model, external validation takes
the developed model with the same predictors and assigned weights and is applied to
external datasets, which provide the heterogeneity necessary to mimic real life
applications to determine the model’s predictive performance.37,33
There are generally three forms of external validation: 1) temporal, 2) geographical, and
3) domain validation (Table 2).33 Geographical and domain validation tend to be more
robust forms, taking drastically different populations within which to examine the
performance of the model, compared to temporal validation, which remains within the
same institution from which the model was developed.
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Table 2. Forms of external validation conducted in prediction model studies. Adapted
from Moons et al.33
Type of Validation

Description

Temporal

External validation conducted on individuals from the
same institution in a different time period. There generally
is not any crossover of data from the development dataset
and the validation dataset. It can be conducted through
non-random splitting of the existing dataset based on the
moment of inclusion, but reduces the amount of data used
for development, with greater similarities between the
development and validation populations. It can be
conducted by collecting data prospectively for the purpose
of validation after model development as well.

Geographical

Geographical validation examines the transportability of
the model to different institutions or countries, often
applying different inclusion or exclusion criteria as well as
different methods of measuring predictors in those
populations compared to the development population.

Domain

Domain validation is an extension of temporal or
geographical validation, where the validation population
differs greatly from the development population. An
example of this would be assessing the predictive
performance of a model for CVD that was developed in a
healthy population amongst individuals with type 2
diabetes mellitus.

2.3.3

Impact analysis

Impact analysis or model impact studies determine whether or not the model: 1) is
actually used by physicians; 2) guides clinical decision making; 3) modifies behaviour;
4), improves clinically relevant processes; or 5) reduces costs.37,33 Indeed, physicians
will be unlikely to use risk prediction models to inform their decision making without the
evidence to support the effectiveness of models, which would be analogous to prescribing
drugs on the basis of in vitro testing alone.75 Validation and impact analysis have
different goals, and therefore different study designs. Validation studies are preferably
conducted on a cohort of individuals with a specific set of inclusion and exclusion criteria
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applied, whereas impact studies require a comparator population.48,78 In other words, the
two groups assessed in impact studies are generally those who receive an estimated risk
score (intervention) and those who do not (control).33 At present, there are no formal
guidelines for the conduct of impact analysis studies; however, there are suggestions for
how to assess the impact of the use of models on clinical practice.
The provision of information is the source of the first categorization of model impact
studies; is any information in addition to the estimated risk provided? Two approaches
exist: directive and assistive.33,37,78 In the assistive approach, the probability of outcome
is the only generated information, while the directive approach is more suggestive,
providing treatment recommendations in addition to the absolute risk.48,79 The assistive
approach is considered more respectful of physician judgment and autonomy allowing for
greater interpretation of the patient’s risk and subsequent treatment decisions, although
the evidence suggests a greater effect is found through the directive approach.78,80
Comparisons between groups, namely the intervention and control groups, are
scientifically strongest when the study design is a randomized trial.48 A variant, the
cluster randomized trial where the unit of randomization is the clinic or hospital, may be
preferable to avoid contamination, or a learning effect where the physician alternately
applies and does not apply the model in alternating patients, as well as the possibility for
exchange of information between physicians at a single centre.37,81
Non-randomized studies, such as pre-post studies, can be conducted as an alternative to
randomized studies, which can be time-consuming and costly.33 For example, the impact
of the Ottawa ankle rule, a diagnostic risk prediction model assessing for risk of fracture
amongst patients experiencing ankle and foot injuries, was assessed using a pre-post
study.82,83 Where the outcome of interest does not require long-term follow-up, such as
the decision making of physicians, a cross-sectional study can suffice to capture decisions
immediately upon provision of the patient’s absolute risk.33
Appropriate conduct of model impact studies can prove to be vital to the uptake of risk
prediction models in clinical practice, ensuring that (validated) models help guide
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treatment decisions, affect the behaviour of both physician and patient, and improve the
long-term health of patients assessed for absolute risk.
2.4

Terminology

The terminology used in the study of risk prediction models is varied with many names
used to describe the same basic tool.84 Risk prediction models are often operationalized
dependent on their function, presentation, or setting, which is where much of the
ambiguity resides. This section presents a list of terms commonly used for risk
prediction models as well as poses reasons for their distinction.
Regression models that apply to health outcomes are denoted as prediction models, the
root term used for these tools.77 Prediction models generate an individual’s risk, creating
the amalgam of risk prediction model.84 The addition of the term ‘risk’ can be considered
unnecessary, as models usually only provide a probability as their output, hence they are
often simply referred to as prediction models in the literature. The term clinical
prediction model can also be used, and is contingent upon the setting, specifically a
clinical setting.52 Clinical prediction models are thus tools or rules derived from
systematic clinical observations, with the intention of assisting physicians in identifying
patients who require diagnostic tests, treatment, or hospitalization.46
One commonly used set of adjectives is dependent on the function of the output. In this
instance, whether the model predicts the risk that a person has the health outcome or will
develop the health outcome over a prespecified period of time warrants the addition of an
adjective to the root term: diagnostic or prognostic prediction model.30,33,56 The inclusion
of either adjective can specify the temporal function of the model.
There exist a few terms that focus on the multivariable model created to derive the
projected risk. These terms include risk algorithm, risk function, and risk equation,
among others.85–88 More attention is directed to the statistical relationship between the
predictors and the outcome and how they can, in turn, generate a predicted risk. 52,89
These terms do not address the presentation of the model, such as whether the risk is
presented in nomogram format or icon arrays, for example.
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Conversely, terms pertaining to the presentation of the model exist as well. These terms
include risk chart, risk score, risk calculator, risk engine, and score cards.86,87,90,91,92
Risk charts and risk scores are both tools that simplify the derivation of absolute risk.
Risk scores, as previously mentioned, are simplifications to the calculation of the
patient’s absolute risk, attributing points for each predictor, with the summed total points
corresponding to the absolute risk of outcome.67,71 Risk charts, conversely, simplify the
process by providing a visual aid where absolute risk is presented based on the values of
predictors.86 Though they may both simplify the process, risk charts are absolute global
risks derived from combinations of classes of risk factors, whilst risk scores are more
precise evaluations derived from absolute global risks calculated by continuous levels of
risk factors.93 Risk scores can be depicted in a visual fashion through the use of score
cards, which provide the score associated with absolute risk on individual cards with
each card pertaining to a combination of classes of predictors.94
Risk calculators are tools that make risk prediction models accessible to broader
audiences.89 Risk prediction models at their core can be difficult to understand; the
simplification of the model to a more user-friendly format can ease their implementation
in practice. Risk calculators allow for healthcare providers to easily input the predictor
values, automatically generating the estimated risk of outcome. In essence, they are
standalone tools that can be electronic or paper-based.95
Risk engines are similar to risk calculators in terms of simplifying the calculation of risk.
They are often used to describe a relationship through the use of technology, such as the
development of mobile phone applications or web-based tools that calculate risk upon
input of predictors.96 One of the more prominent examples is the UKPDS Risk Engine, a
model that predicts coronary heart disease amongst patients with type 2 diabetes, using a
web-based automated calculation format.97,98
This series of terms is by no means exhaustive, but does provide an overview of the most
commonly used terms. Despite the wide range of terms used in the field of prediction
model research, they exist to describe the same basic tool with the same goal: to provide
an accurate measure of risk of health outcome in patients based on the use of predictor
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variables.52 As such, a potentially more useful method of understanding prediction
models is to provide an overarching classification under which models can be
categorized.
2.5

Classifying risk prediction models according to their dominant characteristics

As previously seen, there exists numerous disparities in how researchers refer to risk
prediction models. As such, it may be more useful to focus on a few key characteristics
that define these tools rather than focusing on the terminology.
There are four primary ways that risk prediction models in present use can be classified
(Figure 1). The classifications were selected because they encompass all existing
prediction models in use. Note that the four peripheral nodes in the figure are not
mutually exclusive of one another; rather, each risk prediction model can be classified
according to one or more categories.
2.5.1

Temporality

All risk prediction models can be viewed through the lens of temporality. As previously
described, they can be dichotomized as being prognostic or diagnostic, depending on
whether the prediction is for a health outcome that is present or will occur in the future.
Given that all risk prediction models calculate the risk for an outcome occurring,
applying the concept of temporality on this outcome-dependent categorization provides
an irrevocable measure of classification.
2.5.2

Type of outcome

Risk prediction models can also be classified according to the outcome for which they
predict risk. Prediction models apply to several fields apart from medicine, including
physics, meteorology, and astronomy.30 When applied to medicine, they can be
developed for several different health outcomes, including both acute and chronic
conditions. One systematic review sought to synthesize all studies assessing the accuracy
of tools predicting fracture risk, an acute outcome, such as the FRAX score, identifying
13 unique tools in 45 different studies that met their inclusion criteria.99,100 Chronic
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health outcomes, such as breast cancer, have been predicted quite extensively; one
systematic review and meta-analysis identified 17 unique breast cancer models.101
Indeed, given that all risk prediction models predict for at least one outcome, we can
group models according to the nature of the outcome they seek to predict.
2.5.3

Setting of use

Risk prediction models can also, albeit to a lesser extent, depend on the setting of most
appropriate implementation. Though many models apply to a primary care setting, such
as most cardiovascular prediction models, a number apply to secondary and tertiary care
settings.24 For example, the miniPIERS risk prediction model is used in tertiary care
settings to identify pregnant women at increased risk of death or complications due to
hypertension.102 Some overlap exists; the CHAD2 score, a prediction model assessing
for risk of stroke, can be used in primary or tertiary care settings.103 These tools may also
be used in non-clinical settings. There is a growing trend towards publishing prediction
models online, allowing members of the general public to calculate their risks of health
outcome in the comfort of their own homes.104 However, the models published online are
typically less invasive and rely on more easily discernable risk factors, such as age or sex.
2.5.4

Format of presentation

Lastly, there are only a limited number of ways that clinicians can use a prediction model
to ascertain the absolute risks of their patients. As such, the format of the risk prediction
models can be used as another method of categorization. The two primary subgroups
here would be whether the tool is used as either a paper- or electronic-based one. Within
each group would fall the various specific risk prediction models, such as risk tables or
charts, or risk engines, depending on the medium through which they are used. As such,
one could see the most popular methods of delivery, allowing for the potential to
determine if one is more effective than others.
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Figure 1. The four proposed methods of classifying risk prediction models.
2.6

Conclusion

Prediction models are becoming a common mainstay in clinical settings, being
recommended by health policy makers and clinical guidelines globally. They provide an
objective, evidence-based measure of patient risk of health outcome, and are capable of
informing physicians and patients in making impartial judgements regarding patient
management, potentially reducing the burden of disease faced by populations globally.
Though the literature may be inconsistent in its terminology, agreement regarding the
intended purpose of risk prediction models is consistent across studies, providing a strong
basis for the independent examination of the impact of prediction models.
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Chapter 3
3.0

Introduction

This chapter presents background information regarding chronic disease and the primary
health care setting, particularly as they relate to the focus of this thesis. The literature
regarding the role of risk prediction models in primary prevention, and more broadly in
clinical practice, is explored. This is followed by a description of the rationale for the
study as well as the study objectives.
This chapter explores the literature surrounding features associated with risk prediction
models. It begins with an assessment of the term chronic disease as it has been used in
the literature and for the purposes of the systematic review and meta-analysis. Next will
be a description of primary care settings, the setting within which most preventative
measures against chronic diseases are applied. Following is an exploration of the role of
risk prediction models in terms of primary prevention, as well as reasons for their
possible underuse in clinical practice. To close, the rationale for the study as well as the
study objectives will be outlined.
3.1

Chronic disease

The burden of chronic diseases is vast and increasing rapidly globally. Though reporting
differs dependent upon the source, it has been estimated that in 2001, of the 56.5 million
total reported deaths, approximately 60% were attributed to chronic diseases, increasing
to 68% in 2012.4,105 By 2020, projections indicate that approximately 75% of deaths will
be attributed to chronic diseases.106 The reported prevalence amongst Canadians range
from one in five to one in three living with a chronic disease, with up to four in five
Canadians having at least one modifiable risk factor, such as tobacco smoking, poor diet,
sedentary lifestyle, and harmful alcohol consumption.4,5,107 Though a century ago,
infectious diseases were the eminent causes of mortality, an epidemiologic transition has
occurred in recent years, with chronic diseases dominating the landscape of illness
worldwide.108,109,110 Chronic diseases represent the largest cause of mortality nationally
and internationally, a trend that will continue for the foreseeable future.
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3.1.1

Chronic disease definitions

The term “chronic disease” is etymologically simple, with implications of temporality
and of illness. However, there is lack of a consistent definition for chronic disease.
Indeed, the lack of consistency in key definitions poses a barrier to the prevention and
mitigation of any chronic condition, as it reduces the ability to measure them
effectively.111,112
Researchers often create their own unique definitions to examine chronic diseases or
chronic conditions. One study examining out-of-pocket expenditures for chronic disease
management chose to define chronic conditions as, “…a person…having a chronic
condition if that person’s condition had lasted or was expected to last twelve or more
months and resulted in functional limitations and/or the need for ongoing medical
care.”113 To compile a list of specific chronic conditions, the researchers established a
panel of ten physicians to judge whether the International Classification of Diseases,
Ninth Revision (ICD-9) codes met their definition, resulting in 177 codes being classified
as chronic conditions in adults.113
One systematic review sought to provide an overview of all definitions used for chronic
conditions in children in an effort to establish the prevalence of chronic health conditions
in that population.114 The most frequently used terms were chronic conditions, chronic
health conditions, chronic illness, and special health care needs. Four core definitions
were identified, though not all included articles (64) adhered strictly to these (Table 3).
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Table 3. Four most frequently used definitions of chronic conditions (for children).
Adapted from van der Lee et al 2007.114
Source

Year

Term

Definition

Pless &
Douglas115

1971

Chronic
illness

“A physical, usually nonfatal condition that
has lasted longer than 3 mo in a given year or
necessitated a period of continuous
hospitalization of more than 1 mo; of
sufficient severity to interfere with the child’s
ordinary activities to some degree.”

Perrin et al.116

1993

Chronic
“A condition is considered chronic if (1) it has
health
lasted or is expected to last more than 3 mo
conditions and (2) the definition takes into account the
impact of the condition on the child, e.g., level
of functional impairment or medical need
greater than expected for a child of that age.”

Stein et al.117

1993

Chronic
“Conditions must have a biological,
health
psychological, or cognitive basis; have lasted
conditions or are virtually certain to last for 1 y; and
produce ≥ 1 of the following sequelae: (1)
limitations of function, activities, or social role
in comparison with healthy age peers in the
general areas of physical, cognitive,
emotional, and social growth and
development; (2) dependency on 1 of the
following to compensate for or minimize
limitations of function, activities or social role:
medications, special diet, medical technology,
assistive device, or personal assistance; and
(3) need for medical care or related services,
psychological services, or educational services
above the usual for the child’s age or for
special ongoing treatments, interventions, or
accommodations at home or in school.”

McPherson et
al.118

1998

Children
with
special
health
care
needs

“Children who have or are at increased risk of
a chronic physical, developmental, behavioral,
or emotional condition and who also require
health care and related services of a type or
amount beyond that required by children
generally.”
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Of particular interest is the change in definitions presented over time, demonstrating the
plasticity of the definition and its non-uniform use over time and amongst researchers.
The earliest definition devised in 1971 addressed longevity and its impact on daily
activities, with later definitions addressing the child’s health care needs and functioning,
as well as eventually addressing children at risk for conditions.115,116,117,118
Medicare, the largest health insurance program in the United States, has established their
own categorizations of diseases. Medicare provides health insurance to approximately 40
million beneficiaries amounting to an annual spending exceeding 200 billion USD,
placing an enormous financial responsibility on Medicare managed care and other
capitated programs.119 To ensure the appropriate allocation of benefits, a health-based
Medicare capitation system was adopted creating a diagnostic classification system.119
This system aggregated over 15,000 ICD-CM codes (International Classification of
Diseases, Ninth Revision, Clinical Modification) into 70 Hierarchical Condition
Categories (HCC). For example, the HCC “Acute Liver Failure/Disease” includes the
ICD codes for “Viral Hepatitis, Acute or Unspecified” and “Hepatic Coma”.119
The Centers for Disease Control and Prevention also compiled a list of select definitions
of chronic diseases representing the definitions used in settings including academia and
the government (Table 4).111
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Table 4. List of commonly used definitions for chronic diseases. Adapted from
Goodman et al 2013.111
Source

Year

Definition

Hwang et al.113

2001

“We defined a person as having a chronic condition if that
person’s condition had lasted or was expected to last 12 or
more months and resulted in functional limitations and/or the
need for ongoing medical care.”

Bernstein et al.120

2003

“A chronic disease or condition has 1 or more of the following
characteristics: is permanent; leaves residual disability; is
caused by nonreversible pathological alteration; requires
special training of the patient for rehabilitation; or may be
expected to require a long period of supervision, observation,
or care.”

Friedman et al.121

2008

“Chronic condition is defined as a condition that lasts 12
months or longer and meets 1 or both of the following tests: 1)
it places limitations on self-care, independent living, and
social interactions; and 2) it results in the need for ongoing
intervention with medical products, services, and special
equipment.”

National Center for
Health Statistics122

2011

“A health condition is a departure from a state of physical or
mental well-being. In the National Health Interview Survey,
each condition reported as a cause of an individual’s activity
limitation has been classified as chronic, not chronic, or
unknown if chronic, based on the nature and duration of the
condition. Conditions that are not cured once acquired (such
as heart disease, diabetes, and birth defects in the original
response categories, and amputee and old age in the ad hoc
categories) are considered chronic, whereas conditions related
to pregnancy are not considered chronic. Other conditions
must have been present for 3 months or longer to be
considered chronic.”

McKenna and
Collins123

2010

“They are generally characterized by uncertain etiology,
multiple risk factors, a long latency period, a prolonged course
of illness, noncontagious origin, functional impairment or
disability, and incurability.”

World Health
Organization3

2017

“Noncommunicable diseases, also known as chronic diseases,
are not passed from person to person. They are of long
duration and generally slow progression.”
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Universal within these definitions are the concept of longevity, ranging from greater than
three months to greater than twelve months to a permanent affliction. Some incorporate
aspects of impairment, others mention the need for ongoing medical care, whilst others
still place emphasis on communicability, or rather, lack thereof. Some of these concepts
are in contradiction with one another. For example, human immunodeficiency virus
(HIV) infection has in recent years, due to the advent and introduction of combination
antiretroviral (ART) therapy, prolonged life in HIV-infected patients by a measure of
decades.124 As such, due to its lengthy duration and the need for medical products (ART
therapy), it would meet the Friedman definition of chronic diseases.121 However, due to
its certain etiology and its contagious origin, it would fail to meet the McKenna and
Collins definition.123 In other words, there exists no consistent universal definition of
what comprises a chronic disease.
3.1.2

Chronic disease definition used in thesis

In recognition of this lack of consistency, a different approach was chosen for this
systematic review. Rather than taking an approach similar to Hwang et al.113, for
example, where potential chronic diseases were vetted by physicians, this systematic
review chose to focus on overarching categorizations of chronic diseases. The method
used by Hwang et al. takes a top-down approach where characteristics of what constitute
a chronic disease are applied to specific diseases in order to decide amongst a panel of
individuals whether they are classified as chronic. This process is prone to bias and is
time-consuming given the enormity of conditions or diseases that may be considered
chronic. Instead, the World Health Organization (WHO) categories of chronic disease
were used herein.
The WHO recognizes four main types of chronic diseases (referred to as
noncommunicable diseases, or NCDs, by the WHO), which are: 1) cardiovascular
diseases, 2) cancers, 3) chronic respiratory diseases, and 4) diabetes.125 In 2012, 56
million deaths occurred globally, with 38 million of those as a result of NCDs; 82% of
these were attributed to the four aforementioned NCDs.126 The broadness of these
categories, their large rates of morbidity and mortality, and the fact that they make up a
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sizable majority of diseases, make this system of classification more feasible and
practical for the conduct of this systematic review.
3.1.3

How does risk prediction modelling apply to chronic diseases?

Previously when the types of diseases that affected populations were of a primarily
infectious nature, such as diarrheal diseases, applicable risk factors, commonly referred to
as “traditional risks”, were undernutrition, unsafe sex, unsafe water, poor sanitation and
hygiene, and indoor smoke, and were often associated with low-income populations.109
However, with the epidemiologic shift towards chronic diseases and away from
communicable diseases, there has been a corresponding shift in the prevalence of
different risk factors.127 The leading global risks for chronic diseases are high blood
pressure, tobacco use, alcohol use, high blood glucose, physical inactivity, high
cholesterol, and overweight/obesity.109,127,128
As a relatively small number of risk factors can cause or are predictive of several chronic
diseases, and may interact in their impact on the risk of disease, the attributable risk of
individual risk factors add up to more than 100%.109 Otherwise, the assumption would be
that each case of disease has but a single cause, and that multiple risk factors cannot
cause the same case of disease.109,129 This makes it difficult to quantify the impact of
single risk factors on an individual’s absolute risk of disease. This lends credence to the
concept of targeting the absolute risk of chronic disease for intervention as opposed to
individual risk factor levels.22,130,131 Risk prediction models account for the additive and
interactive effects of predictors, where they exist, on the absolute risk of disease,
providing an objective measure for physicians and patients to target for intervention.45,132
For example, the Harvard Cancer Risk Index assesses for a person’s risk of 12 forms of
cancer, including lung, breast, and colon cancer.133 Epidemiologic investigation revealed
a set of risk factors, including: sex, age, height, weight, medication use, medical history,
diet, physical activity, family history, and prior screening. Using this knowledge of the
effects of risk factors and their synergistic effect, an objective measure of cancer risk can
be determined, allowing for multitargeted interventions to reduce the absolute risk.133
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These known relationships between both modifiable and non-modifiable risk factors
allow for the prediction of the development of chronic diseases in individuals.
3.2

Primary care settings

The Declaration of Alma-Ata of 1978, adopted at the International Conference on
Primary Health Care, stated the goal of the WHO and United Nations was to achieve,
“Health for All by 2000,” positioning primary health care as the strategy to achieve their
goal.134,135 The role of primary health care was to ensure equitable provisions of quality
health services to all persons in an efficient, sustainable, and universal manner.135 It was
considered the most effective strategy to ensure health for all was obtainable, and was
grounded upon a set of principles including universal access, addresses the movement
toward health equity, and the intersectoral approach to health.134,136 However, despite
primary care taking the foremost role in achieving equitable global health, dependent
upon the setting, it can stand to mean something quite different. For instance, in areas
with higher levels of healthcare accessibility (i.e. high- and middle-income countries),
primary health care can be viewed as the first level of care; conversely, where challenges
in accessibility are highly prevalent (i.e. low-income countries), it can be viewed as a
system-wide approach.136
It can thus be useful to view primary care as a set of activities as well as a set of
principles. In terms of the activities engaged within primary care are the delivery of firstcontact medicine, the assumption of longitudinal responsibility by practitioners for the
patient, as well as responsibility of health (defined as the complete physical, mental and
social wellbeing and not merely the absence of disease or infirmity) within the limits of
health personnel.136,137 Primary care can be condensed to its four essential components:
first contact, longitudinality, comprehensiveness, and coordination.137
3.2.1

Primary care as an avenue for prevention

The functions of primary care are enormous, providing a wide spectrum of services
ranging from acute and chronic health care to preventive care and health promotion.138
As the point of first contact for patients with the health care system, primary care seeks to
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coordinate use of other levels of care (secondary and tertiary, respectively), making
arrangements with specialists where necessary.137,138 The varying levels of care represent
different functions; where primary care physicians, for example, are considered
generalists, resource and knowledge constraints may necessitate a referral to a specialist
with a higher degree of skill in a particular area of medicine.137
On the other hand, specialized care often receives “sicker” patients, and thus the
emphasis of care is to sustain life in the ill individual.137 As such, little emphasis is
placed on the prevention of disease onset in specialist settings, while comparatively, a
greater amount of energy is dedicated to the prevention of illness in primary care.137,139
As such, the primary care physician plays an integral role in the prevention of disease.34
Continuity of care, or longitudinality, is more likely to occur in primary care settings,
which has been associated with a greater use of preventive services, compared to
different subspecialty practices, which see more first-time patients.137,140,141,142 Indeed, in
one study examining factors associated with preventive services, having a regular place
of care was most associated with receipt of preventive care when adjusted for
demographic and financial characteristics as well as health status.140 A larger percentage
of visits to primary care practices are related to prevention when compared to more
specialized care.137 As a result of its very nature, primary care settings are well
established to help prevent the onset of chronic disease.
3.3

Risk prediction models as a tool for prevention

Risk prediction models have the potential to play an integral role in prevention. Within
the constructs of public health and healthcare in general, prevention is often segmented as
either primary, secondary, or tertiary prevention, categorizations that pertain to the state
of disease or injury. Secondary and tertiary prevention aim to reduce the impact of
disease or injury either early in its course (secondary) or when it is already established
(tertiary).143 Conversely, primary prevention aims to prevent disease or injury in healthy
individuals.143,144
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Two options exist when addressing primary prevention: 1) the “population-based”
approach, where preventive actions are generally applied to groups of people, and 2) the
“high risk” approach, where interventions are targeted to those at highest risk of
developing the outcome.145,146 Primary prevention in a healthcare setting seeks to
identify high risk individuals, thereby allowing the targeting of interventions to those
who would benefit greatest.93,147 Given the limited preventive resources available, taking
a high risk approach and allocating those resources to high risk individuals can
potentially enable the greatest reduction in adverse events for patients treated in primary
care.148 This can provide a complement to a public health approach where interventions
are generally ‘targeted’ to the population.149
Due to the enormous burden of disease-related morbidity and mortality associated with
chronic diseases, their primary prevention is of high importance.150,151 As the patient’s
medical “home”, primary care is well-positioned to prevent the onset of these diseases
through the provision of evidence-based preventive care.147,152 Though time constraints
reduce the ability of primary care physicians to recommended preventive services to their
patients, within the present construct of medical care, primary care settings still play an
important role in primary prevention.153 Indeed, numerous national guidelines suggest
implementation of preventive services in primary care. The National Health Service in
the United Kingdom, for example, recommends that primary prevention for CVD occur
in primary care.154
The interventions employed in primary care settings for the primary prevention of
chronic diseases should be cost-effective, practical, possible, and positively affect risk
status and outcomes.155 For example, tobacco cessation can be promoted through brief
counselling and cessation advice, which may result in a lifestyle modification, ultimately
reducing the patient’s risk of several chronic diseases.155,156 Pharmacotherapy may
indicated for the prevention of cardiovascular disease and type 2 diabetes.155,157 Any
number of interventions may be used in primary care settings dependent upon the
resources available and the disease outcome of interest.
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Numerous guidelines have been published with the goal of preventing the onset of
chronic diseases. Several of these recommend the usage of risk prediction models to
predict patients’ absolute risk of developing chronic diseases. Guidelines published by
the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom,
the American Heart Association (AHA) in the United States, the New Zealand Guidelines
Group (NZGG) in New Zealand, and the Canadian Cardiovascular Society (CCS) in
Canada, amongst several others, each recommend the assessment of absolute
cardiovascular risk using a risk prediction model.158,159,160,161 Given that these tools can
stratify patients, determining who is at greatest risk for chronic disease, they can provide
appropriate and objective guidance to assist in the prevention of disease.
3.4

Intended effects and explanations

Despite the numerous recommendations to incorporate risk prediction models in clinical
practice, few studies have assessed whether they have an effect.78,162 Risk prediction
models are intended to guide clinical decision-making and patient management, such as
conducting additional testing, issuing prescriptions, as well as informing patients of their
risk of outcome.48 They are not intended to replace physicians, but to complement and
assist their clinical judgment.48,163 When appropriately applied and interpreted, physician
judgement of clinical information can be made more accurate and efficient.164 The
Evidence-Based Medicine Working Group stated that risk prediction models can,
“…change clinical behavior and reduce unnecessary costs while maintaining quality of
care and patient satisfaction.”162
Risk prediction models provide an absolute measure of risk for outcomes. In doing so,
they reduce the amount of uncertainty faced in medical practice by making apparent and
evident the impact of clinical findings on long-term risk.164 This is in contrast to the use
of clinical experience, whereby intuition, a more subjective method of evaluation, is the
final arbiter of medical decision-making.162 Though clinical judgment through use of
heuristics may sometimes provide an accurate measure of absolute risk, statistical models
are capable of integrating data quickly and accurately, providing an objective measure.165
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The implementation of risk prediction models can assist in shared decision-making.
Shared decision-making is defined as: “…an approach where clinicians and patients share
the best available evidence when faced with the task of making decisions, and where
patients are supported to consider options, to achieve informed preferences.”166 Risk
prediction models can be used as shared decision-making tools. Shared decision making
tools are intended to foster a consideration of the risk, benefits, and trade-offs associated
with a decision, and the way in which a patient’s preferences are incorporated into the
discussion and decision process.167,168 In this fashion, there can be improvements in risk
communication and objective discussions between physician and patient, allowing
patients to participate informedly in shared decision-making.169
The information provided to patients by physician and model can improve risk
perception, and with increased risk perception, there is the possibility of associated
behaviour change. The ‘teachable moment’, an event or circumstances leading persons to
alter their behaviour, can promote health behaviour change in numerous settings.170
Medical procedures, such as cancer screening, have been posited to constitute a teachable
moment.171 Teachable moments may also be created by physicians rather than waiting
for an unpredictable opportunity, leading to patient activation, or instilling in patients the
knowledge, skills, and confidence to effectively manage their health.172,173 Though
analogous, the provision of personalized risk estimates may constitute a teachable
moment, providing patients with the knowledge associated with their health thereby
improving their risk perception. In this fashion, patients may thus feel more confident in
their ability to improve their long-term risk of disease.
3.5

Barriers to model usage in clinical practice

Though model usage in clinical practice is often recommended in clinical guidelines,
evidence suggests that practitioners often do not adhere to guideline recommendations.
One study of Belgian general practitioners found that 53% of participants reported having
never used a tool for global cardiovascular risk assessment, with 80% of participants
erroneously believing total cholesterol is an accurate proxy for cardiovascular risk.174
Further, it has been noted that physicians often take poor account of increasing age and
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other risk factors, indicating there is a need for models to help in the assessment of
risk.175
Numerous reasons have been given for why models are not used in clinical practice.
Some physicians experience a lack of belief in the risk estimates, fearing that they do not
account for other factors that are crucial, while others believe they are more capable of
estimating the global risk without the model.176 Some physicians believe models
overpredict CVD risk because of these models were developed using older data.177,178
One study examined automated prompts to conduct risk assessments, which led to what
they referred to as “prompt fatigue”, or a form of clinical inertia where physicians failed
or refused to answer computerized prompts despite recommendations to do so.179
Others still cite a lack of time or lack of physician knowledge and training as key reasons
for their lack of use.180 It is possible that the use of educational interventions targeted at
physicians could increase the uptake of risk prediction models in clinical settings. One
study examining the impact of a continual medical education session training general
practitioners on the use of global cardiovascular risk found that trained physicians used a
tool to assess risk more often than untrained physicians (76% vs. 52%).181
Even with the use of risk prediction models, adherence to treatment guidelines based on
risk stratification remains poor. One examination of the CHA2DS2VASc tool, a model
predicting the risk of stroke in patients with atrial fibrillation, found that low-risk patients
were being treated with warfarin, an anticoagulant, despite a lack of evidence regarding
its clinical benefit.182 The misinterpretation of generated outputs from risk prediction
models may be to blame, with some studies demonstrating that physicians experience
some difficulties with statistical concepts.183
The presentation of risk may or may not have an impact on outcomes. For example, one
study conducted in the United Kingdom assessed for changes in prescribing patterns and
changes in risk factor levels following the presentation of risk as either an absolute risk
level or a number needed to treat, and found no differences between the two groups.184
Some clinicians have called for the number needed to treat (NNT) to be presented as well
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to improve the dialogue between physician and patient, though they recognized that
individual patients may not understand the concept.177
Several barriers exist preventing the uptake of risk prediction models in clinical practice.
Though these factors are not necessarily insurmountable, they provide a greater
understanding of the issues faced by physicians when presented with novel tools for use,
as well as areas for interventions to increase their uptake.
3.6

Study rationale and objectives

There is a growing body of literature surrounding risk prediction models. Though a
negligible number of studies with the terms ‘prognostic model’ or ‘prediction model’
were found dating from the 1970s and 1980s, an exponential increase has occurred in
recent years, with well over half a million studies identified in the year 2005.30 This
increase in literature parallels the growing movement towards evidence-based medicine
and the corresponding incorporation of risk prediction models in clinical
guidelines.34,96,185 Further, the Cochrane Collaboration has recently developed reporting
guidelines for prediction modelling studies, which could help shape the conduct of future
research and reporting.60
However, a lack of evidence and poor reporting remain prevalent in the realm of
prediction model research.12,186 Despite numerous tools being available, few are used in
clinical practice, indicating physicians may lack confidence regarding model usage for
preventive patient management.186 Though risk prediction models have been
recommended for use in clinical practice by several guidelines to calculate the absolute
risk of several chronic health outcomes, it has been suggested that physicians fail to use
them consistently when indicated. Their implementation and use should help guide
physician’s behaviour, thus affecting patient behaviour, and ultimately showing an
improvement in patient health outcomes.187
The recent paradigm shift towards evidence-based medicine provides one potential
reason for their underuse. Clinicians are recommended to evaluate the weight of the
evidence from which the guidelines are derived in keeping with the tenets of evidence-
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based medicine, and to examine whether the incorporation of models can affect a positive
change. At present, few impact analysis studies have been conducted, with no consensus
amongst clinicians and researchers regarding the impact of model use.188
Therefore, the objective of this study was to: conduct a systematic review and metaanalysis to assess whether or not risk prediction model use in primary care settings can
positively influence the prevention of chronic diseases. The study research question was:
What is the impact of chronic disease risk prediction model use in primary care settings
on: 1) physician behaviour, 2) patient behaviour, and 3) patient health outcomes?
In conducting this systematic review and answering the research question, uncertainties
regarding the third domain of risk prediction model research, or assessing the impact of
model use, would be addressed. Though a tremendous number of models for several
outcomes have been developed, the literature remains unclear regarding the impact of
model use on clinical practice. Answering this knowledge gap will help to inform the
future use and implementation of models, and may ultimately help to reduce the global
burden of chronic disease.
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Chapter 4
4.0

Methods

This chapter provides a detailed account of the steps undertaken in the conduct of the
systematic review and meta-analysis. The presented research study was conducted in
accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines, the Meta-analysis Of Observational Studies in
Epidemiology (MOOSE) Guidelines, and the CHecklist for critical Appraisal and data
extraction for systematic Reviews of prediction Modelling Studies (CHARMS Checklist),
developed by the Cochrane Collaboration Prognosis Reviews Methods Group.60,189
A systematic review aims to provide an unbiased answer to a specific research question
by collecting and synthesizing all evidence presently available in the literature that meet
an a priori specified eligibility criteria.190 This review seeks to answer: what is the
impact of chronic disease risk prediction models on physician behaviour, patient
behaviour, and patient health outcomes? Addressing the components of checklists such
as PRISMA allows for the reproducibility of the review by providing an explicit,
transparent methodology, including but not limited to the systematic search of the
literature, or assessments of the validity of findings through means such as a risk of bias
tool.190 Where possible, a meta-analysis may be conducted, which is a statistical
summary of the results of independent studies, therefore producing a more precise
summary estimate of the impact of healthcare interventions.190 The generation of figures
such as forest plots may allow readers to examine the consistency of the evidence and
provide insight into the differences between studies.
4.1

Search strategy

A search strategy was iteratively created in consultation with a research librarian. Search
terms were developed for the following databases: MEDLINE, Embase, the Cochrane
Library, CINAHL, and Web of Science. Additional e-sources were searched for grey
literature, specifically The Canadian Agency for Drugs and Technologies in Health
(CADTH), OpenGrey.eu, and ClinicalTrials.gov. Medical subject headings (MeSH),
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where applicable, and keywords were tailored to each database to ensure the
comprehensiveness of the search. The search was restricted to publications from 1976 to
2017, those in the English language, and those assessing human subjects. Four primary
concepts pertaining to the PICOS, or the types of Participants, the Intervention and
Comparison, the Outcomes, and Study design, of the research question to inform the
search strategy, specifically: 1) risk, 2) prediction model, 3) chronic disease, and 4)
primary care setting. The search terms used for the three databases using MeSH terms or
subject headings are included below in Table 5.
Table 5. MeSH terms and keywords used for Medline, Embase, and CINAHL.
Concept
Risk

Medline
Risk/ OR Risk
Factors/ OR Risk
Adjustment/

Embase
Risk/ OR Patient
Risk/ OR
Expectancy/ OR
Risk Factor/

CINAHL
(MH “Risk
Factors+”) OR
(MH “Health
Screening+”) OR
(MH “Patient
Assessment+”)

Keywords
Risk adj3
(adjust* OR
factor*) OR
Probabilit* OR
Likelihood

Prediction
models

Technology
Assessment,
Biomedical/ OR
Algorithms/ OR
Probability/ OR
Bayes Theorem/
OR Likelihood
Functions/ OR
Proportional
Hazards Models/
OR “Sensitivity
and Specificity”/
OR ROC Curve/
OR exp Decision
Support
Techniques/ OR
Area Under
Curve/ OR
Clinical
DecisionMaking/ OR exp
Risk Assessment/

Cardiometabolic
Risk/ OR
Cardiovascular
Risk/ OR
Coronary Risk/
OR Probability/
OR Reynolds risk
score/ OR
Framingham risk
score/ OR
CHADS2 Score/
OR
Cardiovascular
Disease
Assessment/ OR
PROCAM Score/
OR QRISK
Score/ OR
Multiple
Regression/ OR
Receiver
Operating
Characteristic/
OR exp Area
Under the Curve/
OR exp
“prediction and

(MH "Predictive
Value of Tests")
OR (MH
“Predictive
Research”) OR
(MH “Models,
Statistical”) OR
(MH “Decision
Support
Techniques+”)
OR (MH
“Decision
Making,
Clinical”) OR
(MH “Clinical
Assessment
Tools”) OR (MH
“Risk
Assessment”) OR
(MH “ROC
Curve”) OR (MH
“Regression+”)
OR (MH
“Survival
Analysis+”)

“Risk scor*”
OR
risk tool* OR
risk estimat*
OR risk assess*
OR risk
function* OR
risk equation*
OR risk calc*
OR risk scor*
OR risk
predict* OR
risk factor calc*
OR risk chart*
OR risk engine*
OR risk
appraisal* OR
prediction
model* OR risk
algorithm* OR
scoring*
method* OR
scoring
scheme* OR
roc curve OR
area under
curve OR AUC
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Chronic
disease

Primary care

forecasting”/ OR
survival
prediction/ OR
survival rate/ OR
exp decision
support system/
OR clinical
decision making/
OR medical
decision making/
OR medical
assessment/
Chronic Disease/ Chronic Disease/
OR
OR
Cardiovascular
Cardiovascular
Diseases/ OR exp Disease/ OR
Heart Diseases/
Heart Disease/
OR exp Vascular OR Vascular
Diseases/ OR exp Disease/ OR
Lung Diseases,
Lung Disease/
Obstructive/ OR
OR Chronic Lung
Diabetes
Disease/ OR
Mellitus/ OR
Chronic
Diabetes
Obstructive Lung
Mellitus, Type 1/ Disease/ OR
OR exp Diabetes Asthma/ OR
Mellitus, Type 2/ Diabetes
Mellitus/ OR
Insulin
Dependent
Diabetes
Mellitus/ OR Non
Insulin
Dependent
Diabetes
Mellitus/
Primary Health
Care/ OR
Comprehensive
Health Care/ OR
Continuity of
Patient Care/ OR
Patient-Centered
Care/ OR exp
General Practice/

Exp Primary
Health Care/ OR
General Practice/

OR c-statistic*
OR C index*
OR C indices*
OR hazard ratio

(MH “Chronic
Disease”) OR
(MH
“Cardiovascular
Diseases”) OR
(MH “Heart
Diseases”) OR
(MH “Vascular
Diseases”) OR
(MH “Lung
Diseases”) OR
(MH “Lung
Diseases,
Obstructive+”)
OR (MH
“Diabetes
Mellitus”) OR
(MH “Diabetes
Mellitus, Type
1”) OR (MH
“Diabetes
Mellitus, Type
2”)

Chronic
disease* OR
Chronic illness*
OR chronically
ill OR noncommunicable
disease* OR
cardiovascular
disease* OR
vascular
disease* OR
heart disease*
OR stroke OR
respiratory
disease* OR
asthma OR
COPD OR
chronic
obstructive
pulmonary
disease* OR
diabetes OR
diabetes
mellitus OR
diabetic
(MH “Primary
Primary health
Health Care”) OR care OR
(MH “Family
primary care
Centered Care+”) OR primary
healthcare OR
primary medical
care OR family
practice OR
family medicine
OR general
practi*
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To ensure the completeness of the search, backward and forward searching was
conducted, whereby backward searching was conducted through examination of included
articles’ bibliographies, and forward searching was conducted through use of Google
Scholar to determine where the article had been cited in the literature. Forward and
backward searching provides an additional opportunity to identify studies that fulfill the
eligibility criteria of the review that may not have been captured in the initial search.
4.2

Eligibility criteria

The eligibility criteria through which articles were screening (section 5.3) were selected
to align with the objectives of the study by identifying the key components associated
with the research question through adaptation of the PICOS framework.
4.2.1

Participants

There are two main groups of participants associated with the research question:
physicians and patients. The physician population applicable to the research question
were those practicing in primary care settings, which generally refers to family
physicians or general physicians. A preliminary search found that the type of physician
was not consistently specified in studies, so the criterion was expanded to include the
primary care setting. Specifically, a primary care setting was defined as the first point of
contact for patients into the health care system, and includes rural and urban general
practice clinics, either group or solo physician practices, as well as community-based
programs.
The second group of participants are the patients. Patients were not restricted by any
demographic characteristic, such as age or sex. Patients were required to be
asymptomatic for the disease outcome of interest at study intake, however, because to
assess a patient presenting with symptoms of the disease outcome for the risk of
developing the disease is unlikely when compared to alternative measures, such as the
conduct of diagnostic testing. Of most importance is that patients assessed were
appropriate for the prediction model assessed in each study.
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4.2.2

Intervention

The present study aims to assess the impact of risk prediction models, specifically the
provision of long-term risk of health outcomes as a result of risk prediction model use.
The intervention was restricted to prognostic—not diagnostic—models that predict for
the long-term risk of a chronic disease. The chronic diseases of interest were those that
fall under the four main categories of NCDs as per the WHO: CVD, cancers, diabetes,
and chronic lung diseases. Though there are several models that are diagnostic or assess
for non-chronic health outcomes, they were excluded in this systematic review.
Therefore, models assessing for the risk of behavioural, mental, or acute health outcome,
such as risk of sexually transmitted infections, risk of schizophrenia, or risk of fracture,
were excluded. The comparison group were patients who were treated without risk
prediction models.
4.2.3

Outcome

Three outcomes were assessed: 1) physician behaviour, 2) patient behaviour, and 3)
patient health outcomes.
1) Physician behaviour: any study that evaluated the impact of physician use of a
risk prediction model on either behavioural outcomes or health outcomes was
considered. The specific types of outcomes of interest were those with the
potential to impact the patient’s risk of developing a chronic disease. Therefore,
physician behaviours of interest include prescribing behaviours, provision of
lifestyle or dietary counselling, and referrals to specialists or other healthcare
providers.
2) Patient behaviour: behaviours of interest include fulfilment or dispensing of
prescriptions, medication adherence, lifestyle changes such as smoking cessation,
and dietary changes.
3) 3) Patient health outcomes: these outcomes were defined as risk factor levels,
absolute risk of disease, and event rates.
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Though examples of each outcome are provided, the examples only provided a measure
of guidance. Given the sparsity of studies assessing model impact and the differences in
methodology, specific outcomes not previously stated were independently assessed to
determine their eligibility to be classified as one of the three outcomes.
4.2.4

Study design

All study designs were considered including experimental, observational, and qualitative
designs. For experimental and observational studies, the design was considered
appropriate only if it contained a comparison group to provide a measure of risk
difference attributable to the intervention. Therefore, case studies and narrative reviews
were excluded. Pre-post studies were included for data synthesis as per the systematic
review, but were not considered appropriate for meta-analysis due to the lack of a control
group. Pre-post studies are used to demonstrate causality between an intervention and an
outcome; however, they are prone to errors such as regression to the mean or
confounding.191 Further, as per the statistical analysis plan (Section 4.5), the effect sizes
are generated by comparing the absolute change from baseline to follow-up between the
intervention and control group, allowing the final effect size to represent both the
direction and magnitude of effect. Studies were restricted to those published on or after
1976, the year the first prediction model was published.13 No geographic restrictions
were placed on the location of studies to ensure comprehensiveness of the search.
4.3

Screening

Citations identified from the search were imported into Covidence, a systematic review
software, which automatically eliminated duplicated articles, followed by a manual
search for duplicates.192 Two levels of screening were employed to identify studies that
met the prespecified eligibility criteria. The first level of screening was conducted by
two reviewers (PK, JB) independently through an assessment of the titles and abstracts of
the citations. Once the title/abstract screening was completed by both reviewers,
disagreements were reconciled through discussion of each conflict, with any unresolved
articles being reviewed by a third party (DL) to reach consensus. Studies that proceeded
to the second level screening were reviewed by two reviewers (PK, KN), who first
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conducted a pilot of 15 articles to ensure reliability, then completed the screening of fulltext articles with conflict resolution occurring upon completion. Any irreconcilable
conflicts were resolved by a third party (DL). The specific criteria by which articles were
screened derived from the eligibility criteria are listed in Appendix C.
4.4

Data extraction

Data were extracted from the complete list of included articles using a form based on the
Cochrane Consumers and Communication template.193 The Cochrane template
recommends that data be extracted according to seven categories: 1) general review
information, 2) methods of the study, 3) risk of bias assessment, 4) study characteristics –
participants, 5) study characteristics – interventions and comparisons, 6) study
characteristics – outcomes, and 7) data and results.193 The risk of bias assessment step
was conducted using an independent tool as the Cochrane template outlines bias
assessment items that are not applicable to observational studies. The data extraction
form was tested using three of the included studies. A panel of researchers reviewed the
results to ensure the comprehensiveness and appropriateness of the form. The form was
amended based on this feedback. Subsequently, data were extracted by one reviewer
(PK) from all the included studies using this form.
4.4.1

Items extracted

Items were extracted based on the seven categories outlined in the Cochrane template.
1) General review information: To identify the article and associated study. Items
extracted were DOI, author(s), year of publication, country, and name of study
where applicable.
2) Methods of study: To determine what methodology was employed per each study.
Items extracted for the methods of the study category included study objective(s),
study setting, and study design.
3) Risk of bias assessment: Data were not extracted specifically for risk of bias
assessment as a separate risk of bias assessment tool was used.
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4) Study characteristics were divided into three categories: participants,
interventions and comparisons, and outcomes.
a. Participants: Items extracted pertaining to the participants and
interventions were participant demographics including age and sex, as
well as all numbers pertaining to participants (e.g. number of participants
recruited, number of participants lost to follow-up).
b. Interventions and comparisons: Items extracted included the name of
prediction model used, health outcome of model, a brief description of the
intervention as well as any procedures in addition of the provision of
projected risk (e.g. dietary counseling, lifestyle recommendations).
c. Outcomes: The outcomes extracted were categorized into physician
behaviour, patient behaviour, and patient health outcomes. Both
qualitative and quantitative data were extracted. Information pertaining to
methods of outcome assessment (e.g. survey, face-to-face), methods of
follow-up, and frequency and length of follow-up were also recorded.
5) Data and results: Items extracted were dependent upon study design, though
generally provided the absolute numbers as opposed to relative measures where
possible to allow for accurate comparisons between studies in addition to mean
differences and standard deviations, where reported. For example, where an
outcome assessed for changes in systolic blood pressure, dependent on study
design, baseline and follow-up blood pressure in the intervention and control
group were recorded, in addition to standard deviations. Where available,
absolute changes in blood pressure with the corresponding standard deviation
were recorded. In the case of dichotomous outcomes, number of baseline and
follow-up events in both the intervention and control group were recorded in
place of risk or odds ratios. Further, where applicable, qualitative themes were
recorded in the data extraction form with notations denoting their location in the
original article.
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4.5

Statistical analysis plan

A meta-analysis was conducted to allow for the statistical synthesis of outcome data
presented in the identified studies. At its core, a meta-analysis is a statistical process
whereby the effect sizes of two or more studies may be combined, creating a summary
effect measure.194 This process is supported by weighting studies by placing greater
importance or impact on the summary effect on studies with relatively good precision.194
The analysis was completed using Stata v. 14.195
Firstly, the number of studies reporting on the same outcome measure was tallied; where
two or more studies reported on the same outcome, they were explored for numeric
similarities, which would allow for the calculation of a summary effect measure. When
conducting a meta-analysis for dichotomous data, the number of events and non-events
are required in order to calculate a measure of effect, such as an odds ratio or relative
risk. For continuous data, for each group, the sample size, mean value, and standard
deviation are required to calculate the standardized mean difference.
Where only proportions of binary data were reported, the number of new events was
calculated by subtracting the follow-up number of events from the baseline, while the
number of non-events was calculated by subtracting the total number of participants by
the number of new events. For continuous outcomes, where only baseline and follow-up
mean values were provided, with no measure of absolute change reported, it was
calculated by subtracting the follow-up value from the baseline value. The standard
deviation of the absolute change was calculated by imputing a correlation coefficient
value derived from studies reporting absolute changes in the continuous outcome into
equations provided by the Cochrane Handbook for Systematic Reviews of Interventions
and Borenstein et al.190,194
The calculated data were then inputted in Stata. For binary data, the two-by-two
contingency tables of each study were generated, whereas for continuous data, the
calculated sample sizes, means, and standard deviations of the absolute change were
imported. Using the metan function, forest plots, a visual representation of the magnitude

45

and direction of effect, were generated, as well as measures of uncertainty (i.e. 95%
confidence intervals).
For the binary data, the odds ratio was selected as the measure of effect. The designs of
studies included for meta-analysis were varied, and included case-control studies, where
the prevalence of the outcome of interest was artefactually created. Relative risks are
only appropriate where the true prevalence can be calculated, while odds ratios are robust
to fabricated prevalence rates, hence their selection to calculate a summary effect
measure.190
The calculation of a summary effect measure requires a distinction between fixed- and
random-effect models. Fixed-effect models assume that there is one true effect size
across all studies in the analysis, and that any differences between studies in terms of
observed effect is attributable to sampling error.194 The random-effect model,
conversely, assumes that the observed effect differs across included studies, and aims to
estimate the mean of this distribution.194 Fixed-effect models are generally considered
appropriate if all studies are essentially identical; however, the studies included for
analysis, though similar in terms of outcome, were performed in independence of one
another on varying populations, and thus an assumption of a true or common effect size
would be inappropriate.194 Therefore, a random-effect model was used to conduct the
meta-analysis to account for the heterogeneity between studies.
4.6

Risk of bias assessment

A risk of bias assessment was conducted using the Downs and Black tool, and checklist
assessing the methodological quality of randomized and non-randomized studies.196 The
Downs and Black tool consists of 27 items assessing the quality of five domains: 1)
reporting, 2) external validity, 3) bias, 4) confounding, and 5) power.196 The completion
of the checklist allows for the calculation of an overall, composite score for study quality,
but also scores for each of the five aforementioned domains.
The Downs and Black tool is one of the most commonly used numerical rating scales
with frequent application in systematic reviews, and is well-validated with a high degree
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of interrater reliability.197,198 Further, it is one of the few tools capable of assessing the
risk of bias of both randomized and non-randomized studies.197 Therefore, the Downs
and Black tool was selected to assess the risk of bias for studies included in this
systematic review.
The checklist was used for each of the 22 included studies. A cumulative summary score
was calculated by averaging the total scores derived from the checklist for each study.
However, a summary score is discouraged by the Cochrane Handbook, as it differentially
assigns a weight to different aspects of the checklist.190 Hence, a bar graph was
constructed to demonstrate the risk of bias in each domain.
Chapter 5
5.0

Results

Presented in this chapter are the results of the systematic review and meta-analysis. It
begins by describing the results of the study selection process, and the characteristics of
the included studies. The results of the individual studies are then assessed as per their
outcomes in alignment with the study objectives in the form of a qualitative synthesis and
the meta-analysis. Lastly, the risk of bias assessment is also presented.
5.1

Study selection

The database search was conducted on March 3rd, 2017, identifying 10,403 citations.
Among these citations 1,971 duplicates were removed, leaving 8,432 citations. After the
first level of screening, 124 citations proceeded to the full-text level of screening. A total
of 22 remained after this level of screening. The following reasons for exclusion were as
follows: the risk prediction model was not the primary intervention (n=43); the study was
not conducted in primary care (n=11); the study assessed for outcomes not applicable to
this study (n=13); the article only described the methods (n=6); the method of risk
assessment did not incorporate a prediction model (n=16); the study only assessed for
behavioural intentions, perceived risks, or knowledge (n=9); the model used measured a
non-chronic outcome (n=1). The PRISMA flow chart depicting the screening process as
per the PRISMA template is presented in Figure 2.189

47

Figure 2. PRISMA flow chart.
5.2

Risk of bias assessment

The Downs and Black tool was used to assess the risk of bias for the included studies.
Figure 11 displays the information using a bar graph. The risk of bias is presented as per
the five domains assessed by the Downs and Black tool: 1) reporting, 2) external validity,
3) bias, 4) confounding, and 5) power. Cumulative scores are presented for each domain
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pertaining to the level of bias present in the included studies. Overall, the score for risk
of bias is 67.7%, indicating a moderate risk of bias.

Risk of Bias Summary
100.00%
90.00%
80.00%
70.00%
60.00%
50.00%
40.00%
30.00%
20.00%
10.00%
0.00%
Reporting

External Validity
Low risk of bias

Bias

Confounding

Power

High risk of bias

Figure 3. The risk of bias of the systematic review measured by compounding the risk of
bias of individual studies.
5.3

Study characteristics

The study characteristics are presented according to demographic characteristics (Table
6) and intervention characteristics (Table 7).
5.3.1

Demographic characteristics

The studies were geographically diverse across developed nations, with representation
from the United Kingdom (n=5), the United States (n=4), Canada (n=4), Denmark (n=3),
the Netherlands (n=2), Australia (n=2), Hong Kong (n=2), Italy (n=2), and New Zealand
(n=1). All the studies took place in a primary care setting under the supervision of one or
more physicians, and reported on 400,758 patients. After accounting for loss to followup, a total of 383,005 patients remained. There was inconsistent reporting of number of
physicians, with nine studies not providing a number of physicians, and five only
providing the number of practices included. Six studies reported that there were 555
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general practices. Of the 11 studies that reported a number of physicians, there were
3801 primary care physicians.
Most studies included patients who had a mean age over 50 years, with only 1 study
including patients under the age of 18 years (Burgess et al., 2011). Distribution of patient
sex varied greatly between studies. The full table of demographic characteristics is
provided in Table 6.
Table 6. Demographic characteristics of studies included in the systematic review.
Author,
country,
year

Name of
study

Patient inclusion

BachNielsen et
al.,
Denmark,
2005199
Bellows et
al., USA,
2014200
van den
BrekelDijkstra et
al.,
Netherlands,
2016201
Burgess et
al.,
Australia,
2011202

The Ebeltoft
Project

- Receipt of elevated
cardiovascular risk score

IndiGO

- IndiGO total benefit
score in top third

Personalized
Prevention in
the Local
Community
(PPLC)
Programme
AHC Study

- 45-70 years
- No CVD or diabetes

Chang et al.,
UK, 2016
UK203

NHS Health
Check

Cochrane et
al., UK,
2012204

NHS Health
Check

Number of
participants
(lost to followup)
Patients:
14

% of male
patients

Age of
patientsa

64.3%

33-50 years

Patients: 489

66%

59

Physicians: 10
Patients: 230
(101)

47.80%

52.2 (6.3)

- Residence in
community for 3 years
prior and post AHC
participation
- Elevated CVD risk
- Participation in AHC
program
- 40-74 years
- Registered with
practice participating in
the Clinical Practice
Research Datalink from
April 1, 2009 to March
31, 2013
- No CVD or diabetes

Patients: 64 (6)

67%

15-54

Before
matching:
Attendees:
47.4%
Nonattendees:
50%

Before
matching:
Attendees: 53.5
Non-attendees:
50.1

- Elevated CVD risk
(≥20%)

Patients:
Intervention:
365 (11)

Physicians: 15

Patients:
138,788
General
practices: 462

After
matching:
Attendees:
47.4%
Nonattendees:
47.4%
Intervention:
90.1%

After matching:
Attendees: 53.5
Non-attendees:
53.4

Intervention:
63.9 (6.5)
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Author,
country,
year

Name of
study

Courtney et
al., US,
2015205

NA

Engberg et
al.,
Denmark,
2002206

NA

Ford et al.,
UK, 2001207

NA

Grover et
al., Canada,
2007208

The CHECKUP Study

Grover et
al., Canada,
2008209

The CHECKUP Study

Patient inclusion

- ≥30 years
- No diabetes
- Received PreDx test
from June 2010 to
December 2010
- 30-49 years by January
1, 1991

- Patients who had a
CHD risk request in 1998
at the Birmingham
Heartlands Hospital
- 30-70 years

- 30-70 years

Number of
participants
(lost to followup)
Intervention
plus: 236 (9)
General
practices: 38
Patients:
Intervention:
696 (139)
Control: 2002
(1147)
Patients:
Intervention:
1006 (282)
Control: 501
(132)
Physicians: 9
Patients: 906
General
practices: 14
Patients:
Intervention:
1510 (166)
Control: 1543
(200)
Physicians: 230
Patients: 2631

% of male
patients

Age of
patientsa

Intervention
plus: 86.4%

Intervention
plus: 63.3 (6.4)

Intervention:
60.1%
Control:
60.0%

Intervention: 53
Control: 53

Intervention:
48.8%
Control:
48.3%

Intervention:
40.5 years (5.6)
Control: 40.4
(5.8)

55.2%

NA

Intervention:
66.9%
Control:
70.0%

Intervention:
56.4 (8.3)
Control: 56.3
(7.9)

NA

Treatment
initiation:
Intervention: 56
(7.6)
Control: 55.8
(7.9)

Physicians: 230

Jiao et al.,
Hong Kong,
2014210

The RAMPDM

- All persons with
diabetes covered under
general out-patient
clinics in Hong Kong

Jiao et al.,
Hong Kong,
2015211

The RAMPDM

- ≥18 years
- International
Classification of Primary
Care codes T89/T90
before participation

Patients:
Intervention:
1248 (176)
Control: 1248
(176)
Patients:
Intervention:
9094
Control: 9094

Intervention:
49.8%
Control:
49.8%

Treatment
modification:
Intervention:
58.2 (7.6)
Control: 58.3
(7.4)
Intervention:
64.3 (10.9)
Control: 65.3
(11.7)

Intervention:
48.2%
Control:
47.5%

Intervention:
64.23 (11.05)
Control: 64.29
(11.96)
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Author,
country,
year

Name of
study

Law et al.,
Canada,
2014212

The
PARADIGM
Study

Lowensteyn
et al.,
Canada,
1998213

CHAS Study

Mehta et al.,
New
Zealand,
2014214

PREDICT
CVD-16

Palmieri et
al., Italy,
2011215

CUORE
Project

Powers et
al., USA,
2011216

NA

Patient inclusion

- ≥ one public primary
clinic visit before
participation
- No diabetes, cancer,
chronic lung disease, and
psychological conditions
- Ambulatory men (≥40
years) and women (≥ 50
years)
- No CVD or diabetes
- No lipid-lowering
medications at baseline
- 30-74 years
- No CVD

- 30-80 years
- First risk assessment
using PREDICT
conducted between
January 1, 2006, and
October 15, 2009
- No CVD-related
hospitalization
- No anti-anginal
medication dispensement
- 35-69 years
- No CVD or prior
cardiovascular event

- ≥55 years
- Enrolled in primary
care for at least one year
- ICD hypertension
diagnosis with
hypertensive medication
prescription
- Systolic blood pressure
at least 140 mmHg or
diastolic blood pressure
at least 90 mmHg
- Electrocardiogram
within past five years

Number of
participants
(lost to followup)

% of male
patients

Age of
patientsa

Patients: 3015

59%

56

Intervention:
64.8%
Control:
64.8%

Intervention:
50.5 (10.8)
Control: 50.7
(11.3)

56%

30-80

44.7%

NA

98%

Intervention: 68
(9)
Control: 65 (8)

Physicians: 105

Patients:
Intervention:
782 (580)
Control: 176
(87)
Physician:
Intervention:
170 (73)
Control: 83
(51)
Patients:
90,631

Patients:
117,345
(12427)
Physicians:
1032
Patients:
Intervention: 44
Control: 45
General
practice: 1
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Author,
country,
year

Price et al.,
UK, 2011217

Name of
study

Understanding
Risk Study

Romero et
al., USA,
2008218

NA

Usher-Smith
et al., UK,
2015219

NHS Health
Check

Sorensen et
al.,
Denmark,
2011220

DanRisk
Study (Danish
Risk Score
Study)

Vagholkar
et al.,
Australia,
2014221

NA

Volpe et al.,
Italy, 2007222

ForLife Study

Patient inclusion

- No CVD, stroke,
myocardial infarction,
psychosis or dementia
- Increased CVD risk
(≥20%)
- Fluent in English
(reading/writing)
- No CVD or physical
disability

- CHD risk more than
10% or diabetes with one
other cardiac risk factor
- Indication of prior
CHD, bleeding risk,
aspirin allergy,
inadequate data, or low
CHD risk
- Attend NHS Health
Check between April 1,
2011 to December 1,
2014
- Risk between 10% to
20%
- Born in 1949 or 1959
- Live in Southern
Denmark
- No CVD or diabetes

- 45-69 years
- No CVD
- Fluent in English
- No cognitive
impairments

- Diagnosed hypertension
(both treated and
untreated)

Number of
participants
(lost to followup)

% of male
patients

Age of
patientsa

Patients:
Intervention: 99
Control: 95
9 patients lost
to follow-up

67%

62.3

Preintervention:
62%
Postintervention:
54.5%

Preintervention: 71
Postintervention: 71

Patients: 410
(310)

56%

64.7 (6.11)

Patients: 1156
(81)

Baseline:
47.1%
Follow-up:
46.3%

Patients:
Intervention:
567 (92)
Control: 507
(76)

Intervention:
45%
Control:
38.5%

Baseline: 50year: 49.8%
60-year: 54.0%
Follow-up:
50-year: 48.6%
60-year: 51.4%
Intervention:
56.2 (6.6)
Control: 56.6
(6.9)

General
practices: 4
Patients:
Preintervention:
294
Postintervention:
202

General
practices:
Intervention: 20
(2)
Control: 16
Patients: 12792
(1326)
Treated: 7512
Untreated:
5280
Physicians:
1800

Treated: 51%
Untreated:
49.6%

Treated: 68
Untreated: 64
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a

Author,
country,
year

Name of
study

Patient inclusion

Wind et al.,
Netherlands,
2015223

NA

- Type 2 diabetes
mellitus treated with
lifestyle advice and/or no
more than two oral blood
glucose lowering drugs

Number of
participants
(lost to followup)
Patients: 933
(220)

% of male
patients

Age of
patientsa

53.2%

64.4 (10.5)

Physicians: 117

Age presented in years as: mean (standard deviation), and range, where applicable.

5.3.2

Intervention characteristics

Overwhelmingly, the risk prediction models used as the intervention or as a component
of the intervention in each study predicted the risk of cardiovascular diseases. Twentyone of the twenty-two studies included predicted for the long-term risk of either
cardiovascular disease, coronary heart disease, myocardial infarction, or stroke. Of the
21 studies, 4 were predictive of cardiovascular disease amongst patients with diabetes.
Only one of the twenty-two studies included predicted for type 2 diabetes. No studies
examined risk prediction models that were predictive of either cancer or chronic
respiratory diseases, two of the four WHO categorizations of chronic disease used in this
systematic review.
The actual prediction models used varied; the majority (n=12) used a Framingham
equation or derivative thereof. The next most common tool used was the UKPDS risk
engine (n=3). Other tools used were SCORE (n=1), QRisk (n=2), the European
HeartScore (n=1), PreDx (n=1), the JADE Classification System (n=2), the 10-CR Score
(n=1), the Anggard Modified Risk Score (n=1) and the IndiGO Prediction Tool (n=1).
One study did not specify which tool was used, and one other study used an unnamed
multilevel linear regression equation as a component of the NHS UK Health Check.
Individual study designs were not always ascertainable because in some studies they were
mixed. However, the general study methods employed by researchers were: randomized
controlled trial (n=8), pre-post study (n=5), prospective cohort (n=5), retrospective cohort
(n=4), case-control study (n=2), and qualitative interviews (n=1).
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Fifteen of the twenty-five studies reported on physician behaviour. Patient behaviour
was reported by 11 studies, and the patient health outcomes were reported by 17 studies.
There is some overlap, with most studies reporting on multiple objectives. Complete
intervention characteristics are presented in below (Table 7).
Table 7. Characteristics of the interventions presented in the included studies.
Author,
year
BachNielsen et
al., 2005199
Bellows et
al., 2014200

van den
BrekelDijkstra et
al., 2016201
Burgess et
al., 2011202

Study design

Model

Qualitative
(interview)

Unknown

Case-control
(propensity
score
matched)
Pre-post

Pre-post

Chang et
al., 2016203

Retrospective
cohort

Cochrane
et al.,
2012204

Randomized
controlled
trial

Courtney et
al., 2015205

Case-control
study

Engberg et
al., 2002206

Randomized
controlled
trial
(populationbased)
Retrospective
cohort (prepost)
Randomized
controlled
trial

Ford et al.,
2001207
Grover et
al., 2007208

Outcome of
model
CVD risk

Recruitment
period
1991

Follow-up

IndiGO
Prediction Tool

5-year heart
attack and
stroke risk

November
2008-April
2009

3-6 months

-1
-3

SCORE

10-year CVD
risk

2012-2013

6 months

-2

New Zealand
Guidelines
Group handheld
chart (based on
Framingham
equations)
QRISK2

5- and 10year CHD
risk

March 2005September
2005

3 years

-1
-2
-3

10-year CVD
risk

2 years
(median)

Multilevel
linear
regression
equation
PreDx

10-year CVD
risk

April 1,
2009-March
31, 2013
September
2009February
2010
June 2010December
2010

-1
-2
-3
-3

Modified
Anggard Risk
Score

CVD

December
1991-June
1992

Framingham
equations

10-year CHD
risk

Based on
Framingham
equations

10-year CVD
risk

5-year risk of
type 2
diabetes

4 years

12 months

Study
outcome(s)b
-2

Intervention:
17 weeks
(mean)
Control: 15
weeks
(mean)
1 and 5
years

-1
-2
-3

1998

NA

-1

May 10,
2001-August
25, 2003

1 year (3
month
intervals)

-3

-3
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Author,
year
Grover et
al., 2008209

Study design

Model

Randomized
controlled
trial

Based on
Framingham
equations

Jiao et al.,
2014210

Prospective
cohort with
matched
exposure-nonexposure
groups

Jiao et al.,
2015211

Prospective
cohort

JADE
Classification
System (Joint
Asia Diabetes
Evaluation
Program) and
10-year
Framingham
Risk Function
for CVD, and
UKPDS for
CHD and stroke
JADE
Classification
System (Joint
Asia Diabetes
Evaluation
Program)

Law et al.,
2014212
Lowensteyn
et al.,
1998213

Prospective
cohort
Randomized
controlled
trial

Mehta et
al., 2014214

Prospective
cohort

Palmieri et
al., 2011215

Pre-post
(retrospective)

Powers et
al., 2011216

Randomized
controlled
trial
Randomized
controlled
trial
Retrospective
cohort

Price et al.,
2011217
Romero et
al., 2008218

Outcome of
model
10-year CVD
risk

Recruitment
period
After August
2003

10-year
CVD, CHD,
and stroke
risk

August
2009-June
2010

Diabetes
microvascular
complications
(CHD, heart
failure,
stroke) and
mortality
CVD

August 1,
2009-July
31, 2010

3 years
(median)

-1
-2
-3

March 2009March 2010
NA

NA

-1

3-6 months

-2
-3

5-year CVD
risk

January 1,
2006October 15,
2009

Up to 3
years (6
month
intervals)

-1

10-year risk
of fatal and
non-fatal
CVD events

January
2007-May
2010

Within 1
year of
baseline

-3

NA

3 months

-2
-3

UKPDS risk
engine

10-year CHD
and stroke
risk
10-year CVD
risk

NA

1 month

Framingham
risk score

10-year CHD
risk

April 1,
2003-June
30, 2003

October 1,
2004-

-1
-2
-3
-1

Framingham
risk score
8-year CHD
prevention
model (based on
Framingham
equations)
New Zealand
adjusted risk
score (based on
Framingham
risk score)
10-CR Score
(from Progetto
CUORE
longitudinal
studies)
Framingham
Risk Score

8-year CHD
risk

Follow-up
Baseline: 24 weeks
following
screening
Follow-up
visits: 3, 6,
9, and 12
months
12 months

Study
outcome(s)b
-1

-1
-3
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Author,
year

b

Study design

Model

Outcome of
model

Follow-up

Study
outcome(s)b

After
December 1,
2014
2009

December
31, 2004
(18-21
months after
baseline; 1114 months
after
intervention)
28.0 (SD
10.3)
months
6 months

2008-2010

12 months

10-year
stroke risk

February
2003-July
2003

4±1.5
months

-3

10-year nonfatal and fatal
CHD risk

NA

1.0±0.2
years

-1
-3

UsherSmith et al.,
2015219
Sorensen et
al., 2011220
Vagholkar
et al.,
2014221

Retrospective
cohort

QRISK

10-year CVD
risk

Pre-post

10-year CVD
mortality risk
CVD

Volpe et al.,
2007222

Prospective
cohort

Wind et al.,
2015223

Pre-post

Europe
HeartScore
New Zealand
CV risk
calculator
(based on
Framingham
risk score)
Modified
Framingham
equations
(modification to
account for
antihypertensive
treatment)
UKPDS

Cluster
randomized
controlled
trial

Recruitment
period

-2
-3
-1
-2
-1
-3

1=physician behaviour; 2=patient behaviour; 3=patient health outcomes.

5.3.3

Intervention descriptions

The studies each incorporated the use of a risk prediction model as a main component of
their intervention. However, components in addition to the provision of absolute risk as
derived by the risk prediction models were present in most of the studies such as
providing measures of relative risk or threshold-dependent lifestyle advice. These
characteristics could have their own impact on the study outcomes, providing a degree of
heterogeneity between included studies. This section describes each study’s application
of risk prediction models and how the impact of the models was determined. A complete
overview of each intervention is provided in Appendix D.
The presentation of risk to either the physicians or patients varied between studies.
Modes of presenting risk also varied. Paper-based presentation of risk was the most
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common, with 13 studies providing a printed risk profile. Second most common was a
computer- or web-based presentation (n=8). In four of the studies, risk was
communicated verbally between the physician and the patient. Some studies used
multiple formats. For example, the risk may have been calculated using a computerbased software, and was subsequently printed for patients to take home (n=6). Lastly, in
three studies it was not possible to determine how risk was presented.
In addition to the absolute measure of risk, some studies chose to provide a relative or
additional representations of risk (n=9). Usher-Smith et al. provided patients with both
the baseline QRisk score, as well as a projected score, demonstrating the effect of
lifestyle changes. Bellows et al. provided the absolute risk of heart attack or stroke as
well as projected absolute risks if interventions were implemented. Similarly, Price et al.
provided the absolute risk as well as an achievable risk, an estimation of absolute risk if
risk factor targets were met. Grover et al. 2007 and 2008 provided the absolute risk as
well as a relative risk, comparing the patient to other Canadians matched for age and sex.
Courtney et al. provided patients with their absolute likelihood of developing type 2
diabetes as well as compared to the general population. Lowensteyn et al. presented the
8-year coronary risk as well as how much the risk would be reduced if one or more risk
factors were modified. Palmieri et al. provided two additional measures of risk: first, a
hypothetical risk for a person of the same age and sex as the patient with favourable
modifiable risk factor levels, and secondly, the risk of a smoker one year after smoking
cessation and with a decrease of 10% in modifiable risk factors. Alongside their personal
risk, Powers et al. also presented the average and optimal risk for the patient’s 5-year age
group in graphical format.
Eleven studies chose to incorporate lifestyle advice in addition to the provision of the
patient’s absolute risk. Cochrane et al. included consultation with lifestyle coaches who
assisted in developing health improvement plans, in addition to setting priorities for
lifestyle goals. Usher-Smith et al. provided all participants with an information leaflet
including recommendations for individuals to improve their lifestyle through smoking
cessation, healthy diet, reduction in alcohol consumption, and physical activity. Bach
Nielsen et al. provided feedback, including lifestyle modification advice, to their patients
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when their calculated risk and risk factor values fell outside of normal range. van den
Brekel-Dijkstra et al. personalized the lifestyle advice to each patient based on their risk
profile, the associated risks and benefits of preventive action, and individual
opportunities for lifestyle change depending on motivation, self-efficacy, and
preferences. Chang et al. 2016 evaluated the NHS Health Check, which provides a risk
assessment allowing for a tailored strategy for patient management, including lifestyle
advice. Engberg et al. provided 45-minute consultations with a general practitioner
where lifestyle-related goals were established for the following year as well as providing
all patients with a pamphlet on leading health lifestyles as per the Danish Heart
Foundation. Palmieri et al. provided patients with lifestyle recommendations pertaining
to nutrition, physical activity, and smoking cessation. Strategies to improve risk through
risk factor modification (e.g. medication, patient lifestyle factors) were presented to
intervention patients by Powers et al. Price et al. chose a more interactive format for
patients to receive lifestyle advice, with a self-conducted slide show aimed at first setting
goals to reduce risk, and the direction of behaviours towards achievement of goals. The
intervention used by Bellows et al. included a face-to-face discussion of options for risk
reduction providing a more tailored approach. Upon inclusion in the study, Burgess et al.
provided a patient-centered consultation to discuss chronic disease care planning, which
includes patient education and goal setting, in addition to consultations at each point of
follow-up with either a remote access nurse or an Aboriginal health worker.
Decision support was a component of three studies, providing physicians with
recommendations regarding patient management given a specific threshold of risk (i.e.
targeting high risk patients). The JADE classification system stratifies patients as low,
medium, or high risk; decision support was provided in terms of recommending
appropriate interventions and education based on the risk threshold. Romero et al.
provided decision support in the form of a poster providing a visual representation of the
guideline recommended thresholds for aspirin initiation to prevent CHD.
Four studies incorporated referrals to other health care professionals as a component of
the intervention. van den Brekel-Dijkstra et al. provided links to local providers of
lifestyle interventions with suggestions for individual activities, group activities, or online
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services, allowing for a variety of evidence-based lifestyle programs to be pursued by
participants. The RAMP-DM intervention provided referrals to a team of healthcare
professionals, including registered nurses, advanced practice nurses, optometrists,
dietitians, podiatrists, physiotherapists amongst others dependent upon the patient’s
stratified risk level. Cochrane et al. provided referrals to free support sessions regarding
weight management, physical activity, dietary counselling, and positive thinking upon
request by participants.
Lastly, only three studies specifically reported that training was provided to physicians
regarding the implementation of the intervention. Physicians in the Vagholkar et al.
study were provided a 3-hour workshop regarding the use of the risk calculator, as well as
the corresponding guideline-based recommendations for the risk strata. Physicians in the
Palmieri et al. study incorporated training as per a national program regarding the
assessment of cardiovascular risk using the 10-CR score, methods for identifying patients
eligible for counseling or treatment, promoting shared decision-making, and evaluating
and discussing collected data. Study sponsors in the Wind et al. study instructed
physicians on how to use the UKPDS risk engine, interpretation of CHD risk, and
appropriate prescription of medication.
5.4

Outcome descriptions

Presented in this section is an overview of the outcomes of each included study as they
correspond to the three objectives of this systematic review. First is a summary of studies
that assessed for changes in physician behaviour (n=15), then an overview of study
outcomes pertaining to patient behaviour (n=11), and lastly a summary of changes in
patient health outcomes (n=17).
5.4.1

Physician behaviour

Eleven studies assessed for the impact of risk prediction model use on physician
behaviour. Each of these studies chose to measure the impact of prediction model use
specifically on prescribing patterns. Differences or changes in prescription pattern were
measured for several types of drugs, but primarily in five categories: lipid-lowering
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medications (n=10), antihypertensives (n=9), antidiabetics including insulin and glucoselowering medications (n=5), aspirin (n=3), and antiplatelets (n=2). Of these 11 studies, 9
found a statistically significant improvement in prescription with at least one of the risk
reducing medications. One study also measured the monitoring of risk factors between
the intervention and control group.
Sorensen et al. examined the change in prescription of antiplatelets, antihypertensives,
and lipid-lowering medications from baseline to the six month follow-up.220 Amongst
patients with low risk (n=842), defined as <5% 10-year cardiovascular mortality risk,
prescription with antiplatelets increased from 18 patients at baseline to 19 at follow-up
(p=0.71), prescription with lipid-lowering medication increased from 84 to 94 patients
(p=0.07), and prescription with antihypertensives increased from 151 to 163 patients
(p=0.04). Amongst patients with high risk (n=233), defined as ≥5% 10-year
cardiovascular mortality risk, prescription with antiplatelets increased from 14 to 17
patients (p=0.32), prescription with lipid-lowering medication increased from 25 to 44
patients (p<0.0001), and prescription with antihypertensives increased from 55 to 74
patients (p=0.0009). Overall (n=1075), prescription with antiplatelets increased from 32
to 36 patients (p=0.32), lipid-lowering medication from 109 to 138 (p<0.0001), and
antihypertensives from 206 to 237 (p=0.0002).
Chang et al. compared the prescription for statins or antihypertensive medication between
the intervention group (n=29,672) and the control group (n=109,116). The crude
numbers of prescription with antihypertensives and statins is presented in Appendix E.
After propensity score matching, the intervention was associated with significantly
greater increases in percentage of participants being given a statin (3.83%, 95% CI 3.52,
4.14) and antihypertensive prescription (1.37%, 95% CI 1.08, 1.66).
Vagholkar et al. assessed for changes in antihypertensive and lipid-lowering medications
at baseline and a 12-month follow-up in both the intervention and control group, as well
as treatment intensification or reduction. Amongst intervention patients (n=475),
antihypertensive prescription increased from 136 (28.6%) to 148 patients (31.2%), with
56 patients (11.8%) having their prescription intensified and 32 (6.7%) having reductions.
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Lipid lowering increased from 101 (21.3%) to 108 (22.7%), with 37 (7.8%) intensified
and 24 (5.1) reduced. 59 patients (12.4%) were prescribed both at baseline and 63
(13.3%) at follow-up. Amongst control patients (n=431), antihypertensives increased
from 133 (30.9%) to 148 (34.3%) at follow-up, with 46 (10.7%) having their prescription
intensified and 25 (5.8%) having it reduced. For lipid-lowering medications, 120
(27.8%) were prescribed at baseline and 130 (30.2%) at follow-up, with 41 experience
intensifications (9.5%) and 26 experiencing reductions (6.0%). 60 control patients
(13.9%) were prescribed both at baseline, and 69 (16.0%) at follow-up. Changes in
pharmacologic management were not statistically significant except for the increase in
patients on antihypertensives within the control group (30.9% to 34.3%, p=0.03).
Grover et al. (2008) assessed for the initiation and intensification of antihypertensive
medication between the risk profile group (n=629) and the control group (n=668). 34.9%
of risk profile patients increased treatment compared to 27.7% of control patients, with a
difference of 7.2% (95% CI 1.1, 13.3; p<0.05). For treatment initiation, 31.4% of risk
profile patients started antihypertensives compared to 24.1% of control patients, with a
difference of 7.3% (95% CI -1.4, 15.9). Overall, 33.8% of risk profile patients initiated
or increased treatment compared to 26.7% of control patients with a difference of 7.1%
(95% CI 2.1, 12.1; p<0.01).
Courtney et al. found that there were higher rates of prescription amongst risk-tested
patients for all medications examined (antihypertensives, lipid-lowering, antidiabetics,
and aspirin) during the follow-up period compared to the control group; no numeric
figures were provided. They also found that patients who received the risk test were
more likely to receive follow-up measurements of risk factors compared to control
patients, including blood pressure (91.5% versus 42.7%), weight (91.1% versus 42.8%),
LDL-cholesterol (71.8% versus 24%), HDL-cholesterol (72.7% versus 24.3%), HbA1c
(58.6% versus 11.5%), triglycerides (96.8% versus 82.8%) and fasting glucose (98.4%
versus 72.4%). All differences reached statistical significance (p<0.001), and indicate
more careful and targeted monitoring for risk-tested patients compared to control
patients.
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In a pre-post study design, Ford et al. found that at baseline, 10.7% of patients (97/906)
were prescribed with statins, and 11% (100/906) after coronary heart disease risk
assessment. Amongst those with a 10-year CHD risk of <30% (n=825), 62 patients were
already taking a statin, 4 patients discontinued statin use, and 4 patients began statin use.
Amongst patients with a 10-year CHD risk of 30% or greater (n=81), 35 patients were
already taking a statin, and 3 patients began a statin.
Jiao et al. (2015) assessed the prescription of 4 medications (glucose-lowering,
antihypertensive, and lipid-lowering drugs, and insulin) at baseline and following the
implementation of the RAMP-DM intervention for both the risk profile group (n=9094
baseline; n=8892 follow-up) and the control group (n=9094 baseline; n=8542 follow-up).
At baseline, 87.3% of intervention patients were prescribed glucose-lowering drugs at
baseline compared to 87.2% of control patients (p=0.755); at follow-up, 90.0% of
intervention patients were compared to 83.6% of control patients (p<0.001). For
antihypertensive drugs, 73.0% of intervention patients were prescribed compared to
73.4% of control patients at baseline (p=0.547), while at follow-up, 80.0% of intervention
patients were prescribed compared to 76.0% of control patients (p<0.001). 13.1% of
intervention patients were prescribed lipid-lowering drugs at baseline compared to 13.5%
of control patients (p=0.431), while at follow-up 51.2% of intervention patients were
prescribed compared to 45.7% of control patients (p<0.001). Lastly, 1.2% of intervention
patients were prescribed insulin at baseline compared to 1.4% of control patients
(p=0.101) and at follow-up, 6.0% of intervention patients were prescribed insulin
compared to 4.5% of control patients (p<0.001).
Jiao et al. (2014) assessed the RAMP-DM intervention and its impact of prescription with
glucose-lowering drugs, insulin, antihypertensive drugs, and lipid-lowering drugs as well
from baseline to a 12-month follow-up within the intervention and control arm. Only
differences in insulin prescription were significant at both baseline and follow-up
(baseline: p<0.001; follow-up: p<0.001). Differences in prescription at baseline and
follow-up for glucose-lowering medications (baseline: p=0.593; follow-up: p=0.207),
antihypertensive drugs (baseline: p=0.382; follow-up: 0.302), and lipid-lowering drugs
(baseline: p=0.437; follow-up: p=0.354) were not statistically significant.
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Price et al. made note of risk-reduction prescriptions from baseline to follow-up amongst
intervention and control groups, and found a greater number of prescriptions were given
to those for whom risk was calculated. Amongst the intervention patients, there were 17
new prescriptions in 12 individuals compared to 5 new prescriptions in 5 individuals in
the control group (p=0.01). Specifically, in the intervention group, there were new
prescriptions for aspirin (n=2), antihypertensives (n=8), glucose-lowering medications
(n=3), and lipid-lowering medications (n=4).
Romero et al. assessed for changes in aspirin prescription in a retrospective analysis.
They found that at baseline, 63.5% (127/202) patients used aspirin for the primary
prevention of CHD, while the post-intervention rate of aspirin use was 72.8% (147/202),
representing a 9.3% (p=0.054) absolute increase in rate of aspirin use, indicating a
marginally insignificant result.
Bellows et al. reported on the impact of the IndiGO individualized clinical guidelines on
new prescription of statins and antihypertensives. Though no difference was found
between intervention (n=489) and control (n=489) groups with regards to
antihypertensive medication (17% versus 15%, p=0.39), patients in the intervention
group were significantly more likely to be prescribed statins compared to control patients
(39% versus 8%; p<0.01).
Burgess et al. examined the impact of the Aboriginal and Torres Strait Islander Adult
Health Check on prescription of medications related to CVD risk reduction in a pre-post
study design. At baseline (n=64), 18 patients (28%) were prescribed, and at follow-up
(n=63), 56 patients (89%) were prescribed. Significant increases in prescription from
baseline to follow-up were found for antiplatelets (4.7% to 68.3%, p<0.001), lipid
lowering medication (6.3% to 65.1%, p<0.001), angiotensin converting enzyme
inhibitors/angiotensin receptor blockers (25% to 63.5%, p<0.001), and oral hypoglycemic
medications (17.2% to 33.3%, p=0.04) were found. No significant increase in
prescription with beta blockers (4.7% to 12.7%, p=0.09), nitrates (3.1% to 4.8%, p=0.49),
thiazide diuretics (0% to 3.2%, p=0.24), or calcium channel blockers (1.6% to 1.6%,
p=0.75) were found.
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5.4.2

Patient behaviour

Risk reducing patient behaviours as a result risk prediction models use were examined in
11 studies. A greater number of measures were studied when compared to practitioner
behaviours. Most common was cigarette smoking, with eight studies evaluating the
impact of risk prediction models use on smoking cessation. Other measures evaluated
included changes in physical activity (n=4), diet (n=2), medication use (n=2), continuity
of care or return for follow-up visit (n=2), and alcohol consumption (n=1). Of the eight
studies examining smoking cessation, two studies found a significant result, while six
were non-significant. Of the six studies, three studies demonstrated a non-significant
absolute reduction of smoking prevalence, while one study reported a significant
reduction in number of cigarettes smoked per day. Though all the studies reporting
changes in physical activity noted increases in exercise levels, none reported a significant
change; two stated there was a non-significant effect, one was conducted qualitatively,
and one only reported the change in proportions.
van den Brekel-Dijkstra et al. examined patient behaviour through use of a pre-post study
design. Of the patients that responded to the follow-up questionnaire (56%), 40 of 129
(31%) patients reported initiations of health behaviour change, 41 (32%) reported
improvements in physical activity, and 36 (28%) improved their diet. 23 of 96 (24%)
current drinks reduced their alcohol intake. Forty four percent (6/16) current smokers
reduced or quit smoking.
Usher-Smith et al. conducted a study examining the change of statin prescription
threshold from 20% absolute cardiovascular risk to 10%, the corresponding provision of
a cardiovascular risk score to the patient, and subsequently the patients’ decision
regarding statin prescription. In this fashion, the onus of statin prescription fell unto the
patients. Among 410 statin-naïve patients, 45 (11%) chose to start a statin. An
association was found between increasing QRisk score and statin initiation (OR 1.34
(1.13, 1.60)).
Sorensen et al. examined smoking cessation amongst participants. At baseline, 253 of
1075 (24%) participants were current smokers. At follow-up, 39 participants had quit
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smoking, while 10 subjects started smoking again. The number of active smokers
decreased to 224 (p<0.0001). Similarly, Wind et al. found that among their participants
in a pre-post study design (n=713), the percentage of smokers decreased from 18.3% at
baseline to 15.0% at follow-up (p<0.05).
Chang et al. also examined smoking cessation between the intervention and the control
group. Complete smoking prevalence is presented in Appendix E. Smoking prevalence
decreased more in the intervention group than in the control group; after propensity score
matching, the difference in prevalence was -0.11% (95% CI -0.35, 0.13), though not
statistically significant.
Jiao et al. (2015) assessed patients for smoking status at both baseline and follow-up in
the intervention and control groups, and found no significant change in smoking status at
the end of follow-up between groups (smoking prevalence of 10.2% and 10.0% at
baseline for the intervention and control groups, respectively, p=0.605; smoking
prevalence of 9.0% and 8.6% at follow-up for intervention and control groups,
respectively, p=0.651), though both groups did experience a reduction in smoking
prevalence.
Lowensteyn et al. noted the absolute change in number of smokers among those who
were reassessed between intervention (n=202) and control groups (n=89). 20.8% of
intervention groups were smokers at baseline; at follow-up, 3 had quit smoking for an
absolute change of -1.5%. Comparatively, in the control group, at baseline there were 21
smokers (23.6%); at follow-up, 2 people had quit smoking (absolute change: -2.3%). The
difference in absolute change between intervention and control groups was 0.8%
(p=0.64). Though a greater absolute change was noted in the control group, it was
statistically non-significant.
Though the Australian Health Check found a decrease in percentage of smokers from
83% at baseline to 78% at follow-up, the decrease was not significant (p=0.51).
However, the number of cigarettes smoked per day did decrease significantly (p<0.001),
from 3.5 (SD 0.1) to 2.6 (SD 0.2) according to smoking categories.
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Bach Nielsen et al. conducted a qualitative study examining the effect of cardiovascular
risk scores on lifestyle changes. Several participants made radical changes, contacting
dietitians and reorganizing their diets, involving their families and cooking different types
of food for different family members, and began exercising. These changes were only to
the extent that their perceived quality of life wouldn’t suffer, what the authors referred to
as the “pain limit”. Others took an active interest in their progress over time, asking their
general physician for examinations to determine whether their efforts had any effect.
Courtney et al. reported that patients assessed for risk of diabetes (n=696) as determined
by the PreDx risk score were more likely to return for a follow-up visit than the control
group (n=2002). 80% of the risk group (557/696 patients) returned for a visit compared
to the control group, where 42.7% (800/2002) returned, indicating the intervention
positively influenced the likelihood of continuity of care.
Powers et al. reported on three aspects of patient behaviour: self-reported medication
adherence, current exercise level, and smoking. They then compared the intervention and
control arms for between-group differences. For self-reported medication adherence, at
baseline, 50% of the intervention arm reported medication adherence compared to 51%
of the control patients; at 3 months, 46% in the intervention arm compared to 49% in the
control arm reported medication adherence (p=0.55). Patients in both arms improved the
amount of exercise they engaged in (48% to 57% from baseline to follow-up in
intervention arm, 42% to 53% from baseline to follow-up in the control arm, p=0.77).
Smoking cessation occurred in the intervention group, decreasing from 18% to 14%,
while it remained at 18% at both baseline and follow-up in the control arm (p=1.00).
Overall, no significant differences were noted when comparing self-reported medication
adherence, current exercise levels, and smoking status between intervention and control
arms.
Price et al. monitored physical activities in all participants using a hip-worn
accelerometer measuring the amount and intensity of human activity. Though 53% of
participants increased their physical activity, there was a non-significant net 0.5% (95%
CI -0.6, 1.8) increase in accelerometer counts in the intervention group (p=0.56).
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5.4.3

Patient health outcomes

Fourteen studies explored the impact of prediction models on patient health outcomes.
Commonly assessed were the impact on biometric, or risk factor, values (n=13) as well as
on estimated absolute risk of health outcome (n=13). Specific risk factor values
evaluated were: systolic blood pressure (n=10), diastolic blood pressure (n=8), HDL
cholesterol (n=8), total cholesterol (n=7), BMI (n=7), LDL cholesterol (n=6), total
cholesterol to HDL cholesterol ratio (n=4), HbA1c levels (n=4), weight (n=2), and two
studies examined blood pressure without specification of diastolic or systolic. Only three
studies examined event rates, specifically cardiovascular disease (n=2), coronary heart
disease (n=2), stroke (n=1), heart failure (n=1), all-cause mortality (n=1), and type 2
diabetes mellitus (n=1).
Chang et al. compared to the absolute reduction in cardiovascular risk between the
intervention group and control group, finding the intervention group (n=29,672) reduced
their 10-year cardiovascular risk from 6.7% (SD 5.9) to 6.2% (SD 5.3) with a difference
of -0.48% (95% CI -0.5, -0.46), while the control group (n=109,116) reduced their risk
from 5.1% (SD 5.3) to 4.9% (SD 5.0), with a difference of -0.19% (95% CI -0.19, -0.18).
The crude differences-in-differences between the intervention and control group was 0.29% (95% CI -0.31, -0.27), and after propensity-score matching, was -0.21 (95% CI 0.24, -0.19).
Chang et al. also reported on changes in risk factors, namely systolic blood pressure,
diastolic blood pressure, body mass index, and total cholesterol. The crude levels of risk
factors are provided in Appendix E. After propensity score matching, the following
reductions in risk factor values comparing the intervention group to the control group
were found to be significant: systolic blood pressure (-2.51 mm Hg, 95% CI -2.77, -2.25),
diastolic blood pressure (-1.46, 95% CI -1.62, -1.29), BMI (-0.27, 95% CI -0.34, -0.20),
and total cholesterol (-0.15 mmol/L, 95% CI -0.18, -0.13).
Cochrane et al. had two groups: the NHS Health Check group and the NHS Health Check
plus additional support group. Baseline and 1-year follow-up measures were collected
for both trial arms. Both groups showed similar beneficial reductions in risk factors:
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about 7 mmHg in systolic blood pressure, 4 mmHg in diastolic blood pressure, 0.65
mmol/L in total cholesterol, 0.5 in total cholesterol/HDL ratio, and 2 cm in waist
circumference. Changes in HDL cholesterol, weight, and BMI were negligible, though a
small significant reduction in overall BMI was noted (0.3 kg/m2). Complete figures are
available in Appendix F.
Cochrane et al. also noted changes in absolute CVD risk from baseline to 1-year followup (Appendix F). In the Health Check group, absolute risk was reduced from a mean of
32.9% (SD 9.7) at baseline (n=365) to 29.4% (SD 9.7) at follow-up (n=295). In the
Health Check plus group, absolute risk was reduced from 31.9% on average amongst 236
participants to 29.2% (SD 10.1) at follow-up (n=191). This difference corresponds to a
relative risk of 0.89 (95% CI 0.87, 0.92) amongst the Health Check group, and a relative
risk of 0.91 (95% CI 0.88, 0.94) amongst the Health Check plus group.
Courtney et al. found that significantly more risk-tested patients experienced
improvements in risk factor levels, including weight, blood pressure, LDL-cholesterol,
HDL-cholesterol, triglycerides, glucose, and HbA1c levels (all differences were
statistically significant at p<0.001). The total percentages of patients with improved risk
factors was not provided.
Grover et al. (2007) conducted a randomized controlled trial comparing patients receiving
a risk profile (n=1510 baseline; n= 1344 follow-up) to usual care patients (n=1543
baseline; n=1343 follow-up). Changes in risk factor levels from baseline to the 12-month
follow-up were reported, as well as the difference in changes between intervention and
control patients. Intervention patients showed absolute changes of -58.4 mg/dL (SD
34.1) for total cholesterol, -51.2 mg/dL (SD 29.5) LDL cholesterol, 1.0 mg/dL (SD 6.0)
HDL cholesterol, -1.5 TC:HDL cholesterol ratio (SD 1.1), -6.3 mmHg (SD 13.5) systolic
blood pressure, and -3.8 mmHg (SD 7.9) diastolic blood pressure. Control patients
showed absolute changes of: -54.5 mg/dL (SD 35.4) total cholesterol, -48.0 mg/dL (SD
29.7) LDL cholesterol, 0.8 mg/dL (SD 5.7) HDL cholesterol, -1.3 (SD 1.0) TC:HDL
cholesterol ratio, -5.3 mmHg (SD 13.2) systolic blood pressure, and -3.6 mmHg (SD 7.7)
diastolic blood pressure. Difference between the intervention and usual care group were:
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-3.9 (p=0.02) total cholesterol, -3.3 (p=0.02) LDL cholesterol, 0.2 (p=0.37) HDL
cholesterol, -0.1 (p=0.002) TC:HDL ratio, -0.9 (p=0.005) systolic blood pressure, and 0.2 (p=0.01) diastolic blood pressure.
Grover et al. (2007) also assessed the likelihood of high risk patients in either the
intervention or control group reaching lipid target levels. Intervention patients were more
likely to reach their lipid targets (OR 1.26; 95% CI 1.04, 1.53). They found that 70% of
intervention patients were identified as high risk, and 57% reached their lipid targets,
while 68% of control patients were identified as high risk, and 54% reached their lipid
targets. When patients of all risk levels were considered, the intervention group was no
more likely to reach their target lipid levels than the control group (55.2% versus 52.2%;
OR 1.13, 95% CI 0.98, 1.30). For changes in 10-year cardiovascular disease risk,
intervention patients experienced an absolute change of -5.9% (SD 4.5) while control
patients experienced an absolute change of -5.3% (SD 4.3), with a difference between the
two groups of -0.6% (p<0.001), indicating that intervention patients obtained a
statistically significant reduction in absolute risk when compared to control patients.
Jiao et al. (2015) assessed for changes in risk factor levels from baseline to the 3-year
follow-up point between intervention and control groups, including BMI, systolic blood
pressure, diastolic blood pressure, HbA1c, total cholesterol, both HDL and LDL
cholesterol, triglyceride levels, and estimated glomerular filtration rates. Though
baseline characteristics with comparable between both arms, the intervention group
experienced significant changes (p<0.001) for both systolic and diastolic pressure,
HbA1c levels, total cholesterol, and both HDL and LDL cholesterol levels. Further, a
greater percentage of intervention patients achieved treatment targets for blood pressure
and HbA1c levels compared to control patients (p<0.001). Complete figures are
available in Appendix G.
Jiao et al. (2015) also reported the rates of cardiovascular disease, coronary heart disease,
stroke, heart failure, and all-cause mortality at 36 months in both study arms. 4.39% of
intervention patients developed CVD compared to 6.69% of control patients; 1.87%
experienced CHD compared to 3.08% of control patients; 2.25% of intervention patients
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experienced a stroke compared to 3.40% of control patients; 0.79% of intervention
patients experienced heart failure compared to 1.37% of control patients; and lastly, allcause mortality incidence was 2.22% in the intervention group compared to 6.07% in the
control group. Jiao et al. (2015) also constructed a multivariable Cox proportion hazard
regression model comparing the intervention to the control group, adjusting for
sociodemographic and clinical characteristics. The following hazard ratios were
calculated: CVD (0.629, 95% CI 0.554, 0.715, p<0.001), CHD (0.570, 95% CI 0.470,
0.691, P<0.001), stroke (0.652, 95% CI 0.546, 0.780, p<0.001), heart failure (0.598, 95%
CI 0.446, 0.802, p=0.001), and all-cause mortality (0.363, 95% CI 0.308, 0.428,
p<0.001).
Jiao et al. (2014) examined the effect of the RAMP-DM from baseline to follow-up in the
intervention arm of their study compared to the control arm for changes in biomedical
outcomes, predicted cardiovascular risk, and percent of participants reaching treatment
targets. In a fully adjusted model, differences between groups for changes in HbA1c
levels (p<0.05), diastolic blood pressure (p<0.05), reaching treatment targets for diastolic
blood pressure (p<0.05), the UKPDS 10-year CHD risk (p<0.05), the UKPDS 10-year
stroke risk (p<0.01) were found to be significant, with intervention patients experiencing
greater improvements. Cardiovascular events found to be significant were observed
CHD (p<0.001) and total CVD (p=0.003), with RAMP-DM patients experiencing
significantly fewer events.
Lowensteyn et al. reported the absolute changes in risk factors and 8-year coronary risk
from baseline to follow-up in both the intervention arm (n=202) and the control group
(n=89) amongst patients who were reassessed. Statistical significance was found for 8year coronary risk (difference in absolute change between intervention and control group:
-1.426%, p<0.01). Intervention patients compared to control patients also experienced a
greater absolute change for total cholesterol (-0.49 mmol/L (SD 0.99) versus -0.09 (SD
0.87); estimated group difference -0.238, p<0.05), LDL-cholesterol (-0.40 (SD 0.87)
versus -0.01 (SD 0.80); estimated group difference -0.226, p<0.05), and the totalcholesterol/HDL-cholesterol ratio (-0.6 (SD 1.3) versus -0.2 (SD 1.2); estimated group
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difference -0.287, p<0.05). Non-significant changes were found for HDL-cholesterol,
systolic and diastolic blood pressure, and BMI.
Palmieri et al. obtained complete data on 5,948 patients (3185 men, 2763 women).
Amongst the men, 305 (10%) improved their risk factors, shifting from the high- or
moderate-risk category to the low-risk category. 162 women (6%) shifted from high or
moderate risk to low risk. Overall numbers for all participants was not reported.
Powers et al. reported on changes in systolic and diastolic blood pressure, and changes in
10-year CHD and stroke risk from baseline to follow-up amongst intervention and control
groups. The between-group differences were not significant for any of the changes,
indicating that the intervention did not have an effect in this study. The risk estimate for
CHD was found to have increased at follow-up for both the intervention (25.0% (SD 1.6)
to 26.9% (SD 1.8)) and control (24.1% (SD 1.5) to 24.6% (SD 1.8)) as well as the risk
estimate for stroke (intervention: 21.0% (SD 2.3) to 23.3% (SD 2.7); control: 17.9% (SD
2.3) to 18.0% (SD 2.6)). Further, diastolic blood pressure was found to have increased at
follow-up for both groups (intervention: 73.5 mmHg (SD 1.9) to 74.9 mmHg (SD 2.0);
control: 76.6 mmHg (SD 1.8) to 76.7 mmHg (SD 1.9)). Only systolic blood pressure
decreased in both arms (intervention: 128.4 mmHg (SD 2.7) to 128.2 mmHg (SD 2.9);
control: 126.0 mmHg (SD 2.7) to 125.0 mmHg (SD 2.8)).
Price et al. also reported on changes in risk factor levels from baseline to follow-up in the
intervention and control arms. Non-significant within or between group differences were
found for weight, blood pressure, HDL cholesterol, triglyceride levels, or estimated 10year CVD risk (no values were provided). However, a net 7% (95% CI -11.7, -3.2,
p=0.004) decrease in mean LDL-cholesterol was found in the intervention arm.
Volpe et al. sought to determine the impact of a systematic stroke risk assessment on
patients with hypertension that are treated (n=6971) and untreated (n=4718). They
reported a significant decrease is both systolic and diastolic blood pressure from baseline
to follow-up in both the treated and untreated patients. The treated group presented with
baseline blood pressure (systolic/diastolic) of 150.1/87.4 mmHg and a follow-up of
136.7/81.0 mmHg, while untreated groups presented with a baseline blood pressure of
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158.9/93.2 mmHg and a follow-up of 135.6/81.5 mmHg, with both differences highly
significant (p<0.0001). Amongst all patients, there was a significant reduction of 13.3%
in absolute stroke risk score, which the researchers attributed to the reduction in blood
pressure.
Wind et al. examined the effect of the UKPDS risk engine on clinical management of
coronary heart disease in a pre-post study design. At baseline, patients (n=713) had a 10year CHD risk of 18.7% (SD 11.7); at follow-up, the absolute risk increased to 20.1%
(SD 13.7). The increase in absolute risk was significant (p<0.05). Significant decreases
(p<0.05) were also noted from baseline to follow-up for systolic blood pressure (139.8
mmHg (SD 17.7) to 138.3 mmHg (SD 16.4)), total cholesterol (4.5 mmol/L (SD 1.0) to
4.4 mmol/L (SD 1.0)), and BMI (31.1 (SD 5.2) to 30.8 (SD 5.3)). Nonsignificant
changes in HbA1C (6.7% (SD 0.8) to 6.6% (SD 0.9)) and HDL cholesterol (1.2 mmol/L
(SD 0.3) to 1.2 mmol/L (SD 0.3)) were reported as well.
The IndiGO clinical guidelines as assessed by Bellows et al. was assessed for its impact
on predicted 5-year risk of heart attack or stroke. The intervention group experienced a
reduction in risk from 6.7% at baseline to 5.1% at follow-up, a significant reduction
compared to the control group, which experienced a reduction from 7.5% to 6.5%
(p=0.015). Non-significant reductions in LDL cholesterol and systolic blood pressure
were also noted, with LDL reductions of 114 to 106 in the intervention group and 114 to
109 in the control group (p=0.37), and systolic blood pressure reductions from 134 to 125
in the intervention group and 137 to 131 in the control group (p=0.07). No units were
provided for blood pressure or LDL cholesterol levels. Though numeric values were not
provided, there were no significant between-group differences in BMI change.
Burgess et al. examined the impact of prediction models on risk factors for CVD,
specifically BMI, waist circumference, systolic blood pressure, total and HDL
cholesterol, ratio of total to HDL cholesterol, and type 2 diabetes. Reductions from
baseline to follow-up were significant for waist circumference (n=56; 98.3 cm (SD 1.8)
to 96.4 cm (SD 1.8), p=0.04), HDL cholesterol (1.01 mmol/L (SD 0.03) to 1.11 mmol/L
(SD 0.04), p=0.001), and ratio of total to HDL cholesterol (5.7 (SD 0.2) to 5.0 (SD 0.2),
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p<0.001). Non-significant changes were reported for BMI (n=56; 27.3 (SD 0.9) to 27.3
(SD 0.8), p=0.81), systolic blood pressure (128 mmHg (SD 2.6) to 124 mmHg (SD 3.0),
p=0.2), and total cholesterol (5.5 mmol/L (SD 0.2) to 5.3 mmol/L (SD 0.2), p=0.07).
Type 2 diabetes status remained constant from baseline to follow-up.
Further, Burgess et al. assessed difference in absolute 5- and 10-year CVD risk. They
first calculated the expected risk at follow-up calculated by modifying only age, and
compared it to the observed risk. Expected 5-year risk was 4.6% (0.4), and the observed
risk was 3.6% (0.4), and the 1.0% (SD 0.4) difference was significant (p<0.001).
Similarly, the expected 10-year risk was 10.2% (SD 0.8), and the observed risk was 8.2%
(SD 0.7), with a difference of 2.0% (SD 0.7) was significant (p=0.004).
5.5

Subgroup

The subgroup of interest for this systematic review are those determined to be at high risk
for the predicted health outcome. Four studies demonstrated the difference in effect
between low and high risk groups.
Sorensen et al. compared to the prescription of antiplatelets, lipid-lowering and
antihypertensive medications between patients at low-risk (<5% 10-year cardiovascular
mortality risk) with patients at high-risk (≥5% 10-year cardiovascular mortality risk).
They found that a high risk scores were associated with a 3-fold greater likelihood of
being prescribed lipid lowering agents (OR 2.9; 95% CI 1.6, 5.5; p<0.0008), an almost
3.5-fold greater likelihood of being prescribed antihypertensive treatment (OR 3.4; 95%
CI 1.9, 6.0; p<0.0001), and a 2-fold greater likelihood of being prescribed antiplatelet
medication (OR 2.3; 95% CI 0.8, 6.6; p=0.14).
Chang et al. found that absolute risk reduction (-0.54%, 95% CI -0.93, -0.15) for
participants with high risk (20% or greater) was not significantly greater than those with
moderate risk (10% to 20%: -0.34%, 95% CI -0.44, -0.24) or low risk (<10%: -0.14%,
95% CI -0.16, -0.12).
Vagholkar et al. examined prescription of medications (antihypertensives, lipid-lowering,
or both), treatment intensification, and treatment reduction between low, moderate, or
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high risk groups and between intervention and control patients. Both between- and
within-group analyses showed no significant differences in the 12-month medication
proportions and changes in therapy.
Mehta et al. examined the prescription of both antihypertensive and lipid-lowering
medications amongst patients at baseline and six month follow-up periods for up to three
years within the low (<10%), moderate (10-14%) and high risk (≥15%) strata.
Dispensing rose most sharply in the six month period following baseline and
implementation of the intervention, and differed between risk strata.
5.6

Conclusion

In conclusion, many studies examining the impact of risk prediction model use on
physician behaviour, patient behaviour, and patient health outcomes found that there
were some improvements. The majority of studies identified a significant increase in
prescription of preventive medications; changes not found to be statistically significant
may still be clinically relevant. Several unique outcomes were categorized as patient
behaviour. Though some studies identified an effect of prediction model use on patient
behaviour, overall the outcome was too heterogenous to determine whether or not an
impact exists. Lastly, though few studies examined event rates, several identified
improvements in soft outcomes such as blood pressure or total cholesterol, indicating that
risk prediction model use may ultimately result in some improvements in patient health
outcomes. The following chapter will present the results of the quantitative assessment,
or the meta-analysis, of the data.
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Chapter 6
6.0

Meta-analysis

In this chapter, the results of the meta-analyses are presented. Though as a whole,
numerous forms of model impact were described in the systematic review, only five
outcomes were found to be meta-analyzable: 1) new prescription with antihypertensive
medications, 2) new prescription with lipid-lowering medication, 3) smoking cessation,
4) absolute changes in systolic blood pressure, and 5) absolute changes in diastolic blood
pressure. Two main types of data were concluded to be appropriate for meta-analysis:
dichotomous data, or the number of events and non-events, and continuous data, or
changes in mean values. As such, the two summary effect measures calculated for this
study were summary odds ratios and standardized mean differences. Studies reporting on
similar outcomes were combined in a summary effect measure and visually depicted
using a forest plot. Lastly, the results of the risk of bias assessment using the Downs and
Black tool are presented.
6.1

Results of individual studies

This systematic review and meta-analysis sought to address what the impact of risk
prediction models was on: 1) practitioner behaviour, 2) patient behaviour, and 3) patient
health outcomes. Upon completion of the systematic review, five outcomes were
identified as being appropriate for the conduct of a meta-analysis as per the three main
study objectives. Changes in practitioner behaviour (defined as prescription of
antihypertensive or lipid-lowering medications) were found in four studies, patient
behaviour change (expressed as smoking cessation) was found in four studies, and patient
health outcomes (defined as changes in blood pressure (both systolic and diastolic)) were
found in five studies.
6.2

Physician prescribing patterns

The meta-analyses for the outcomes of new prescriptions with antihypertensive and lipidlowering medications from baseline to follow-up are presented below.
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6.2.1

New prescriptions with antihypertensives

Four studies reported the changes in prescription with antihypertensives in patients
following the use of a prediction model; the information presented in each study is
displayed in Table 8.
Table 8. Reported changes in proportions of patients prescribed with antihypertensive
medications from baseline to follow-up in both the intervention and control group.
Intervention

Control

Author (year)

Baseline

Follow-up

Baseline

Follow-up

Chang (2016)

1424/29672

2938/29672

1964/109116

4801/109116

Jiao (2015)

6637/9094

7112/8892

6673/9094

6493/8542

Jiao (2014)

833/1072

871/1072

818/1072

852/1072

Vagholkar
(2014)

136/475

148/475

133/431

148/431

For the purposes of the meta-analysis, the number of events and non-events in both arms
of the studies were required. To derive the number of events, the difference between the
number of patients at follow-up prescribed antihypertensives was subtracted by the
number of patients prescribed antihypertensives at baseline (Table 9).
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Table 9. The calculated number of events (new prescription with an antihypertensive
medication) from baseline to follow-up in both the intervention and control group.
Intervention

Control

Author (year)

Follow-up —
baseline

Number of
events

Follow-up —
baseline

Number of
events

Chang (2016)

2938 - 1424

1514

4801 – 1964

2837

Jiao (2015)

7112 - 6637

475

6493 – 6673

-180

Jiao (2014)

871 - 833

38

852 – 818

34

Vagholkar
(2014)

148 - 136

12

148 – 133

15

The number of non-events was calculated by subtracting the number of total participants
per treatment arm by the number of events (Table 10). Of particular note is Jiao et al.
(2015) where both the intervention and control arms experienced some attrition. When
calculating the number of events, the method of calculating the number of events in
tandem with the loss to follow-up results in a number of -180. This poses a significant
problem for the interpretation and analysis of the data; this value would be interpreted as
180 negative events and not fall within the confines of event or non-event.
The conduct of a complete case analysis was used to account for attrition as
recommended by the Cochrane Handbook, ultimately ameliorating the issue of negative
events.190 The complete case analysis was conducted using the methods proposed by Akl
et al.224 A complete case analysis seeks to exclude patients for whom data are missing at
follow-up, therefore only analyzing data from patients with available data, followed by a
sensitivity analysis using both the best and worst case scenarios where all patients with
missing data are classified as either events or non-events. This creates a range of possible
effect sizes, accounting for the range of uncertainty. First, the complete case analysis
will be presented, followed by the worst- and best-case analysis.
To conduct a complete case analysis, Akl et al. recommends using the following
equation:
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𝐸𝑣𝑒𝑛𝑡𝑠
[𝑃𝑎𝑡𝑖𝑒𝑛𝑡𝑠] 𝑟𝑎𝑛𝑑𝑜𝑚𝑖𝑧𝑒𝑑 − [𝑝𝑎𝑡𝑖𝑒𝑛𝑡𝑠] 𝑤𝑖𝑡ℎ 𝑚𝑖𝑠𝑠𝑖𝑛𝑔 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 𝑑𝑎𝑡𝑎
The formula applies to both the intervention and control arm. To provide a measure of
events and non-events, attrition was first accounted for. Firstly, in the intervention arm at
baseline, approximately 72.98% of patients were prescribed antihypertensive medications
(6637/9094). Two hundred and two patients were lost to follow-up. Assuming nondifferential attrition, this indicates that of the 202 patients lost, 72.98% (~147 patients)
were those who were prescribed antihypertensive medications, and thus 55 patients were
not. Subtracting 147 from the previously stated baseline number (6637) and subtracting
the full 202 from the denominator (9094), a new prevalence, accounting for attrition, of
baseline antihypertensive medication prescription is established (6490/8892). The same
method of accounting for attrition was used for the control arm, resulting in a new
prevalence of baseline antihypertensive medication prescription (6268/8542).
The calculation of events was completed by subtracting the original follow-up count of
patients prescribed with antihypertensives by the new baseline count of patients
prescribed. The number of non-events were calculated by using the denominator of the
equation as per Akl et al.:
𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝑎𝑟𝑚:

𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝑎𝑟𝑚:

6637 − 6490
147
=
9094 − 202
8892

6493 − 6268
225
=
9094 − 552
8542

The values for the denominator represent the total number of participants for whom data
is complete. When calculating the number of non-events, this was the value used as the
number of total participants as per a complete case analysis. The number of non-events
for each study is presented below (Table 10).
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Table 10. The calculated number of non-events (no new prescription with
antihypertensive medication) using a complete case analysis for both the intervention and
control group.
Intervention

Control

Author (year)

Total number – Number of
number of
non-events
events

Total number – Number of
number of
non-events
events

Chang (2016)

29672 - 1514

28158

109116 – 2837

106279

Jiao (2015)

8892 – 147

8745

8542 – 225

8317

Jiao (2014)

1072 – 38

1034

1072 – 34

1038

Vagholkar
(2014)

475 – 12

463

431 – 15

416

The calculated numbers allow us to establish the number of events and non-events,
allowing for the conduct of a meta-analysis (Table 11).
Table 11. The number of events and non-events for the intervention and control groups
of the studies eligible for meta-analysis.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

1514

28158

2837

106279

Jiao (2015)

147

8745

225

8317

Jiao (2014)

38

1034

34

1038

Vagholkar
(2014)

12

463

15

416

The meta-analysis was conducted using a random-effects model as opposed to a fixedeffects model to account for the variations in effect size between studies, allowing us to
account for the heterogeneity when comparing the studies. A correction factor of 0.5 was
used to account for any zero values. Given the discordant odds ratio in Jiao et al. (2015),
a concurrent sensitivity analysis was also employed allowing us to derive the overall
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summary effect measure in addition to the summary effect measure excluding Jiao et al.
(2015). The results of the meta-analysis are presented below (Figure 3).

Figure 4. Forest plot depicting the impact of risk prediction models on new prescription
with antihypertensive medications.
The overall summary effect indicates that the odds of prescribing are 1.02 times greater
(95% CI 0.47, 2.22) in the prediction model group. The confidence interval spans the
null value (1.0), and thus the effect is considered statistically non-significant.
6.2.1.1

Sensitivity analysis

The effect size for Jiao et al. (2015) essentially assumes that all the attrition (in both the
treatment and control groups) constituted participants who represented non-events. The
result of this is striking particularly in the control group, where the assumption of zero
events leads to an infinite estimated effect size (made finite through smoothing). As
recommended by the Cochrane Handbook, a sensitivity analysis was conducted to
provide a range of values to account for the missing data in using a method referred to as
the ‘best-case” and “worst-case” scenarios. The best-case scenario is where all
intervention patients with missing data are inferred to have experienced the event, and
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those in the control group with missing data are inferred to not have experienced the
event. The inverse would then be labelled the worst-case scenario. Only one study (Jiao
et al., 2015) reported attrition. The calculated events and non-events for both the bestand worst-case scenarios are presented below (Table 12).
Table 12. The absolute frequencies as per the best- and worst-case scenarios to account
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015.
Scenario

Group

Type of event

Absolute frequency

Events

675

Non-events

8419

Events

0

Non-events

9094

Events

475

Non-events

8619

Events

372

Non-events

8722

Intervention
Best-case
Control

Intervention
Worst-case
Control

Using the number of events and non-events as per the best- and worst-case scenarios for
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from
1.29 (95% CI 1.12, 1.48) to 1459.31 (95% CI 91.17, 23358.39), and an overall summary
effect range from 1.34 (95% CI 0.92, 1.94, I2 = 93.0%, p<0.001) to 3.29 (95% CI 0.77,
14.16, I2 = 96.7%, p<0.001). Full forest plots are provided in Appendix H.
6.2.1.2

Subgroup analysis: Antihypertensive medication naïve patients

The previous analysis assessing the impact of prediction models on new prescription with
antihypertensive medications was conducted on the entire sample. It included patients
for whom the event had already occurred. A subgroup analysis was conducted to address
the impact of prediction models amongst antihypertensive medication naïve patients (i.e.
patients who were not prescribed antihypertensive medications at baseline).
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The number of events, or new prescription with antihypertensives, remained constant as
previously derived. The number of non-events is given by the number of patients
randomized to the intervention group who are not taking antihypertensives at baseline
and who do not receive a new prescription. The number of non-events was calculated by
first subtracting the total number of participants by those who were taking
antihypertensive medications at baseline, and then subtracting that figure by the number
of events. For example, in Chang et al. (2016), the intervention arm had 29,672 patients,
1424 patients taking antihypertensives at baseline, and a total number of events of 1514.
Through simple subtraction, the number of non-events was calculated to be 26734, as
demonstrated here:
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑛𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠: 29672 − 1424 − 1514 = 26734
To conduct a complete case analysis and account for the loss to follow-up in the Jiao et
al. (2015) study, the number of non-events was calculated using the modified baseline
numbers that account for attrition. The number of non-events was then calculated using
the same methods used for the other studies, as follows:
𝑁𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 : 8892 − 6490 − 147 = 2255
𝑁𝑜𝑛 − 𝑒𝑣𝑒𝑛𝑡𝑠𝑐𝑜𝑛𝑡𝑟𝑜𝑙 : 8542 − 6268 − 225 = 2049
Inputting all the values into a table allows us to conduct a subgroup analysis in STATA
(Table 13). The results of the meta-analysis are presented in Figure 4.
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Table 13. The number of events and non-events from baseline to follow-up in both the
intervention and control groups amongst patients who were antihypertensive medication
naïve at baseline.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

1514

26734

2837

104315

Jiao (2015)

147

2255

225

2049

Jiao (2014)

38

201

34

220

Vagholkar
(2014)

12

327

15

283

Figure 5. Forest plot depicting the impact of risk prediction models on new prescriptions
with antihypertensive medications amongst antihypertensive medication naive patients.
Therefore, amongst patients who were antihypertensive medication naïve, the odds of
prescription with an antihypertensive medication was 1.03 times greater (95% CI
0.45,2.35) amongst those who received the intervention than those who did not.
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6.2.2

New prescriptions with lipid-lowering medications

The same methods employed in section 6.2.1 were used to derive the number of events
and non-events for new prescription with lipid-lowering medication. Four studies were
determined to be eligible for the conduct of a meta-analysis. The information presented
in each article is displayed in Table 14.
Table 14. Reported changes in proportion of patients prescribed with lipid-lowering
medications at baseline and follow-up in both the intervention and control group.
Intervention

Control

Author (year)

Baseline

Follow-up

Baseline

Follow-up

Chang (2016)

2878/29672

4540/29672

3383/109116

4691/109116

Jiao (2015)

1189/9094

4551/8892

1225/9094

3903/8542

Jiao (2014)

866/1072

935/1072

880/1072

949/1072

Vagholkar
(2014)

101/475

108/475

120/431

130/431

The derived number of events and non-events was calculated in the same manner as in
section 6.2.1 (“New prescription with antihypertensives”), and the values are presented in
Table 15, which were subsequently used to conduct the meta-analysis (Figure 5).
Table 15. The number of events and non-events for the intervention and control groups
of the studies eligible for meta-analysis.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

1662

28010

1308

107808

Jiao (2015)

3388

5504

2752

5790

Jiao (2014)

69

1003

69

1003

Vagholkar
(2014)

7

468

10

421
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Figure 6. Forest plot depicting the impact of risk prediction models on new prescription
with lipid-lowering medications.
Therefore, the overall summary effect measure indicates that the odds of new prescription
with lipid-lowering medications is 1.49 times greater (95% CI 0.58, 3.81) amongst
patients who received the intervention compared to those that did not.
6.2.2.1

Sensitivity analysis

A sensitivity analysis as per the best- and worst-case scenario method was conducted as
per the figures presented in Table 16.
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Table 16. The absolute frequencies as per the best- and worst-case scenarios to account
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015.
Scenario

Group

Type of event

Absolute frequency

Events

3564

Non-events

5530

Events

2678

Non-events

6416

Events

3362

Non-events

5732

Events

3230

Non-events

5864

Intervention
Best-case
Control

Intervention
Worst-case
Control

Using the number of events and non-events as per the best- and worst-case scenarios for
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from
1.06 (95% CI 1.00, 1.13) to 1.54 (95% CI 1.45, 1.64). The summary effect range is
from 1.40 (95% CI 0.48, 4.05, I2 = 99.7%, p<0.001) to 1.58 (95% CI 0.69, 3.63, I2 =
99.5%, p<0.001). Full forest plots are provided in Appendix I.
6.2.2.2

Subgroup analysis

The subgroup assessed for with regards to lipid-lowering medications was new
prescriptions with lipid-lowering medications amongst those that are medication naïve.
The number of events and non-events was calculated similarly to section 6.2.2. The
calculated figures are presented below (Table 17). The results of the corresponding metaanalysis are presented below (Figure 6).
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Table 17. The number of events and non-events from baseline to follow-up in both the
intervention and control groups amongst patients who were lipid-lowering medication
naïve at baseline.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

1662

25132

1308

104425

Jiao (2015)

3388

4341

2752

4639

Jiao (2014)

69

137

69

123

Vagholkar
(2014)

7

367

10

301

Figure 7. Forest plot depicting the impact of risk prediction models on new prescription
with lipid-lowering medications amongst medication naive patients.
Overall, it was found that the odds of new prescription with lipid-lowering medication
amongst medication naïve patients favoured the intervention (OR 1.45, 95% CI 0.54,
3.91), though the result was statistically non-significant.
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6.3

Patient behavioral outcomes

Though several articles assessed for patient behavioural outcomes as a result of
prediction model use, including changes in physical activity and diet, or continuity of
care, there were only a sufficient number of studies to conduct a meta-analysis for
smoking cessation.
6.3.1

Smoking cessation

Four studies reported baseline and follow-up proportions of smokers in both the
intervention and control groups. The information presented in the articles is displayed
below (Table 18).
Table 18. Reported changes in proportions of smokers from baseline to follow-up in both
the intervention and control groups.
Intervention

Control

Author (year)

Baseline

Follow-up

Baseline

Follow-up

Chang (2016)

5311/29672

4837/29672

24224/109116

22692/109116

Jiao (2015)

927/9094

346/8892

906/9094

235/8542

Lowensteyn
(1998)

42/202

39/202

21/89

19/89

Powers (2011)

8/44

6/44

8/45

8/45

Similar to the previous two outcomes (prescription with antihypertensive and lipidlowering medications), the number of events and non-events was calculated. Events were
defined as patients who had quit smoking from baseline to follow-up. The method of
calculating the number of events differed from the previous two dichotomous outcomes
in that the event of smoking cessation decreases the number from baseline to follow-up,
while prescription with antihypertensive or lipid-lowering medications increases the
number from baseline to follow-up. Hence, as opposed to the calculation of events used
previously (follow-up – baseline), the difference from baseline to follow-up was used to
calculate the number of events (Table 19). Note that again for Jiao et al. (2015), the
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baseline numbers were modified to account for attrition, resulting in baseline proportions
of smokers of 906/8892 in the intervention arm and 851/8542 in the control arm.
Table 19. The calculated number of events (i.e. number of patients who quit smoking)
from baseline to follow-up in both the intervention and control groups.
Intervention

Control

Author (year)

Baseline –
follow-up

Number of
events

Baseline –
follow-up

Number of
events

Chang (2016)

5311 – 4837

474

24224 – 22692

1532

Jiao (2015)

906 – 346

560

851 – 235

616

Lowensteyn
(1998)

42 – 39

3

21 – 19

2

Powers (2011)

8–6

2

8–8

0

Calculating the number of non-events was conducted in the same fashion as in previous
examples, where the total number of participants was subtracted by the number of events
(Table 20).
Table 20. The calculated number of non-events from baseline to follow-up in both the
intervention and control groups.
Intervention

Control

Author (year)

Total number – Number of
number of
non-events
events

Total number – Number of
number of
non-events
events

Chang (2016)

29672 - 474

29198

109116 – 1532

107584

Jiao (2015)

8892 – 560

8332

8542 – 616

7926

Lowensteyn
(1998)

202 – 3

199

89 – 2

87

Powers (2011)

44 – 2

42

45 – 0

45
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Compiling the list of events and non-events for smoking behaviour allows us to conduct a
meta-analysis (Table 21; Figure 7).
Table 21. The number of events and non-events for the intervention and control groups
of the studies eligible for meta-analysis.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

474

29198

1532

107584

Jiao (2015)

560

8332

616

7926

Lowensteyn
(1998)

3

199

2

87

Powers (2011)

2

42

0

45

Figure 8. Forest plot depicting the impact of risk prediction models on smoking
cessation.
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Overall, there appeared to be no impact of risk prediction model use on the patient
behaviour of smoking cessation when examining all participants (OR 1.00, 95% CI 0.77,
1.29).
6.3.1.1

Sensitivity analysis

A sensitivity analysis to provide a range of potential effect values accounting for the
attrition in Jiao et al. (2015) was conducted using the best- and worst-case scenarios, as
previously described in section 6.2.1.1. The values used are presented below (Table 22).
Table 22. The absolute frequencies as per the best- and worst-case scenarios to account
for attrition and allow for the conduct of sensitivity analyses for Jiao et al. 2015.
Scenario

Group

Type of event

Absolute frequency

Events

581

Non-events

8513

Events

119

Non-events

8980

Events

379

Non-events

8715

Events

671

Non-events

8423

Intervention
Best-case
Control

Intervention
Worst-case
Control

Using the numbers of events and non-events as per the best- and worst-case scenarios for
the Jiao et al. (2015) study, we find that the study presents with an odds ratio range from
0.55 (95% CI 0.48, 0.62) to 5.15 (95% CI 4.22, 6.29), and an overall summary effect
range from 0.84 (95% CI 0.43, 1.63, I2 = 96.1%, p<0.001) to 2.04 (95% CI 0.59, 6.97, I2
= 98.3%, p<0.001). Full forest plots are provided in Appendix J.
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6.3.1.2

Subgroup analysis: Smoking cessation amongst smokers

The number of non-events in the previous section includes non-smoking patients,
allowing us to estimate the impact of prediction models on smoking behaviour in the
population. To garner a sense of the impact of prediction models on smoking cessation
amongst smokers, a subgroup analysis was conducted. Similar to the previous subgroup
analyses, the number of events remained constant, while the number of non-events
excluded non-smokers. The completed number of events and non-events is presented
below (Table 23). The results of the meta-analysis are presented in Figure 8.
Table 23. The number of events and non-events from baseline to follow-up in both the
intervention and control groups amongst patients who were smokers at baseline.
Intervention

Control

Author (year)

Events

Non-events

Events

Non-events

Chang (2016)

474

4837

1532

22692

Jiao (2015)

560

346

616

235

Lowensteyn
(1998)

3

39

2

19

Powers (2011)

2

6

0

8

93

Figure 9. Forest plot depicting the impact of risk prediction models on smoking cessation
amongst smokers.

When examining smokers, there appears to be no impact of risk prediction model use on
smoking cessation (OR 1.01, 95% CI 0.46, 2.18).
6.4

Changes in systolic blood pressure

Four studies identified through the systematic review process assessing the impact of
prediction models on changes in systolic blood pressure were identified as being
appropriate for a meta-analysis. Table 24 displays the information presented in each
article.
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Table 24. The reported changes in systolic blood pressure from baseline to follow-up in
both the intervention and control groups. Mean and absolute change values are presented
in mmHg; parenthesized values are the reported standard deviations.
Intervention

Control

Author
(Year)

Sample
size

Baseline
mean

Followup
mean

Absolute Sample
change
size

Baseline
mean

Followup
mean

Absolute
change

Chang
(2016)

29672

131.9
(17.4)

130.0
(12.7)

NA

109116

128.5
(13.6)

129.3
(11.3)

NA

Jiao (2015)

9094

135.41
(17.05)

130.12
(14.68)

NA

9094

135.45
(16.56)

132.35
(15.51)

NA

Lowensteyn 202
(1998)

133.0
(15.8)

NA

-2.0
(14.2)

89

129.2
(15.5)

NA

-1.2
(14.1)

Powers
(2011)

128.4
(2.7)

128.2
(2.9)

NA

45

126.0
(2.7)

125.0
(2.8)

NA

44

Three of the four studies did not report the absolute change in SBP from baseline to
follow-up. The sample mean difference (D), otherwise referred to as the absolute change,
was calculated by subtracting the baseline mean (𝑥̅1 ) by the follow-up mean (𝑥̅2 ) in
studies where only the baseline and follow-up means were provided. Using the equation:
𝐷 = 𝑥̅1 − 𝑥̅2 ,
the absolute change in SBP was calculated for both the intervention and control groups
(Table 25).
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Table 25. The calculation of absolute change in systolic blood pressure from baseline to
follow-up in both the intervention and control groups.
Intervention

Control

Author (year)

𝑥̅1 − 𝑥̅2

Chang (2016)

131.9 – 130.0

1.9

128.5 – 129.3

-0.8

Jiao (2015)

135.41 –
130.12

5.29

135.45 –
132.35

3.1

Powers (2011)

128.4 – 128.2

0.2

126.0 – 125.0

1.0

Absolute
change

𝑥̅1 − 𝑥̅ 2

Absolute
change

In order to calculate the standard deviation of the difference, the following equation as
per Borenstein et al. was applied:
𝑆𝑑𝑖𝑓𝑓 = √𝑆12 + 𝑆22 − 2 × 𝑟 × 𝑆1 × 𝑆2 .194
The correlation coefficient, r, was not provided. Using the Cochrane Handbook for
Systematic Reviews of Interventions, r was imputed based on the absolute change for
SBP and DBP as calculated by Lowensteyn et al. based on the equation:
𝑟=

2
2
2
𝑆𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
+ 𝑆𝑓𝑖𝑛𝑎𝑙
− 𝑆𝑐ℎ𝑎𝑛𝑔𝑒

2 × 𝑆𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × 𝑆𝑓𝑖𝑛𝑎𝑙

. 190,213

The article by Lowensteyn et al. only provided the standard deviation S for the baseline
SBP and the absolute change. However, as per the Cochrane Handbook, “Where either
the baseline or final standard deviation is unavailable, then it may be substituted by the
other, provided it is reasonable to assume that the intervention does not alter the
variability of the outcome measure” (p. 487).190 Therefore, the final SBP standard
deviation was substituted by the baseline standard deviation. Thus, the correlation
coefficient values for the intervention and control groups were calculated as follows:

𝑟𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛

15.82 + 15.82 − 14.22
=
~ 0.60
2 ×15.8 ×15.8
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𝑟𝑐𝑜𝑛𝑡𝑟𝑜𝑙

15.52 + 15.52 − 14.12
=
~ 0.59
2 ×15.5 ×15.5

Because the correlation coefficient values are greater than 0.5, it is indicated that
assessing the change score from baseline to follow-up provides greater value and
precision than analyzing the final values of blood pressure. The calculated r was imputed
to calculate the standard deviation of the absolute change in SBP for the additional three
studies (Table 26).
Table 26. The calculated standard deviation of the absolute change in systolic blood
pressure from baseline to follow-up in both the intervention and control groups using the
imputed correlation coefficient values derived from Lowensteyn et al.
Intervention

Control
𝑆𝑑𝑖𝑓𝑓

Autho
r
(year)

√𝑆12 + 𝑆22 − 2 × 𝑟 × 𝑆1 × 𝑆2

Chang
(2016)

√17.42 + 12.72 − 2 × 0.6 ×17.4 ×12.7

Jiao
(2015)

√17.052 + 14.682 − 2 ×0.6 ×17.05 ×12.7 15.7
0

Power
s
(2011)

√2.72 + 2.92 − 2 ×0.6 ×2.7 ×2.9

14.1
0

2.51

√𝑆12 + 𝑆22 − 2 × 𝑟 × 𝑆1 × 𝑆2

√13.62 + 11.32 − 2 ×0.59 ×13.6 ×11.4

𝑆𝑑𝑖𝑓𝑓

11.3
9

√16.562 + 15.512 − 2 ×0.59 ×16.56 ×15.5114.5
5
√2.72 + 2.82 − 2 ×0.59 ×2.7 ×2.8

2.49

Completing the initial table (Table 27) provides the data necessary required to conduct a
meta-analysis comparing the mean difference in systolic blood pressure from baseline to
follow-up between the intervention and control groups (Figure 9).
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Table 27. The absolute change values in standard deviation (mmHg) and associated
standard deviations for both the intervention and control groups.
Intervention

Control

Author
(Year)

Sample
size

Absolute
change

Standard
deviation

Sample
size

Absolute Standard
change
deviation

Chang
(2016)

29672

-1.9

14.10

109116

0.8

11.39

Jiao (2015)

9094

-5.29

15.70

9094

-3.1

14.55

Lowensteyn 202
(1998)

-2.0

14.20

89

-1.2

14.10

Powers
(2011)

-0.2

2.51

45

-1.0

2.49

44

Figure 10. Forest plot depicting the impact of risk prediction models on absolute changes
in systolic blood pressure.
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The forest plot indicates that overall, the absolute change of systolic blood pressure is
0.16 mmHg (95% CI -0.24, -0.08) lower in patients who receive the intervention
compared to those who do not.
6.5

Changes in diastolic blood pressure

Similarly, four studies were identified that were considered to be appropriate for metaanalysis for changes in diastolic blood pressure (DBP). Table 28 presents the information
provided in each of these four studies.
Table 28. The reported changes in diastolic blood pressure from baseline to follow-up in
both the intervention and control groups. Mean and absolute change values are presented
in mmHg; parenthesized values are the reported standard deviations.
Intervention

Control

Author
(Year)

Sample Baseline Follow- Absolute Sample Baseline Follow- Absolute
size
mean
up
change
size
mean
up
change
mean
mean

Chang
(2016)

29672

80.2
(10.5)

78.5
(7.7)

NA

109116 78.7
(8.2)

78.7
(6.7)

NA

Jiao (2015)

9094

75.11
(10.34)

71.6
(10.26)

NA

9094

75.08
(9.77)

73.23
(9.72)

NA

Lowensteyn 202
(1998)

82.3
(10.2)

NA

0.9 (8.1)

89

79.8
(11.2)

NA

-0.1
(9.8)

Powers
(2011)

73.5
(1.9)

74.9
(2.0)

NA

45

76.6
(1.8)

76.7
(1.9)

NA

44

The absolute change in DBP was calculated for the three articles that did not present
them using the formula as presented in section 6.4 (Table 29).
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Table 29. The calculation of absolute change in diastolic blood pressure from baseline to
follow-up in both the intervention and control groups.
Intervention

Control

Author (year)

𝑥̅1 − 𝑥̅2

𝑥̅1 − 𝑥̅2

Chang (2016)

80.2 – 78.5

1.7

78.7 – 78.7

0

Jiao (2015)

75.11 – 71.6

3.51

75.08 – 73.23

1.85

Powers (2011)

73.5 – 74.9

-1.4

76.6 – 76.7

-0.1

Absolute
change

Absolute
change

The correlation coefficient (r) was calculated for both the intervention and control group
using the data presented by Lowensteyn et al., and imputed to calculate the standard
deviation of the mean difference (Table 30).

𝑟𝑖𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛

𝑟𝑐𝑜𝑛𝑡𝑟𝑜𝑙

10.22 + 10.22 − 8.12
=
~ 0.68
2 ×10.2 ×10.2

11.22 + 11.22 − 9.82
=
~ 0.62
2 ×11.2 ×11.2

Table 30. Calculation of the standard deviation of the change in diastolic blood pressure.
Intervention
Author
(year)
Chang
(2016)
Jiao
(2015)
Powers
(2011)

√𝑆12 + 𝑆22 − 2 × 𝑟 × 𝑆1 × 𝑆2

Control
𝑆𝑑𝑖𝑓𝑓

√𝑆12 + 𝑆22 − 2 × 𝑟 × 𝑆1 × 𝑆2

𝑆𝑑𝑖𝑓𝑓

√10.52 + 7.72 − 2 × 0.68 ×10.5 ×7.7

7.72

√8.22 + 6.72 − 2 ×0.62 ×8.2 ×6.7

6.12

√10.342 + 10.262 − 2 ×0.68 ×10.34 ×10.26

8.24

√9.772 + 9.722 − 2 ×0.62 ×9.77 ×9.72

7.80

√1.92 + 2.02 − 2 ×0.68 ×1.9 ×2.0

1.56

√1.82 + 1.92 − 2 ×0.62 ×1.8 ×1.9

1.48

Again, given that r exceeds 0.5, we proceeded to conduct the meta-analysis (Figure 10)
based on the absolute change in diastolic blood pressure using the figures provided in
Table 31.
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Table 31. The calculated absolute changes in diastolic blood pressure and associated
standard deviations and sample sizes for both the intervention and control groups.
Intervention

Control

Author
(Year)

Sample
size

Absolute
change

Standard
deviation

Sample
size

Absolute
change

Standard
deviation

Chang
(2016)

29672

1.7

7.72

109116

0.0

6.12

Jiao (2015)

9094

3.51

8.24

9094

1.85

7.80

Lowensteyn 202
(1998)

0.9

8.1

89

-0.1

9.8

Powers
(2011)

-1.4

1.56

45

-0.1

1.48

44

Figure 11. Forest plot depicting the impact of risk prediction models on absolute changes
in diastolic blood pressure.

101

The summary effect measure indicates that patients who receive the intervention
experience a 0.18 mmHg (95% CI 0.10, 0.27) greater increase in diastolic blood pressure
compared to those who did not.
6.6

Conclusion

The results of the meta-analysis found that risk prediction model use favourably impacts
practitioner behaviour, specifically prescription of antihypertensive and lipid-lowering
medications, though neither effect was statistically significant. There appeared to be no
impact of prediction model use on the patient behaviour of smoking cessation. Lastly,
though intervention patients did experience a slight increase in diastolic blood pressure
when compared to control patients, there was a small improvement in the patient health
outcome of systolic blood pressure, with intervention patients experiencing a statistically
significant greater reduction in systolic blood pressure.
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Chapter 7
7.0

Discussion

The use of risk prediction models in primary care settings provides an objective,
evidence-based estimate of a patient’s absolute risk of having (diagnostic) or developing
(prognostic) an outcome. Though not intended to replace a physician’s clinical judgment,
they have the potential to complement the clinical decision-making process. Their
incorporation in numerous guidelines indicates a growing movement towards using risk
prediction models in routine clinical practice. However, the evidence regarding their
impact is sparse and dispersed.
This study sought to collect, collate, and present evidence regarding the impact of chronic
disease risk prediction model use in primary care settings on both patient and physician
behaviour, and patient health outcomes. Few studies have attempted to define the impact
of risk prediction models and the literature remains sparse regarding their effects,
necessitating a need for an objective, comprehensive systematic review and meta-analysis
to compile the presently available evidence. Through a systematic search of the
literature, a narrative summary of the results, and where possible, a meta-analysis of
changes in behavioral and health outcomes, the present evidence regarding the impact of
risk prediction models is presented, forming a foundation from which future studies
examining the impact of prediction models may be conducted.
As far as it is known, this is one of the first systematic reviews and the first meta-analysis
addressing the impact of risk prediction model use in primary care settings. Previous
systematic reviews have focused primarily on the development and validation of existing
models for single health outcomes. For example, Damen et al. sought to provide an
overview of existing risk prediction models for CVD.24 Another systematic review
examined the existing models for melanoma incidence, reporting what the possible risk
factors were as well as measures of model performance, such as sensitivity and
specificity.225 Of the limited number of studies that have addressed the potential impact
of model use, assessments of impact were often conducted secondary to assessments of
development or validation.226,227 Further, no studies were identified that have attempted
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to conduct a meta-analysis for clinically relevant outcomes associated with model use in
primary care settings.33 By providing an overview of all identified studies examining the
impact of risk prediction models, this systematic review has helped to address this gap in
the literature.
This chapter summarizes the results obtained from the systematic review and metaanalysis, discussing possible reasons for any existent or non-existent effects. The
strengths and limitations will also be discussed, and where possible, methods for
overcoming any limitations will be explored. Lastly, suggestions and guidance for future
exploration in this area will be explored.
7.1

Overview of study results

There have been few studies that have examined the impact of risk prediction models in
primary care settings for chronic diseases. Though the initial systematic search identified
well over 8,000 articles, only 22 studies met the eligibility criteria for this review. Not all
the included studies reported on each of the three primary outcomes; most frequently, the
impact was assessed for patient health outcomes (77%), followed by physician behaviour
(68%) and lastly patient behaviour (50%).
Generally, the evidence does not strongly support the use of risk prediction models for
the primary prevention of chronic disease. Physician behaviour appeared to be most
strongly affected, with the majority of included studies experiencing some increases in
prescription of preventive medications, though the effect becomes non-significant when
meta-analyzed. Risk-reducing patient behaviours were the least affected by prediction
model use, with few studies indicating a significant effect on changes in physical activity
or smoking cessation, and the effect tending towards the null when combined. Lastly,
overall event rates for cardiovascular- or diabetes-related health outcomes were only
reported in a limited number of study. Though generally it appeared that recipients of the
prediction model experienced fewer events, the study samples were highly homogenous,
reducing the generalizability of the finding. When examining proxy measures for health
outcomes, such as levels of risk factors, though a statistically significant effect was noted
for changes in blood pressure (both systolic and diastolic), these results may not have
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clinical significance given their small magnitude. The meta-analyses did demonstrate I2
values ranging from 77.2% to 99.6%, indicating a higher degree of inconsistency of study
findings across studies, suggesting heterogeneity between studies. Section 5.3.3 lists the
variations in intervention used; though each study used the risk prediction model as a
main component of their intervention, some provided relative measures of risk in addition
to the absolute measure, the format of risk presentation varied, while others still in a more
directive approach provided lifestyle consultations with other healthcare providers.
Given the possibility of bias and the heterogeneity present in the meta-analysis, these
findings should be interpreted with caution.
7.2

Physician behaviour

Risk prediction models are intended to ultimately improve the health of patients, a goal
that is achieved, at least in part, through modification of the providers’ behaviour. The
prescription of preventive medications, a form of physician behaviour, is indicated for
patients at high risk of disease as they may reduce the patients’ absolute risks. The
results of this study indicate there may be some changes in physician prescribing patterns.
Eleven studies reported the impact of prediction model use on an aspect of physician
behaviour, largely changes in prescription patterns. A meta-analysis was only considered
appropriate for changes in two medications, namely antihypertensives and lipid-lowering
medications. It was found through the meta-analysis that physicians who used a risk
assessment tool were more likely to prescribe these medications, though these changes
were not statistically significant (Figure 3 and Figure 5). However, the impact of model
use on prescribing patterns may still be clinically relevant.
The meta-analysis may have been prone to issues of representativeness; though changes
in prescription were identified in nine and ten studies for antihypertensives and lipidlowering medications respectively, less than half reported data appropriate for a metaanalysis. Indeed, through simple vote counting, increases in antihypertensive
prescription were found to be statistically significant in five studies (55.6%), while
increases in lipid-lowering medication prescription were found to be significant in six
studies (60%). Further, an effect in favour of prediction model use, though not
significant, was noted in three additional studies for antihypertensive prescriptions and
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four additional studies for lipid-lowering medications. If all the identified studies had
data reported allowing for their incorporation in the meta-analysis, it is possible that that
a significant change may have been obtained. As it stands, this indicates that the metaanalysis may have been underpowered to detect a significant change in favour of new
prescription with preventive medications, and the inclusion of additional studies may lend
credence to the belief that risk prediction models positively influence physician
behaviour.
The event rates to calculate measures of effect were in many cases extrapolated and may
not have been entirely accurate. For example, several participants were already
prescribed antihypertensive medications at baseline. The number of events was
calculated by subtracting the counts of persons prescribed medication at follow-up by
those prescribed at baseline, which may be problematic. For example, if one patient were
de-prescribed and two new patients were prescribed during the follow-up period, the
arithmetic would conclude that only one new prescription was given, when in reality, two
were. Though an unlikely scenario, given the nature of a secondary analysis, it is
difficult without the original data to ensure that all prescriptions were amongst new
participants. Further, though an available case analysis was used to account for attrition
in the meta-analysis, again, without the original data, assumptions were made to estimate
the number of events and non-events, namely that the participants that were lost to
follow-up did not differ from those that remained in the study. Despite this potential
limitation, without the original data, this remains the most appropriate method to account
for attrition and calculate the number of events.
This thesis defined physician behaviour primarily as changes in preventive medications,
such as antihypertensive or lipid-lowering medications. This was inherently flawed an
increase in prescription in and of itself does not necessarily indicate an improvement in
clinical patterns. Indeed, a more useful measure of improvements in physician behaviour
may have been quantified as the appropriate prescription with preventive medications,
where medications are given in accordance to clinical guidelines or thresholds of risk.
However, there is evidence to suggest preventive medications for chronic diseases are
underutilized where recommended.228,229,230 Given that preventive medications are
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under-prescribed, any increases in their prescription may be viewed as beneficial. For
greater accuracy in terms of benefits of model use, future studies should draw attention to
the appropriateness of prescription with preventive medications rather than adopting an
all-encompassing approach.
7.3

Patient behaviour

Patient behaviour outcomes were found to be the most variably examined in model
impact analysis studies, with measures used inconsistently across studies. The most
common aspect of patient behaviour assessed in this review was smoking cessation,
examined in eight studies and most consistently defined, especially when compared to the
next most common measure, physical activity, which was assessed in four studies and
measured in four different ways. The impact of risk prediction models on these two areas
of patient behaviour remains inconclusive. Though some changes in physical activity
were noted at the individual study level, it was difficult if not impossible to determine if
an effect existed at the review level. Interestingly, though there exists no impact of risk
prediction models on smoking cessation in the meta-analysis, at the individual study
level, several studies found decreases in smoking prevalence, indicating that there may be
an effect but the meta-analysis was underpowered to detect a change. Overall, the
evidence does not support that model use has an impact on patient behaviour, but given
some effects noted at the study level, this relationship warrants further investigation to
more quantitatively and accurately to be determined.
Though there are several health-related behaviours that patients may initiate to reduce
their risk of chronic disease, no evidence of impact for risk prediction model use was
found on patient behaviour. This relationship, or rather lack thereof, may be
understandable. One study examined the clustering of five health-related behaviours (not
smoking, engaging in physical activity, consuming no to moderate amounts of alcohol,
maintaining normal body weight, and obtaining daily sufficient sleep), finding that
amongst US adults, only 6.3% of participants engaged in all of the behaviours, with
variations of prevalence for each behaviour.231 The researchers proposed that the five
behaviours were not equal in health consequence or in terms of amenability to
intervention, indicating a multifaceted approach through several avenues is necessary to
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positively affect changes in individual behaviour.231 Though several studies included in
this review incorporated aspects of lifestyle advice in the intervention (section 5.2.3), the
scope of the advice was limited in terms of content and modes of delivery; some only
provided a leaflet of information, while only three included verbal consultations with
health care professionals. The limited nature of lifestyle intervention may explain, at
least in part, why health-related patient behaviours were not found to be affected by
prediction model use.
Further, the present body of research assumes equivalence regarding patient perception of
risk, though this is not necessarily the case. For example, the acceptable risk of nuclear
meltdown through the lens of the public, or the risk at which no further safety
improvements are deemed necessary, is often considered to be approximately one in a
million.232 However, this level of acceptable risk is derived from risk perceptions, which
encompass not just the probability of the outcome but also the magnitude of harms, the
latter which may differ greatly from person to person, affecting individual levels of
acceptable risk.233 Depending on the patient and the physician’s level of numeracy, the
interpretation of risk may also vary and affect behavioural outcomes.234 Applied to risk
prediction models and measures of absolute risk, the acceptable, or tolerable, risk may
differ from person to person, with a spectrum of associated behavioural responses
ranging from apathy to anxiety with regards to preventive measures, providing a possible
explanation for the consequent patient behaviours found in this study.
7.4

Patient health outcomes

One of the primary outcomes of interest of this systematic review and meta-analysis was
to assess the impact of risk prediction models on patient health outcomes. The definition
of patient health outcomes was intentionally left broad to provide a full spectrum of
possible outcomes, from hard outcomes, such as incidence of stroke, to proxies for health
outcomes or soft outcomes, such as changes in systolic blood pressure. The studies
included in this review focused primarily on changes in absolute risk and changes in risk
factor levels. At the individual study level, there was a lack of consistency in terms of
the findings. For example, though risk prediction model use is expected to improve a
patient’s absolute risk of experiencing a chronic disease, decreases in absolute risk were
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found in fewer than half the included studies. This trend of uncertainty was consistent
across most reported health outcomes, including changes in blood pressure or cholesterol
levels.
Several of the studies identified in the systematic review were not considered metaanalyzable given the inconsistency in data reporting. Only two soft outcomes were metaanalyzable: changes in systolic and diastolic blood pressure. The results of the metaanalysis indicate that there is a small but significant decrease in systolic blood pressure.
Our results suggest that risk prediction models may have an impact on reducing systolic
blood pressure amongst patients, though caution must be used when generalizing the
results due to concerns of representativeness, heterogeneity, and the small magnitude of
effect; the small decrease in systolic blood pressure may not have any effect on the
patient’s absolute risk of disease. Interestingly, in terms of diastolic blood pressure, a
significant increase was found. Though this may appear to be contradictory given that
model use should, theoretically speaking, result in a decrease in diastolic blood pressure,
again, this effect should be interpreted cautiously as once again, there exists the potential
for unrepresentativeness and the small magnitude of effect may have no impact on
absolute risk. In other words, though the changes in blood pressure were statistically
significant, given their small magnitude, they may not be clinically significant.
The inconsistency of evidence may be attributed to a few key factors. The pathway from
risk prediction model use to changes in patient health outcomes requires changes in
behaviour, both physician and patient. Preventive interventions may be enacted by the
physician, such as the prescription with preventive medications, with patients making the
necessary corresponding changes in health-related behaviours, such as adhering to the
medication schedule, but without the health-related behavioural modifications, the impact
of model use on health outcomes may be muted. Further, the studies included varied in
terms of follow-up periods, possibly not allowing enough time for changes to be noted or
at least providing some explanation for heterogeneity in terms of the magnitude of
change. Given the novelty of impact analysis studies, future research in the area would
benefit from quantifying the impact of model use on behavioural modifications and
adopting a consistent length of follow-up period of sufficient time.
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Most studies reporting on changes in risk factor values reported baseline and follow-up
values without a measure of change. In many circumstances, analyses conducted on the
follow-up values can provide a measure of effect assuming that at baseline, both the
intervention and control group are equivalent, and therefore, any differences at follow-up
are a measure of treatment effect. However, this does not allow us to examine the
magnitude of impact. In other words, by providing the baseline and follow-up values, the
researchers seek to resolve whether there is any effect of intervention use; by calculating
the absolute change from baseline to follow-up, the researchers would be resolving a
different question, namely how large is the impact of risk prediction models? Though the
two purposes may differ, by only assessing for significant changes in follow-up values,
the assumption is that values are the same at baseline, an assumption which may be void
in some cases. A measure of statistical “sameness” does not indicate that the values at
baseline are identical, but rather that they are similar. A more accurate measure of effect
would be to determine whether the absolute change in the intervention and control arm
differs, allowing readers to more meaningfully determine if an impact exists, and if so,
whether the magnitude is of clinical significance.
7.5

Strengths

There exists a growing movement towards using risk prediction models in clinical
settings as indicated by the incorporation of prediction models in several guidelines
internationally. However, there exists a lack of evidence regarding the potential
impact(s) of the models on clinical practice and on patient health outcomes. This
strongly indicates that research is required in this field, a need that has been expressed by
several researchers. This study is among the first systematic reviews to extensively
examine the literature for studies investigating the impact of chronic disease risk
prediction models. This is also the first meta-analysis to quantify the impact of model
use on physician behaviour, patient behaviour, and patient health outcomes. As such, this
study sought to provide the strongest level of evidence examining the impact of model
use.
Though previously conducted systematic reviews have focused specifically on
cardiovascular diseases, our eligibility criteria allowed us to expand our scope to include
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other chronic diseases, providing a more holistic perspective of the impact of prediction
models. Though this study may have identified studies assessing primarily the impact of
cardiovascular risk prediction models, this review has identified the need for impact
analysis studies of models predictive of other chronic diseases. The Gail model, for
example, was developed in 1989, and yet no studies assessing for its impact on breast
cancer risk were identified, despite almost 30 years since its inception.26 In identifying
this gap in the literature, future studies may be conducted to further expand the scope of
the literature and provide insights regarding model impact for chronic diseases presently
unexamined.
7.6

Limitations

There exists the possibility that not all the literature pertaining to model impact was
identified. This may be attributable to the lack of database specific terms for concepts
such as ‘risk prediction models’. Further, though the WHO categorizations of chronic
diseases encompass approximately 80% of presently prevalent chronic diseases, not all
diseases are captured within the categories of cardiovascular diseases, diabetes, cancers,
and chronic respiratory diseases. To ameliorate this potential limitation, the search
strategy was completed in consultation with a research librarian to help ensure its
comprehensiveness. The existence of a MeSH term for the concept of risk prediction
models would enable a more directed, comprehensive search within this field, allowing
for the identification of a greater number of studies.
The outcomes examined in this systematic review may also present some concerns,
specifically the outcome of patient behaviour. Though it has been characterized in
existing studies through behaviours or actions such as smoking cessation or changes in
physical activity, one possible area that should be emphasized that exists on the pathway
from medication prescription to health outcome is medication accessibility and
subsequent medication adherence. For example, antihypertensive medications may
reduce a patient’s risk of stroke by almost 40% through reductions in in systolic and
diastolic blood pressure (by 10-12 mmHg and 5-6 mmHg, respectively).235 These
decreases are possible only if patients are taking the medications as prescribed. Measures
of medication accessibility and adherence would provide a strong measure of patient
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behaviour, but also provide some explanation for any changes or lack thereof for patient
health outcomes.
This review may also have been prone to some biases. The risk of bias summary (Figure
11) indicates that this study may have been prone to biases in terms of confounding and
external validity, and was potentially statistically underpowered. This study may also
have been susceptible to publication bias. Publication bias occurs in a systematic review
when studies that fulfill the eligibility criteria are not identified because they have not
been published, resulting in a biased perspective of the literature.190,236 Further, an
assessment of publication bias was not possible as there were an insufficient number of
studies to conduct a formal assessments as per the Cochrane Handbook.190 Other biases
may have been introduced during the conduct of the meta-analyses as well. For example,
though 10 studies reported the impact of model use on systolic blood pressure, only 4
were included in the meta-analysis, which could introduce bias if these 4 studies are not
representative of the entire evidence base.236 Though measures to reduce the risk of
biases were enacted, such as grey literature searches and having multiple reviewers, the
potential for bias still exists.
Variations in terms of study conduct may pose as issues of heterogeneity. For example,
nearly half of all studies in this review provided lifestyle advice in addition to the
patient’s absolute risk of developing disease. Additional studies also provided referrals
to other healthcare providers, and in some cases, provided multiple training opportunities
to physicians regarding model use and intent. Because of these additional intervention
components, it becomes difficult to discern with certainty to what extent the effect is a
result of model use. Risk presentation also varied between studies, with some studies
providing absolute risk in paper format, with others communicating risk verbally or
through use of a computer- or tablet-based platform. Further, in some studies, relative
measures of risk were provided in addition to the absolute measures, potentially
influencing both the physician and patient response to risk. Differences in length of
follow-up may also account for variations in changes in risk factor levels. Indeed, Price
et al. followed their patients for one month, while the period of follow-up for Jiao et al.
(2015) was three years. The combination of these two studies, hypothetically, indicates
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that the magnitude of effect remains constant across the period of follow-up, a potentially
unfair assumption. Given the sparsity of model impact studies, all identified studies that
met the eligibility criteria were included. As the field develops, however, additional
criteria may be applied to future systematic reviews to reduce the risks associated with
study heterogeneity.
7.7

Implications for future research and practice

This systematic review and meta-analysis was most limited by the heterogeneity of
studies. Inspection of the I2 values for the meta-analyses indicates the analyses and thus
the variation across studies was due to heterogeneity, not chance. To strengthen the body
of literature, there is a strong need for consistent, overarching guidance of the appropriate
conduct for impact analysis studies. The Cochrane Collaboration Prognosis Reviews
Methods Group was formed to evaluate the growing body of literature pertaining to
prediction models, and the group developed the CHARMS checklist, a critical appraisal
and data extraction checklist for systematic reviews of prediction models.60 However, the
checklist only accounts for development and validation studies, with little to no
applicability to impact analysis studies given the difference in aims, study designs, and
reporting.60
A tool guiding the conduct of impact analysis studies would ensure the methodological
rigour of studies and strengthen the body of evidence exploring the impact of risk
prediction models. The present body of literature indicates several inconsistencies that
should be addressed. Firstly, a significant amount of heterogeneity in study design exists,
with existing studies ranging from pre-post observational studies to cluster randomized
trials, which, while not necessarily precluding the possibility of, reduces the
comparability between studies. Interventions are also uniquely presented across studies,
such as providing lifestyle advice additional to the model-derived risk. Pertaining to
study conduct, periods of follow-up are non-uniform, ranging from a period of weeks to
years, both reducing the comparability of studies as well as possibly not allowing for
changes in behaviour or health outcomes. The reporting of impact studies is also
inconsistent, with diversity in measurement and presentation of study outcomes. The
development of such a tool could help inform the conceptualization, conduct, analyses,
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and reporting associated with impact analysis studies, creating greater consistency in the
literature, and allowing for the meaningful interpretation of study findings.
Future studies should also examine the implementation of risk prediction models in
primary care settings. The use of risk prediction models in clinical practice faces several
barriers, including those of time and uncertainty. The physician-patient interaction is
already temporally restricted, reducing the amount of time available for preventive
services.153 Further, models exist for several health outcomes, and each model is
designed for a specific target population. As such, there exists uncertainty about which
models are appropriate for a physician’s patients.70 This problem may be compounded
by the rising prevalence in multimorbidity, which would necessitate multiple models
being used for a single patient, significantly increasing the time spent in preventive
services. In recognition of these time constraints, uncertainty, and the rise in
multimorbidity globally, there exists the need to streamline the process. This may be
accomplished through the incorporation of models in routine electronic medical records
allowing for automated calculation of absolute risk, or the creation of models capable of
predicting for multiple health outcomes (multimorbidity risk prediction models). By
streamlining this process, the process of implementing risk prediction models in clinical
practice may be eased.
7.8

Conclusion

This systematic review and meta-analysis brought to light the inconsistencies in the
conduct of impact analysis studies, and inconsistencies in general within the growing
field of prediction modelling. This study identified a small group of studies that
examined the impact of prediction models on clinical and behavioural outcomes. Though
these studies may have been affected by methodological discrepancies and the review
would be strengthened by a unified method for conducting model impact studies, they do
provide some measure of support for the use of prediction models in primary care
settings, and indicate that future research must be undertaken to ascertain the most
effective methods of implementing these tools in clinical practice.
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Appendix A: The Gusto-I Model predicting risk of mortality at 30 days for patients who
experience myocardial infarction.
Probability of death within 30 days = 1 / [1 + exp(-L)], where L is given by:
L= 3.812 + 0.07624*age - 0.03976*minimum(SBP, 120) + 2.0796[Killip class II] +
3.6232[Killip class III] + 4.0392[Killip class IV] - 0.02113*heart rate + 0.03936(heart
rate-50) - 0.5355[inferior MI] - 0.2598[other MI location] + 0.4115[previous MI] 0.03972*height + 0.0001835(height-154.9) + 3 - 0.0008975(height-165.1) + 3 +
0.001587(height - 172.0) + 3-0.001068(height-177.3) + 3 + 0.0001943 (height-185.4) + 3
+ 0.09299 (time to treatment)-0.2190[current smoker]-0.2129[former smoker] +
0.2497[diabetes] - 0.007379*weight + 0.3524[previous CABG] + 0.2142[SK and
intravenous heparin] + 0.1968[treatment with SK and subcutaneous heparin] +
0.1399[combination TPA and SK plus IV heparin] + 0.1645[hx of hypertension] +
0.3412 [hx of cerebrovascular disease] - 0.02124 age*[Killip class II] - 0.03494
age*[Killip class III] - 0.03216 age · [Killip class IV]
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Appendix B: Search strategies and citations retrieved
Embase
Step
1
2
3

4
5
6
7

8
9

10
11
12
13

14
15

Search Terms
Risk/ or Patient Risk/ or Expectancy/ or Risk Factor/
limit 1 to (human and english language and yr="1976 -Current")
((Risk adj3 (adjust* or factor*)) or Probabilit* or Likelihood).mp.
[mp=title, abstract, heading word, drug trade name, original title,
device manufacturer, drug manufacturer, device trade name,
keyword, floating subheading]
limit 3 to (human and english language and yr="1976 -Current")
1 or 3
2 or 4
Cardiometabolic Risk/ or Cardiovascular Risk/ or Coronary Risk/ or
Reynolds risk score/ or Framingham risk score/ or CHADS2 Score/
or PROCAM Score/ or QRISK Score/ or Receiver Operating
Characteristic/ or exp Area Under the Curve/ or exp "prediction and
forecasting"/ or survival prediction/ or survival rate/ or exp decision
support system/ or clinical decision making/ or medical decision
making/
limit 7 to (human and english language and yr="1976 -Current")
("Risk scor*" or risk tool* or risk estimat* or risk assess* or risk
function* or risk equation* or risk calc* or risk scor* or risk predict*
or risk factor calc* or risk chart* or risk engine* or risk appraisal* or
prediction model* or risk algorithm* or scoring* method* or scoring
scheme* or roc curve or area under curve or AUC or c-statistic* or C
index* or C indices*).mp. [mp=title, abstract, heading word, drug
trade name, original title, device manufacturer, drug manufacturer,
device trade name, keyword, floating subheading]
limit 9 to (human and english language and yr="1976 -Current")
7 or 9
8 or 10
Chronic Disease/ or Cardiovascular Disease/ or Heart Disease/ or
Vascular Disease/ or Lung Disease/ or Chronic Lung Disease/ or
Chronic Obstructive Lung Disease/ or Asthma/ or Diabetes Mellitus/
or Insulin Dependent Diabetes Mellitus/ or Non Insulin Dependent
Diabetes Mellitus/ or exp Neoplasm/
limit 13 to (human and english language and yr="1976 -Current")
(Chronic disease* or Chronic illness* or chronically ill or noncommunicable disease* or cardiovascular disease* or vascular
disease* or heart disease* or stroke or respiratory disease* or asthma
or COPD or chronic obstructive pulmonary disease* or diabetes or
diabetes mellitus or diabetic or cancer* or neoplasm* or metastatic*
or metastisi* or metastases or carcinoma* or tumo?r*).mp. [mp=title,

Results
1792018
1455591
1416454

1091256
2225620
1740409
1720383

1289143
586636

477129
2100566
1590351
5711682

3678673
6617097
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16
17
18
19
20
21

22
23
24
25
26

abstract, heading word, drug trade name, original title, device
manufacturer, drug manufacturer, device trade name, keyword,
floating subheading]
limit 15 to (human and english language and yr="1976 -Current")
13 or 15
14 or 16
exp Primary Health Care/ or General Practice/
limit 19 to (human and english language and yr="1976 -Current")
(Primary health care or primary care or primary healthcare or primary
medical care or family practice or family medicine or general
practi*).mp. [mp=title, abstract, heading word, drug trade name,
original title, device manufacturer, drug manufacturer, device trade
name, keyword, floating subheading]
limit 21 to (human and english language and yr="1976 -Current")
19 or 21
20 or 22
5 and 11 and 17 and 23
6 and 12 and 18 and 24

Medline
Steps Search terms
1
Risk/ or Risk Factors/ or Risk Adjustment/
2
limit 1 to (english language and humans and yr="1976 -Current")
3
((Risk adj3 (adjust* or factor*)) or Probabilit* or Likelihood).mp.
[mp=title, abstract, original title, name of substance word, subject
heading word, keyword heading word, protocol supplementary
concept word, rare disease supplementary concept word, unique
identifier, synonyms]
4
limit 3 to (english language and humans and yr="1976 -Current")
5
1 or 3
6
2 or 4
7
Algorithms/ or Probability/ or Bayes Theorem/ or Likelihood
Functions/ or Proportional Hazards Models/ or "Sensitivity and
Specificity"/ or ROC Curve/ or exp Decision Support Techniques/
or Area Under Curve/ or Clinical Decision-Making/ or exp Risk
Assessment/
8
limit 7 to (english language and humans and yr="1976 -Current")
9
("Risk scor*" or risk tool* or risk estimat* or risk assess* or risk
function* or risk equation* or risk calc* or risk scor* or risk
predict* or risk factor calc* or risk chart* or risk engine* or risk
appraisal* or prediction model* or risk algorithm* or scoring*
method* or scoring scheme* or roc curve or area under curve or
AUC or c-statistic* or C index* or C indices*).mp. [mp=title,
abstract, original title, name of substance word, subject heading

4218997
7255289
4569682
221104
159278
330910

232874
330910
232874
8318
7311

Results
782446
669642
1202769

903884
1290060
973836
900317

661515
375007
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10
11
12
13

14
15

16
17
18
19
20
21

22
23
24
25
26

word, keyword heading word, protocol supplementary concept
word, rare disease supplementary concept word, unique identifier,
synonyms]
limit 9 to (english language and humans and yr="1976 -Current")
7 or 9
8 or 10
Chronic Disease/ or Cardiovascular Diseases/ or exp Heart Diseases/
or exp Vascular Diseases/ or exp Lung Diseases, Obstructive/ or
Diabetes Mellitus/ or Diabetes Mellitus, Type 1/ or exp Diabetes
Mellitus, Type 2/ or Neoplasms/ or exp Neoplasms by Histologic
Type/ or exp Neoplasms by Site/
limit 13 to (english language and humans and yr="1976 -Current")
(Chronic disease* or Chronic illness* or chronically ill or noncommunicable disease* or cardiovascular disease* or vascular
disease* or heart disease* or stroke or respiratory disease* or
asthma or COPD or chronic obstructive pulmonary disease* or
diabetes or diabetes mellitus or diabetic or cancer* or neoplasm* or
metastatic* or metastisi* or metastases or carcinoma* or
tumo?r*).mp. [mp=title, abstract, original title, name of substance
word, subject heading word, keyword heading word, protocol
supplementary concept word, rare disease supplementary concept
word, unique identifier, synonyms]
limit 15 to (english language and humans and yr="1976 -Current")
13 or 15
14 or 16
Primary Health Care/ or Comprehensive Health Care/ or exp
General Practice/
limit 19 to (english language and humans and yr="1976 -Current")
(Primary health care or primary care or primary healthcare or
primary medical care or family practice or family medicine or
general practi*).mp. [mp=title, abstract, original title, name of
substance word, subject heading word, keyword heading word,
protocol supplementary concept word, rare disease supplementary
concept word, unique identifier, synonyms]
limit 21 to (english language and humans and yr="1976 -Current")
19 or 21
20 or 22
5 and 11 and 17 and 23
6 and 12 and 18 and 24

300610
989961
712702
5281905

3414820
4887214

3031693
6516965
3962675
133832
92993
231332

1588565
236748
160459
2696
2396

CINAHL
Step

Search Terms and options

Results

144

1

2

(MH “Risk Factors+”) OR (MH “Health Screening+”) OR (MH
“Patient Assessment+”)
Search modes - Boolean/Phrase
(MH “Risk Factors+”) OR (MH “Health Screening+”) OR (MH
“Patient Assessment+”)

176674

85634

3

Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
Risk adj3 (adjust* OR factor*) OR Probabilit* OR Likelihood

36531

4

Search modes - Boolean/Phrase
Risk adj3 (adjust* OR factor*) OR Probabilit* OR Likelihood

27669

5
6
7

8

9

10

Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
1 or 3
2 or 4
(MH "Predictive Value of Tests") OR (MH “Predictive Research”)
OR (MH “Models, Statistical”) OR (MH “Decision Support
Techniques+”) OR (MH “Decision Making, Clinical”) OR (MH
“Clinical Assessment Tools”) OR (MH “Risk Assessment”) OR
(MH “ROC Curve”) OR (MH “Survival Analysis+”)
Search modes - Boolean/Phrase
(MH "Predictive Value of Tests") OR (MH “Predictive Research”)
OR (MH “Models, Statistical”) OR (MH “Decision Support
Techniques+”) OR (MH “Decision Making, Clinical”) OR (MH
“Clinical Assessment Tools”) OR (MH “Risk Assessment”) OR
(MH “ROC Curve”) OR (MH “Survival Analysis+”)
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
“Risk scor*” OR risk tool* OR risk estimat* OR risk assess* OR
risk function* OR risk equation* OR risk calc* OR risk scor* OR
risk predict* OR risk factor calc* OR risk chart* OR risk engine*
OR risk appraisal* OR prediction model* OR risk algorithm* OR
scoring* method* OR scoring scheme* OR roc curve OR area
under curve OR AUC OR c-statistic* OR C index* OR C indices*
Search modes - Boolean/Phrase
“Risk scor*” OR risk tool* OR risk estimat* OR risk assess* OR
risk function* OR risk equation* OR risk calc* OR risk scor* OR
risk predict* OR risk factor calc* OR risk chart* OR risk engine*
OR risk appraisal* OR prediction model* OR risk algorithm* OR

109548
208539
201806

146268

90777

56570
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11
12
13

14

15

16

17
18
19

scoring* method* OR scoring scheme* OR roc curve OR area
under curve OR AUC OR c-statistic* OR C index* OR C indices*
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
7 or 9
8 or 10
(MH “Chronic Disease”) OR (MH “Cardiovascular Diseases”) OR
(MH “Heart Diseases”) OR (MH “Vascular Diseases”) OR (MH
“Lung Diseases”) OR (MH “Lung Diseases, Obstructive+”) OR
(MH “Diabetes Mellitus”) OR (MH “Diabetes Mellitus, Type 1”)
OR (MH “Diabetes Mellitus, Type 2”) OR (MH “Neoplasms”) OR
(MH “Neoplasms by Site+”) OR (MH “Neoplasms by Histologic
Type+”)
Search modes - Boolean/Phrase
(MH “Chronic Disease”) OR (MH “Cardiovascular Diseases”) OR
(MH “Heart Diseases”) OR (MH “Vascular Diseases”) OR (MH
“Lung Diseases”) OR (MH “Lung Diseases, Obstructive+”) OR
(MH “Diabetes Mellitus”) OR (MH “Diabetes Mellitus, Type 1”)
OR (MH “Diabetes Mellitus, Type 2”) OR (MH “Neoplasms”) OR
(MH “Neoplasms by Site+”) OR (MH “Neoplasms by Histologic
Type+”)
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
Chronic disease* OR Chronic illness* OR chronically ill OR noncommunicable disease* OR cardiovascular disease* OR vascular
disease* OR heart disease* OR stroke OR respiratory disease* OR
asthma OR COPD OR chronic obstructive pulmonary disease* OR
diabetes OR diabetes mellitus OR diabetic OR cancer* OR
neoplasm* OR metastatic* OR metastisi* OR metastases OR
carcinoma* OR tumo?r*
Search modes - Boolean/Phrase
Chronic disease* OR Chronic illness* OR chronically ill OR noncommunicable disease* OR cardiovascular disease* OR vascular
disease* OR heart disease* OR stroke OR respiratory disease* OR
asthma OR COPD OR chronic obstructive pulmonary disease* OR
diabetes OR diabetes mellitus OR diabetic OR cancer* OR
neoplasm* OR metastatic* OR metastisi* OR metastases OR
carcinoma* OR tumo?r*
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
13 or 15
14 or 16
(MH “Primary Health Care”) OR (MH “Family Centered Care+”)

235929
167860
359492

129339

521893

194062

200021
39265
39265
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20

21

22

23
24
25
26

Search modes - Boolean/Phrase
(MH “Primary Health Care”) OR (MH “Family Centered Care+”)
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
Primary health care OR primary care OR primary healthcare OR
primary medical care OR family practice OR family medicine OR
general practi*
Search modes - Boolean/Phrase
Primary health care OR primary care OR primary healthcare OR
primary medical care OR family practice OR family medicine OR
general practi*
Limiters - Published Date: 19760101-20170331; English Language;
Human
Search modes - Boolean/Phrase
19 or 21
20 or 22
5 and 11 and 17 and 23
6 and 12 and 18 and 24

13019

78566

32297

83275
33712
857
555
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Appendix C: Study eligibility criteria
Title/abstract level
Inclusion criteria:
- Intervention is or includes a risk prediction model
- The model is prognostic
- The model generates a predicted risk for a chronic disease
- The study must test the effect of the intervention (i.e. model impact)
- Include articles with no age, geographic, or sex restrictions
Exclusion criteria:
- Model is diagnostic
- Model assesses for behavioural, mental, or acute health outcomes (i.e. risk of STI
infection, risk of schizophrenia, risk of fracture)
- Patients are generally symptomatic for the outcome of the model (>20%)
- The study does not occur in a primary care setting
- The healthcare professional is not a physician
- The citation is for an editorial or opinion piece
- The study describes only the development or validation of risk prediction models
Full-text level
- Confirmation of criteria from title/abstract level of screening
Inclusion criteria:
- The study assesses the effect of the intervention on physicians and/or patients
- Include studies with a control group
Exclusion criteria:
- The study does not include some form of a control group (i.e. no pre- data in a pre-post
study)
- Exclude studies that only evaluate economic impact of model use
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Appendix D: Brief description of interventions administered
Author,
year
van den
BrekelDijkstra et
al., 2016201

Description of intervention
Patients completed web-based questionnaire. Those identified at increased risk
based on personal information (e.g. sociodemographic, personal health)
completed biometric and laboratory testing, generating 10-year CVD risk.
Patients receive health plan containing: 1) outcome of risk assessment (normal,
moderately elevated risk, seriously elevated risk), 2) explanation of health risk
and benefits of preventive action, 3) individual opportunities for lifestyle
change, and 4) links to local providers of lifestyle interventions. Follow-up
electronic questionnaire sent six months after receiving tailored advice.

UsherPatients informed of change in NICE guidelines (change in statin prescription
Smith et al., threshold from 20% absolute risk to 10%), provided information leaflet
2015219
regarding recommendations, risk calculation, statins, and lifestyle advice.
Leaflet encourages lifestyle modifications and invited to visit clinics to discuss
statins. At clinic appointment, patients told QRISK score, discuss statins, and
offered opportunity for further review in the future if hesitant. Data were
retrieved from practice electronic records.
Sorensen et
al., 2011220

Patients underwent medical history interview regarding previous disease, and
tobacco and medication use. Risk factors were measured and CVD risk was
calculated. Participants and their general physicians received written reports. If
at elevated risk, participants were notified to contact their physician. Follow-up
questionnaires were mailed to patients six months following screening
examination.

BachNielsen et
al., 2005199

A previous study recruited participants, who were randomly allocated to either a
control group, where lifestyle questions were asked, or an intervention group,
where a health screening, including calculation and written provision of
cardiovascular risk, was conducted. The subject of the present article was a
qualitative study, where patients were interviewed regarding their participation
in screening, their experiences and findings, assessments of their own health,
views regarding health promotion and screening, and opinions on consultations
with their physician.

Chang et
al., 2016203

Data were extracted for patients registered at a practice participating in the
Clinical Practice Research Datalink. Patients were categorized as either Health
Check attendees and nonattendees. Patients during the Health Check received
their cardiovascular risk as well as tailored management strategies including
lifestyle advice.

Cochrane et Patients from 38 general practices were recruited, and practices were
al., 2012204 randomized to the NHS Health Check group or the NHS Health Check plus
additional lifestyle support group. The NHS Health Check included usual
general care, such as smoking cessation or medication services and provision of
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risk score. Lifestyle support included consultation with lifestyle coaches, the
development of health improvement plans, and lifestyle priorities with referrals
to free support sessions for weight management, physical activity, dietary
support, and positive thinking. One year follow-up measures were obtained.
Vagholkar
et al.,
2014221

Randomization occurred at the level of the practice. Physicians were trained (3hour workshop) in the use of the New Zealand CV risk calculator and
recommendations for cardiovascular risk based on Australian and New Zealand
guidelines. Intervention patients received 20-30 minute consultations where risk
was calculated, and were provided appropriate management based on risk levels
and current guidelines. Control patients received a general health check.
Physicians reassessed cardiovascular risk at the 12-month health check.

Grover et
al., 2008209

Patients were stratified by risk level (very high, high, or moderate) and
randomized to receive either printed, individualized risk profiles or usual care.
Risk profiles display probability of coronary disease risk over an 8-year period
as well as cardiovascular age, a life expectancy adjusted for risk of coronary
disease and stroke based on average life expectancy of Canadians of the same
age and sex. Risk profiles were mailed to physicians prior to the next patient
visit, and shown to intervention patients at their visit as well as provided to
patients to take home. Biometric measures (blood pressure, lipids) were taken
2-4 weeks prior to and at each follow-up visit. Updated risk profiles were
discussed with intervention patients at each visit.

Courtney et
al., 2015205

Patients who received PreDx results were identified from a comprehensive
electronic medical database in the Dallas-Fort Worth area. A comparison group
matched for age, sex, selected diagnoses (similar to intervention group), and
metabolic risk factors was also selected from the same database. A report was
provided to patients including the PreDx results, a numerical score
distinguishing risk of type 2 diabetes, as well as the individual patient’s risk
compared to the general population, and the levels of the patient’s individual
biomarkers with their normal ranges. Data were also collected regarding
intensity of care, risk factor monitoring, and prescription medication.

Engberg et
al., 2002206

Patients randomly selected from one district in Denmark, and received a
questionnaire about general demographic information and lifestyle, as well as
questions about psychosocial status and psychosocial life events. Patients
randomly allocated to 1 of 3 groups: 1) questionnaire (includes healthy lifestyle
pamphlet) only, 2) questionnaire and health screening, and 3) questionnaire,
health screening, and follow-up health discussions. Health screenings provided
each patient with an estimate of cardiovascular risk. If at elevated risk, patients
received feedback relating to lifestyle changes, and were encouraged to see their
general practitioner. Health discussions were 45 minute consultations with
general physicians, where patient concerns were addressed and lifestyle goals
were established. Health discussion groups were offered annual consultations;
all other groups had follow-ups at 1 and 5 years post-baseline.
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Ford et al.,
2001207

The Clinical Biochemistry laboratory database at Birmingham Heartlands
Hospital was searched for all CHD risk requests made in 1998. Physicians
made requests by providing a laboratory request form with a blood sample, the
cardiovascular risk is calculated. Researchers visited practices to review patient
case notes for those a risk request was made for. Risk results were confirmed,
as well as reasons why tests were ordered, prescribed drugs both before and
after the risk request, and any other management changes.

Grover et
al., 2007208

Physicians attended a regional investigator meeting, which included training on
interpreting risk profiles, national lipid guidelines, and the study protocol.
Patients were screened with a complete medical evaluation. Patients were
randomized to usual care or ongoing feedback regarding calculated coronary
risk. Risk profiles including 10-year coronary risk were discussed with patients
by study physicians in the intervention arm, while usual care patients did not
receive risk profiles. Risk profiles were computer printouts with disease risk as
well as cardiovascular age, and contained relative risks as well as absolute risk.
Patients were followed for one year with biometric measures taken before and
during each follow-up visit (3 month intervals).

Jiao et al.,
2015211

Patients (in the RAMP-DM group) of public general outpatient clinics
underwent risk factor screening for diabetes-related complications and were
stratified according to JADE classification (high, medium, low risk). RAMPDM subjects received appropriate interventions and education according to risk.
Usual care patients were managed by physicians without risk assessment and
stratification.

Jiao et al.,
2014210

Patients (in the RAMP-DM group) entering the program underwent risk factor
assessment and potential existing diabetic complications upon enrolment, and
were stratified as low, medium, or high risk. Different management strategies
were provided to them, such as consultation with allied health professionals.
Patients under usual care were managed solely by physicians without risk
assessment and stratification.

Law et al.,
2014212

Physicians prospectively collected data amongst ambulatory patients.
Physicians determined patient cardiovascular risk, and reported subsequent
treatment decisions.

Lowensteyn Community-based family physicians were invited for participation, and
et al.,
assigned a study site. Study sites were allocated to the profile group or the
1998213
control group. Physicians then invited patients. Physicians inputted risk factor
data, then patient completed a questionnaire outlining attitudes and knowledge
of CVD as well as current lifestyle and medical problems. Profile patients
received a printed copy of their risk profile. Patients were scheduled for a
follow-up visit 3 to 6 months later. New risk factor data were collected at
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follow-up. Profiles provide 8-year coronary risk, and risk reductions for
modifications of risk factors.
Mehta et
al., 2014214

Patients recruited upon their physician’s use of PREDICT, a web-based clinical
decision program that generates an absolute risk for patients. Patients were
stratified according to cardiovascular risk (high, moderate, or low risk).
PREDICT database was linked to the Pharmaceutical Collections to collect data
on dispensing of medications.

Palmieri et
al., 2011215

Physicians were trained in the USE of the 10-CR score, and downloaded the
CUORE.EXE software, which allows users to calculate CVD risk based on
patient characteristics. It also provides a hypothetical risk based on
modifications of risk factors to favourable levels, and present risk reductions for
behaviour changes. Information is printed along with lifestyle
recommendations, and presented to patients, and sent to a central database.
Updated information on risk factor levels, absolute risk, prescribed therapies
and lifestyle recommendations were sent to the same database. Cardiovascular
events were recorded during follow-up.

Powers et
al., 2011216

Patients who agreed to participate received a baseline survey, and patients were
randomized to either a standard risk factor education group or a personalized
risk communication group. Standard education included written patient
education materials covering established risk factors and how factors can be
improved. Personalized risk communication patients received the standard
education as well as information based on their personal CHD and stroke risk
scores, both verbally and graphically. The average and optimal scores were
published alongside their personal risk. Patients were provided with strategies
to improve their risk (risk factor modification and lifestyle factors). Data were
collected from medical records and interviews.

Price et al.,
2011217

Participants were recruited from four general practices in Oxfordshire, and were
randomized to either the risk factor group or personalized risk group. Risk
factor group patients received their blood pressure, total cholesterol and fasting
glucose values and were told if they were elevated. Personalized risk group
patients received their cardiovascular disease risk estimate. In a 2 x 2 factorial
design, patients were also randomized to receive or not receive lifestyle advice.
The personalized risk information displayed current risk and achievable risk, a
hypothetical risk if all targets for risk factors are obtained.

Romero et
al., 2008218

Medical records of patients from the Internal Medicine Clinic at the Naval
Medical Center San Diego were reviewed to identify eligible patients. Baseline
data were recorded. A poster including the Framingham Risk Score was placed
in examination rooms of the clinic, and physicians were encouraged through
semi-regular announcements to improve guideline adherence. Outpatient
medical records of another patient sample were reviewed and data were
recorded.
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Volpe et al., General physicians recruited patients with a diagnosis of hypertension. Patient
2007222
blood pressure levels and estimated stroke risk was measured at both the initial
visit and during the follow-up visit. Risk factor data were recorded directly in a
computerized scoring algorithm. No recommendations were made to physicians
regarding therapeutic interventions.
Wind et al.,
2015223

Study sponsors recruited general physicians, who then recruited 10 consecutive
patients. Data were collected from the patients’ medical records. At baseline,
physicians estimated patient 10-year CHD risk based on their own subjective
judgement, and then using the UKPDS risk engine. Study sponsors trained
physicians on how to use the risk engine, interpret CHD risk, and determine
whether differences between subjectively calculated risk and UKPDS derived
risk warranted medication adjustment. Data on risk estimates, risk factor levels,
and medication adjustments were recorded.

Bellows et
al., 2014200

Physicians at two clinics in Hawaii were selected. IndiGO guidelines were
implemented using automatic data extraction for all adult patients, which
automatically calculated risk scores. Physicians selected patients, who were
shown videos explaining the guidelines. Physicians and patients then used
IndiGO in a shared decision-making session with a printed summary displaying
all chosen interventions, and predicted risks of heart attack and stroke if
interventions are implemented. Propensity score matching was used to identify
a control group of patients receiving usual care.

Burgess et
al., 2011202

The Aboriginal and Torres Strait Islander Adult Health Check (AHC) was
implemented in remote communities. During the AHC, cardiovascular risk was
assessed identifying patients with elevated CVD risk, and other behavioural risk
factor values were collected via questionnaire. The AHC also consisted of
chronic disease care planning, with patient education and intervention delivery,
treatment goals are negotiated with patients, and follow-up monitoring and care
planning. Patients were followed for three years at six month intervals.
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Appendix E: Comparison of baseline and follow-up measures as per Chang et al.
(2015).203

Before

After

intervention

intervention

Intervention

6.7±5.9

6.2±5.3

risk

Control

5.1±5.3

4.9±5.0

Systolic blood pressure,

Intervention _

131.9±17.4

130.0±12.7

mmHg

Control

128.5±13.6

129.3±11.3

Diastolic blood

Intervention

80.2±10.5

78.5±7.7

pressure, mmHg

Control

78.7±8.2

78.7±6.7

Body mass index

Intervention

27.7±5.1

27.7±5.0

(kg/m2)

Control

26.9±4.1

27.2±4.0

Total cholesterol,

Intervention

5.5±1.0

5.3±0.8

mmol/L

Control

5.3±0.6

5.3±0.6

Smoking prevalence, %

Intervention

17.9

16.3

of group

Control

22.2

20.8

Statin prescribed, % of

Intervention

9.7

15.3

group

Control

3.1

4.3

Antihypertensive

Intervention

4.8

9.9

prescribed, % of group

Control

1.8

4.4

Risk factor

Group

QRISK2, % 10-year

Values are presented as mean ± standard deviation, where available.
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Appendix F: Comparison of baseline and follow-up measures as per Cochrane et al.
(2012)204

Risk factor

Group

Baseline

Follow-up

Health Check

32.9±9.7

29.4±9.7

Health Check Plus

31.9±10.0

29.2±10.1

Systolic blood pressure,

Health Check

146.0±17.0

138.3±14.7

mmHg

Health Check Plus

144.4±16.2

138.7±14.6

Diastolic blood

Health Check

84.9±9.5

80.5±8.8

pressure, mmHg

Health Check Plus

85.3±9.6

81.5±8.9

Total cholesterol

Health Check

5.7±0.9

5.0±1.0

(mmol/L)

Health Check Plus

5.7±0.9

5.1±1.0

Total cholesterol/HDL

Health Check

4.8±1.0

4.2±1.1

cholesterol, mmol/L

Health Check Plus

4.9±1.1

4.4±1.1

Health Check

82.6±13.8

82.8±13.5

Health Check Plus

85.0±14.5

84.3±14.5

Body mass index

Health Check

27.5±4.1

27.6±4.1

(kg/m2)

Health Check Plus

28.7±5.0

28.4±4.9

Waist circumference

Health Check

99.5±11.8

97.9±10.7

(cm)

Health Check Plus

101.3±11.2

99.1±11.4

CVD risk (%)

Weight (kg)

Values are presented as mean ± standard deviation.
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Appendix G: Comparison of baseline and follow-up measures for Jiao et al. (2015)211
Risk factor
BMI (kg/m2)

Before

After

intervention

intervention

Intervention

25.33±3.74

25.07±3.79

Control

25.33±3.90

25.11±3.92

Group

Systolic blood pressure,

Intervention

135.41±17.05 130.12±14.68

mmHg

Control

135.45±16.56 132.35±15.51

Diastolic blood

Intervention

75.11±10.34

71.60±10.26

pressure, mmHg

Control

75.08±9.77

73.23±9.72

Intervention

7.24±1.23

7.13±1.09

Control

7.24±1.24

7.25±1.26

Total cholesterol,

Intervention

5.08±0.94

4.43±0.82

mmol/L

Control

5.08±0.95

4.49±0.86

Intervention

1.22±0.32

1.28±0.34

Control

1.22±0.32

1.31±0.35

Intervention

3.13±0.82

2.51±0.69

Control

3.14±0.83

2.55±0.72

Intervention

1.64±1.10

1.43±0.87

Control

1.64±1.05

1.43±0.97

Intervention

927 (10.2)

346 (9.0)

Control

906 (10.0)

235 (8.6)

On glucose-lowering

Intervention

7943 (87.3)

7999 (90.0)

drugs

Control

7929 (87.2)

7143 (83.6)

On antihypertensive

Intervention

6637 (73.0)

7112 (80.0)

drugs

Control

6673 (73.4)

6493 (76.0)

Intervention

1189 (13.1)

4551 (51.2)

Control

1225 (13.5)

3903 (45.7)

Intervention

105 (1.2)

534 (6.0)

Control

130 (1.4)

386 (4.5)

HbA1c (%)

HDL-C (mmol/L)

LDL-C (mmol/L)

Triglyceride (mmol/L)

Current smoker

On lipid-lowering drugs

On insulin

Values are presented as mean ± standard deviation or n (%).
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Appendix H: Forest plots for best- and worst-case scenarios (antihypertensive medication
prescription)
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Appendix I: Forest plots for best- and worst-case scenarios (lipid-lowering medication
prescription)
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Appendix J: Forest plots for best- and worst-case scenarios (smoking cessation)
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